Fc-silencing antibody-drug conjugates (ADCs) and their uses

By introducing specific amino acid substitutions into the Fc region of antibodies, antibody-drug conjugates (ADCs) that reduce effector function solve the problem of immune stimulation caused by the Fc region of antibodies in existing technologies, thereby improving the engraftment rate and therapeutic effect of hematopoietic stem cell transplants and reducing side effects.

CN113330026BActive Publication Date: 2026-11-10REGENERON PHARMACEUTICALS INC
View PDF 172 Cites 0 Cited by

Patent Information

Application Number
CN201980081477.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-02-19
Filing Date
2019-10-23
Publication Date
2026-11-10
Estimated Expiration
2039-10-23

AI Technical Summary

Technical Problem

When existing antibodies are used to treat hematopoietic system diseases, the effector function of the Fc region often leads to undesirable immune stimulation and side effects, hindering the implantation of exogenous hematopoietic stem cell transplants. Furthermore, the effector function of existing ADCs has not been effectively reduced, which may trigger cytokine secretion and side effects.

Method used

By introducing specific amino acid substitutions, such as L234A, L235A, and D265C/A, into the Fc region of the antibody, effector function is reduced. Antibody-drug conjugates (ADCs) with toxins provide stability and reduce effector function, enabling them to bind to antigens expressed by hematopoietic cells.

Benefits of technology

It achieves the reduction of antibody effector function, decreases host immune response, increases the engraftment rate of exogenous hematopoietic stem cell transplants, reduces cytokine secretion and side effects, and provides a stable ADC composition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113330026B_ABST
    Figure CN113330026B_ABST
Patent Text Reader

Abstract

Antibodies and antibody-drug conjugates having Fc regions with substitutions that produce substantially silent Fc regions are disclosed herein. The antibodies and antibody-drug conjugates described herein can be used for cell depletion and the treatment of various hematopoietic system diseases, metabolic disorders, cancers such as acute myeloid leukemia, and autoimmune diseases. The compositions and methods described herein can be used, for example, to directly treat conditions by depleting, for example, CD45+ or CD117+ cancer cell populations or CD45+ autoimmune cell populations. The compositions and methods described herein can also be used to prepare patients for hematopoietic stem cell transplantation therapy and improve the engraftment of hematopoietic stem cell transplantation by selectively depleting endogenous hematopoietic stem cells prior to transplantation procedures.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims priority to U.S. Provisional Application No. 62 / 749,662, filed October 23, 2018; U.S. Provisional Application No. 62 / 773,839, filed November 30, 2018; and U.S. Provisional Application No. 62 / 807,363, filed February 19, 2019. The contents of each priority application are incorporated herein by reference. Technical Field

[0003] This disclosure relates to the field of antibodies comprising an Fc region or antibody-drug conjugates thereof, wherein the effector function is altered due to substitution of one or more amino acids in the Fc region. This disclosure also relates to the treatment of patients with various pathologies (e.g., blood disorders, metabolic disorders, cancers, and autoimmune diseases) by administering antibodies or antibody-drug conjugates (ADCs) having modified Fc regions, wherein the antibody or ADC is capable of binding antigens expressed by hematopoietic cells (e.g., hematopoietic stem cells or cells of the host immune system). Background Technology

[0004] The Fc region of an antibody controls its cytotoxic activity and can affect its serum half-life. However, in a therapeutic context, the cytotoxic effector function of antibodies is often suboptimal and can lead to safety issues and undesirable side effects by activating the host immune defense. Several amino acid alterations in the Fc region have been reported to silence or reduce the effector function of antibodies. Indeed, previous studies have identified amino acid positions in the antibody Fc region that affect the antibody's ability to bind to the Fc receptor (see, for example, Wang et al. (2018) Protein Cell. 2018 Jan; 9(1):63–73). For example, the Fc mutations S239D and I332E have been described in the literature as enhancing ADCC function (see, for example, Lazar et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 103:4005–4010). Other mutations are associated with reduced binding to FcγR and C1q, such as alterations to the amino acid composition of L234A / L235A in IG1, or to F234A / L235A in IG4 (Xu et al., In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000; 200:16–26). However, it is less well known how Fc mutations may affect antibody-drug conjugates (ADCs), particularly when toxins are conjugated to antibodies or fragments containing Fc within the Fc region.

[0005] Despite advances in the medical field, there remains a need to treat pathologies of the hematopoietic system, such as diseases of specific blood cells, metabolic disorders, cancer, and autoimmune diseases. While hematopoietic stem cells (HSCs) possess significant therapeutic potential, limiting factors hindering their clinical application include challenges related to ensuring the engraftment of HSC transplants in the host. In particular, HSC therapies involving antibodies targeting cell surface antigens on endogenous HSCs may trigger unwanted immune stimulation and effector function, hindering the engraftment of exogenous HSC transplants. There is a need for compositions and methods to facilitate the engraftment of exogenous HSC transplants, thereby preserving the pluripotency and hematopoietic function of these cells post-transplantation. Improved ADCs are also needed, for example, for pretreatment to reduce effector function, thereby minimizing potential cytokine secretion and possible side effects. Summary of the Invention

[0006] This document describes antibodies and their antigen-binding portions comprising an Fc region, the effector function of which is altered by substitution of one or more amino acids in the Fc region, and describes antibody-drug conjugates, compositions, and methods of using said antibodies. In particular, this document provides antibodies or antibody-drug conjugates (ADCs) having modified Fc regions, wherein said antibodies or ADCs are capable of binding antigens expressed by hematopoietic cells (e.g., hematopoietic stem cells or mature immune cells (e.g., T cells)). Furthermore, this document provides ADCs containing Fc mutations, which provide a conjugation site for toxins and reduce effector function, as well as provide stability. Therefore, this disclosure provides unique combinations of Fc mutations to ADCs.

[0007] In one aspect, this document provides an antibody comprising an Fc region, wherein the Fc region comprises an amino acid substitution at positions L234 and L235 (EU index) and an amino acid substitution D265C (EU index), and wherein the antibody is a complete IgG antibody. In one embodiment, the Fc region comprises an amino acid substitution at positions L234 and L235 (EU index) and an amino acid substitution D265A (EU index), and wherein the antibody is a complete IgG antibody. In one embodiment, the L234 amino acid substitution is L234A. In one embodiment, the L235 amino acid substitution is L235A.

[0008] In some embodiments, the Fc region further comprises an amino acid substitution at position H435 (EU index). In one embodiment, the H435 amino acid substitution is H435A. In one embodiment, the antibody containing the amino acid substitution H435A has a reduced half-life compared to the same intact IgG antibody containing the unmodified Fc region.

[0009] On the other hand, this document provides an antibody comprising an Fc region having amino acid substitutions consisting essentially of amino acid substitutions for L234A, L235A, and D265C (EU index), and wherein said antibody is a complete IgG antibody. In one embodiment, said antibody comprises an Fc region having amino acid substitutions consisting essentially of amino acid substitutions for L234A, L235A, and D265A (EU index), and wherein said antibody is a complete IgG antibody.

[0010] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions at positions L234, L235 (EU index), and D265 (EU index). In one embodiment, the D265 amino acid substitution is D265C or D265A (EU index). In another embodiment, the L234 amino acid substitution is L234A or L234V. In another embodiment, the L235 amino acid substitution is L235A. In another embodiment, the Fc region further comprises an amino acid substitution at position N297 (EU index). In another embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position E233 (EU index). In another embodiment, the E233 amino acid substitution is E233P (EU index). In another embodiment, the Fc region further includes a deletion at position G236 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position P331 (EU index). In another embodiment, the P331 amino acid substitution is P331G. In another embodiment, the Fc region does not contain a substitution at position P331 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position P329 (EU index). In another embodiment, the P329 amino acid substitution is P329G. In another embodiment, the Fc region does not contain a substitution at position P329 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position I253 (EU index). In another embodiment, the I253 amino acid substitution is I253A. In another embodiment, the Fc region further comprises an amino acid substitution at position H310 (EU index). In another embodiment, the H310 amino acid substitution is H310A.

[0011] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region containing amino acid substitutions at positions N297 and D265 (EU index). In one embodiment, the amino acid substitution at position D265 is D265C or D265A (EU index). In another embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In another embodiment, the Fc region further comprises amino acid substitutions at positions L234 and L235 (EU index). In another embodiment, the L234 amino acid substitution is L234A or L234V. In another embodiment, the L235 amino acid substitution is L235A. In another embodiment, the Fc region further comprises an amino acid substitution at position E233 (EU index). In another embodiment, the E233 amino acid substitution is E233P (EU index). In another embodiment, the Fc region further comprises a deletion at position G236 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position P331 (EU index). In another embodiment, the P331 amino acid substitution is P331G. In another embodiment, the Fc region does not contain a substitution at position P331 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position P329 (EU index). In another embodiment, the P329 amino acid substitution is P329G. In another embodiment, the Fc region does not contain a substitution at position P329 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position I253 (EU index). In another embodiment, the I253 amino acid substitution is I253A. In another embodiment, the Fc region further comprises an amino acid substitution at position H310 (EU index). In another embodiment, the H310 amino acid substitution is H310A.

[0012] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions at positions E233, L234, L235, and D265 (EU index) and a deletion at G236 (EU index), and an amino acid substitution at position D265 (EU index). In one embodiment, the amino acid substitution at D265 is D265C or D265A (EU index). In another embodiment, the L234 amino acid substitution is L234A or L234V. In another embodiment, the L235 amino acid substitution is L235A. In another embodiment, the E233 amino acid substitution is E233P (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position N297 (EU index). In another embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position P331 (EU index). In another embodiment, the P331 amino acid substitution is P331G.

[0013] In another embodiment, the Fc region does not contain a substitution at position P331 (EU index). In another embodiment, the Fc region also contains an amino acid substitution at position P329 (EU index). In another embodiment, the P329 amino acid substitution is P329G. In another embodiment, the Fc region does not contain a substitution at position P329 (EU index). In another embodiment, the Fc region also contains an amino acid substitution at position I253 (EU index). In another embodiment, the I253 amino acid substitution is I253A. In another embodiment, the Fc region also contains an amino acid substitution at position H310 (EU index). In another embodiment, the H310 amino acid substitution is H310A.

[0014] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region contains amino acid substitutions at positions H435 and D265 (EU index). In one embodiment, the amino acid substitution at position D265 is D265C or D265A (EU index). In another embodiment, the H435 amino acid substitution is H435A. In another embodiment, the Fc region further comprises an amino acid substitution at position N297 (EU index). In another embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In another embodiment, the Fc region further comprises amino acid substitutions at positions L234 and L235 (EU index). In another embodiment, the L234 amino acid substitution is L234A or L234V. In another embodiment, the L235 amino acid substitution is L235A. In another embodiment, the Fc region further comprises an amino acid substitution at position E233 (EU index). In another embodiment, the E233 amino acid substitution is E233P (EU index). In another embodiment, the Fc region also includes a deletion of G236 (EU index). In another embodiment, the Fc region also includes an amino acid substitution at position P331 (EU index). In another embodiment, the P331 amino acid substitution is P331G. In another embodiment, the Fc region does not include a substitution at position P331 (EU index). In another embodiment, the Fc region also includes an amino acid substitution at position P329 (EU index). In another embodiment, the P329 amino acid substitution is P329G. In another embodiment, the Fc region does not include a substitution at position P329 (EU index). In another embodiment, the Fc region also includes an amino acid substitution at position I253 (EU index). In another embodiment, the I253 amino acid substitution is I253A. In another embodiment, the Fc region also includes an amino acid substitution at position H310 (EU index). In another embodiment, the H310 amino acid substitution is H310A.

[0015] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises an amino acid substitution at positions L234 and L235 (EU index) and an amino acid substitution at position P329 (EU index). In one embodiment, the L234 amino acid substitution is L234A or L234V. In another embodiment, the L235 amino acid substitution is L235A. In one embodiment, the Fc region further comprises an amino acid substitution at position D265 (EU index). In one embodiment, the D265 amino acid substitution is D265C or D265A (EU index). In one embodiment, the Fc region further comprises an amino acid substitution at position N297 (EU index). In one embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In one embodiment, the Fc region further comprises an amino acid substitution at position E233 (EU index). In one embodiment, the E233 amino acid substitution is E233P (EU index). In one embodiment, the Fc region further includes a deletion at G236 (EU index). In one embodiment, the Fc region further includes an amino acid substitution at position P331 (EU index). In one embodiment, the P331 amino acid substitution is P331G. In one embodiment, the Fc region does not include a substitution at position P331 (EU index). In one embodiment, the Fc region further includes an amino acid substitution at position I253 (EU index). In one embodiment, the I253 amino acid substitution is I253A. In one embodiment, the Fc region further includes an amino acid substitution at position H310 (EU index). In one embodiment, the H310 amino acid substitution is H310A.

[0016] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises an amino acid substitution at positions L234 and L235 (EU index) and an amino acid substitution P331 (EU index). In one embodiment, the L234 amino acid substitution is L234A or L234V. In one embodiment, the L235 amino acid substitution is L235A. In one embodiment, the Fc region further comprises an amino acid substitution at position D265 (EU index). In one embodiment, the D265 amino acid substitution is D265C or D265A (EU index). In one embodiment, the Fc region further comprises an amino acid substitution at position N297 (EU index). In one embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In one embodiment, the Fc region further comprises an amino acid substitution at position E233 (EU index). In one embodiment, the E233 amino acid substitution is E233P (EU index). In one embodiment, the Fc region further includes a deletion at G236 (EU index). In one embodiment, the Fc region further includes an amino acid substitution at position P329 (EU index). In one embodiment, the P329 amino acid substitution is P329G. In one embodiment, the Fc region does not include a substitution at position P329 (EU index). In one embodiment, the Fc region further includes an amino acid substitution at position I253 (EU index). In one embodiment, the I253 amino acid substitution is I253A. In one embodiment, the Fc region further includes an amino acid substitution at position H310 (EU index). In one embodiment, the H310 amino acid substitution is H310A.

[0017] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions at positions E233, L234, and L235 (EU index), and a deletion at position G236 (EU index). In one embodiment, the L234 amino acid substitution is L234A or L234V. In one embodiment, the L235 amino acid substitution is L235A. In one embodiment, the E233 amino acid substitution is E233P (EU index). In one embodiment, the Fc region further comprises an amino acid substitution at position H435 (EU index). In one embodiment, the H435 amino acid substitution is H435A. In one embodiment, the Fc region further comprises an amino acid substitution at position N297 (EU index). In one embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In one embodiment, the Fc region further comprises an amino acid substitution at position P331 (EU index). In one embodiment, the P331 amino acid substitution is P331G. In one embodiment, the Fc region does not contain a substitution at the P331 position (EU index). In one embodiment, the Fc region further contains an amino acid substitution at the P329 position (EU index). In one embodiment, the P329 amino acid substitution is P329G. In one embodiment, the Fc region does not contain a substitution at the P329 position (EU index). In one embodiment, the Fc region further contains an amino acid substitution at the I253 position (EU index). In one embodiment, the I253 amino acid substitution is I253A. In one embodiment, the Fc region further contains an amino acid substitution at the H310 position (EU index). In one embodiment, the H310 amino acid substitution is H310A.

[0018] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions at positions I253, H310, and H345 (EU index). In one embodiment, the I253 amino acid substitution is I253A. In another embodiment, the H310 amino acid substitution is H310A. In another embodiment, the H435 amino acid substitution is H435A. In another embodiment, the Fc region further comprises an amino acid substitution at position N297 (EU index). In another embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position D265 (EU index). In another embodiment, the D265 amino acid substitution is D265C or D265A (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position E233 (EU index). In another embodiment, the E233 amino acid substitution is E233P (EU index). In another embodiment, the Fc region further includes a deletion of G236 (EU index). In another embodiment, the Fc region also includes an amino acid substitution at position P329 (EU index). In another embodiment, the P329 amino acid substitution is P329G. In another embodiment, the Fc region does not include a substitution at position P329 (EU index). In another embodiment, the Fc region also includes an amino acid substitution at position P331 (EU index). In another embodiment, the P331 amino acid substitution is P331G. In yet another embodiment, the Fc region does not include a substitution at position P329 (EU index).

[0019] On the other hand, this document provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region contains an amino acid substitution at position N297 (EU index). In one embodiment, the Fc region further contains amino acid substitutions at positions L234 and L235 (EU index). In another embodiment, the L234 amino acid substitution is L234A or L234V. In another embodiment, the L235 amino acid substitution is L235A. In another embodiment, the Fc region does not contain substitutions at positions L234 and L235 (EU index). In another embodiment, the N297 amino acid substitution is selected from N297A, N297G, and N297Q. In another embodiment, the Fc region further contains an amino acid substitution at position E233 (EU index). In another embodiment, the E233 amino acid substitution is E233P (EU index). In another embodiment, the Fc region further contains a deletion at position G236 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position P331 (EU index). In another embodiment, the P331 amino acid substitution is P331G. In another embodiment, the Fc region does not contain a substitution at position P331 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position P329 (EU index). In another embodiment, the P329 amino acid substitution is P329G. In another embodiment, the Fc region does not contain a substitution at position P329 (EU index). In another embodiment, the Fc region further comprises an amino acid substitution at position I253 (EU index). In another embodiment, the I253 amino acid substitution is I253A. In another embodiment, the Fc region further comprises an amino acid substitution at position H310 (EU index). In another embodiment, the H310 amino acid substitution is H310A.

[0020] In some embodiments, the antibody or its antigen-binding portion comprises any combination of substitutions for the Fc region as described herein.

[0021] In some embodiments, the antibody or its antigen-binding portion further comprises an amino acid substitution at position S239 (EU index). In one embodiment, the S239 amino acid substitution is S239C.

[0022] In some embodiments, the antibody or its antigen-binding portion further comprises an amino acid substitution at position H435 (EU index). In one embodiment, the H435 amino acid substitution is H435A. In another embodiment, the antibody comprises the amino acid substitution H435A and has a reduced half-life relative to the same intact IgG antibody comprising an unmodified Fc region.

[0023] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions L234A, L235A, S239C, and D265A (EU index).

[0024] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions L234A, L235A, S239C, and D265C (EU index).

[0025] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for L234A, L235A and D265C (EU index).

[0026] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for L234A, L235A and D265A (EU index).

[0027] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for L234A, L235A, S239C, and D265A (EU index).

[0028] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for H435A, L234A, L235A and D265C (EU index).

[0029] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for N297A and D265C (EU index).

[0030] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for N297G and D265C (EU index).

[0031] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for N297Q and D265C (EU index).

[0032] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for N297A and D265A (EU index).

[0033] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for N297G and D265A (EU index).

[0034] On the other hand, this article provides an antibody or its antigen-binding portion comprising an Fc region, wherein the Fc region comprises amino acid substitutions consisting substantially of amino acid substitutions for N297Q and D265A (EU index).

[0035] On the other hand, this document provides an antibody or its antigen-binding portion thereof, wherein the effector function of the antibody is reduced, the reduction in effector function being defined as a decrease in binding to the Fcγ receptor (FcγR) relative to the binding of the same antibody containing an unmodified Fc region to the FcγR. In some embodiments, the reduction in binding is a reduction of at least 70%, up to 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% of the antibody binding to the FcγR relative to the binding of the same antibody containing an unmodified Fc region to the FcγR. In another embodiment, the antibody binds to the FcγR undetectably. In another embodiment, the antibody binding to the FcγR is evaluated by biolayer interferometry (BLI). In another embodiment, the antibody binding to the FcγR is evaluated using an assay known to those skilled in the art. In another embodiment, the FcγR is an FcγR1 receptor. In another embodiment, the FcγR receptor is an FcγR2 receptor or an FcγR3 receptor. In another embodiment, the FcγR2 receptor is FcγR2A, FcγR2B, or FcγR2C. In another embodiment, the FcγR3 receptor is FcγR3A or FcγR3B. In another embodiment, the Fc receptor is a human Fc receptor. In still other embodiments, the FcγR receptor is an FcγR2A 167R receptor. In still other embodiments, the FcγR receptor is an FcγR3A 176V receptor. In still other embodiments, the FcγR receptor is an FcγR3A 176F receptor.

[0036] In another embodiment, this document provides an antibody or its antigen-binding portion thereof, wherein the antibody reduces cytokine release in an in vitro cytokine release assay by at least 50% relative to cytokine release by the same antibody containing an unmodified Fc region. In one embodiment, the reduction in cytokine release is defined as a reduction of at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% relative to cytokine release by the same antibody containing an unmodified Fc region. In another embodiment, the antibody does not show detectable cytokine release. In another embodiment, the in vitro cytokine release assay is a Meso Scale Discovery (MSD) tissue culture pro-inflammatory assay. In another embodiment, the in vitro cytokine release assay is evaluated using an assay known to those skilled in the art. In another embodiment, in an in vitro mast cell degranulation assay, the antibody reduces mast cell degranulation by at least 50% relative to mast cell degranulation by the same antibody containing an unmodified Fc region. In another embodiment, the reduction in mast cell degranulation is defined as a reduction of at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% in mast cell degranulation relative to mast cell degranulation with the same antibody containing the unmodified Fc region. In another embodiment, the antibody does not show detectable mast cell degranulation. In another embodiment, the in vitro mast cell degranulation assay is based on a β-hexosaminease-based mast cell degranulation assay.

[0037] In some embodiments, the IgG isotype is an IgG1 isotype, an IgG2 isotype, an IgG3 isotype, or an IgG4 isotype. In another embodiment, the antibody is a human antibody, a chimeric antibody, or a humanized antibody. In yet another embodiment, the antibody is a bispecific antibody. In another embodiment, the antibody is a monoclonal antibody. In another embodiment, the antibody is a complete IgG antibody. In yet another embodiment, the antibody specifically binds to CD117, CD45, CD2, CD5, CD137, or CD252.

[0038] On the other hand, this document provides antibody-drug conjugates (ADCs) comprising an antibody or its antigen-binding moiety as described herein, wherein the antibody or its antigen-binding moiety is conjugated to a cytotoxin via a linker. In one embodiment, the cytotoxin is an RNA polymerase inhibitor. In another embodiment, the RNA polymerase inhibitor is amatoxin. In yet another embodiment, the amatoxin is represented by formula (III).

[0039]

[0040] Where R1 is H, OH, OR A OR C R2 is H, OH, OR B OR C ;R A and R B Together with the oxygen atoms they are bonded to, they form optionally substituted 5-membered heterocyclic alkyl groups; R3 is H, R C Or R D R4, R5, R6, and R7 are each independently H, OH, and OR. C OR D R C Or R D R8 represents OH, NH2, and OR. C OR D NHR C or NR C R D R9 represents H, OH, and OR. C OR D x is -S-, -S(O-) or -SO2-; R C Yes - LZ; R D Optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 ynyl, optionally substituted C2-C6 heteroyynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; L is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C2-C6 alkenyl, or optionally substituted alkylene. The C2-C6 heteroene group, optionally substituted C2-C6 ynynyl group, optionally substituted C2-C6 heteroynyl group, optionally substituted cycloalkylene group, optionally substituted heterocycloalkylene group, optionally substituted arylene group, optionally substituted heteroarylene group, peptide, dipeptide, -(C=O)-, disulfide, hydrazone, or combinations thereof; and Z is a chemical moiety formed by the coupling reaction between a reactive substituent present on L and a reactive substituent present in an antibody or its antigen-binding fragment, wherein Am specifically contains an R C Substituents. In another embodiment, the amanita toxin is represented by formula (IB).

[0041]

[0042] Where R1 is H, OH, OR A ORC R2 is H, OH, OR B OR C ;R A and R B Together with the oxygen atoms they are bonded to, they form optionally substituted 5-membered heterocyclic alkyl groups; R3 is H, R C Or R D R4, R5, R6, and R7 are each independently H, OH, and OR. C OR D R C Or R D R8 represents OH, NH2, and OR. C OR D NHR C or NR C R D R9 represents H, OH, and OR. C OR D x is -S-, -S(O-) or -SO2-; R C Yes - LZ; R D Optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 ynyl, optionally substituted C2-C6 heteroyynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; L is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C2-C6 alkenyl, or optionally substituted alkylene. The C2-C6 heteroene group, optionally substituted C2-C6 ynynyl group, optionally substituted C2-C6 heteroynyl group, optionally substituted cycloalkylene group, optionally substituted heterocycloalkylene group, optionally substituted arylene group, optionally substituted heteroarylene group, peptide, dipeptide, -(C=O)-, disulfide, hydrazone, or combinations thereof; and Z is a chemical moiety formed by the coupling reaction between a reactive substituent present on L and a reactive substituent present in an antibody or its antigen-binding fragment, wherein Am specifically contains an R CSubstituents. In another embodiment, the RNA polymerase inhibitor is amanita. In another embodiment, the amanita is selected from α-amanita, β-amanita, γ-amanita, ε-amanita, amanitin, amanitamide, amanita nontoxic cyclic peptide, amanita nontoxic cyclic peptide acid, and pro-amanita nontoxic cyclic peptide. In another embodiment, the cytotoxin is selected from Pseudomonas exotoxin A, deBouganin, diphtheria toxin, saponins, maytansine, maytansine alkaloids, oliguria, anthracyclines, galizin, irinotecan, SN-38, pyrrolobenzodiazepines, pyrrolobenzodiazepine dimers, indobenzobenzodiazepines, and indobenzobenzodiazepine dimers. In another embodiment, the oliguria is MMAE or MMAF. In another embodiment, the antibody or its antigen-binding moiety is conjugated to the cytotoxin via interchain conjugation with a natural hinge cysteine ​​residue. In another embodiment, the antibody or its antigen-binding moiety is conjugated to the cytotoxin via a cysteine ​​residue in the Fc domain of the antibody. In another embodiment, the cysteine ​​residue is introduced via amino acid substitution in the Fc domain of the antibody. In another embodiment, the amino acid substitution is D265C. In another embodiment, the amino acid substitution is S239C.

[0043] On the other hand, this document provides pharmaceutical compositions comprising an antibody or ADC according to any one of claims 1 to 218, and a pharmaceutically acceptable carrier.

[0044] On the other hand, this document provides a method for depleting a hematopoietic stem cell (HSC) population in a human patient, the method comprising administering an effective amount of the antibody or ADC described herein to the patient. In one embodiment, the method comprises administering a graft containing hematopoietic stem cells to the patient. In one embodiment, the graft is heterologous. In one embodiment, the graft is autologous.

[0045] On the other hand, this document provides a method of administering a graft containing hematopoietic stem cells to a human patient, wherein the patient has previously been administered an amount of the antibody or ADC described herein sufficient to deplete the patient's hematopoietic stem cell population. In one embodiment, the hematopoietic stem cells are CD117+ or CD45+ cells. In another embodiment, the patient suffers from a blood disorder, metabolic disorder, cancer, or autoimmune disease or severe combined immunodeficiency disease (SCID).

[0046] On the other hand, this article provides a method for treating leukemia in human patients, the method comprising administering the antibody or ADC described herein to a human patient with leukemia.

[0047] On the other hand, this document provides a method comprising administering a graft containing hematopoietic stem cells to a human patient, wherein the patient has previously been administered an amount of the antibody or ADC described herein sufficient to deplete the patient's hematopoietic stem cell population. In one embodiment, the immune cells are CD137+, CD2+, or CD5+ cells. In another embodiment, the immune cells are T cells.

[0048] On the other hand, this document provides compositions comprising the antibodies or ADCs described herein, wherein the compositions contain less than 25% hydrophobic degradants after heat stress. In one embodiment, the composition contains less than 20% hydrophobic degradants after heat stress. In another embodiment, the composition contains less than 15% hydrophobic degradants after heat stress. In yet another embodiment, the composition contains less than 10% hydrophobic degradants after heat stress. In yet another embodiment, the composition contains less than 5% hydrophobic degradants after heat stress.

[0049] On the other hand, this article provides a method for treating stem cell diseases in human patients, the method comprising administering to the patient a therapeutically effective amount of the antibody, its antigen-binding fragment, or ADC described herein.

[0050] On the other hand, this document provides a method for treating immunodeficiency disorders in human patients, the method comprising administering to the patient a therapeutically effective amount of the antibody, its antigen-binding fragment, or ADC described herein. In one embodiment, the immunodeficiency disorder is a congenital immunodeficiency or an acquired immunodeficiency.

[0051] On the other hand, this document provides a method for treating metabolic disorders in human patients, the method comprising administering to the patient a therapeutically effective amount of the antibody, its antigen-binding fragment, or ADC described herein. In one embodiment, the metabolic disorder is selected from glycogen storage diseases, mucopolysaccharidosis, Gaucher's disease, Hurler's disease, sphingolipid metabolism disorders, and metachromatic leukodystrophy.

[0052] On the other hand, this article provides a method for treating autoimmune diseases in human patients, the method comprising administering to the patient a therapeutically effective amount of the antibody, its antigen-binding fragment, or ADC described herein. In some implementations, the autoimmune disease is selected from multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriasis, type 1 diabetes, acute disseminated encephalomyelitis, Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune oophoritis, Barlow's disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Crohn's disease, cicatricial pemphigoid, peritoneal inflammatory diarrhea herpetic dermatitis, cold agglutinin disease, CREST syndrome, malignant atrophic papulosis, discoid lupus, familial autonomic dysfunction. Commonly seen in patients with various conditions including: endometriosis, idiopathic mixed cryoprecipitate globulinemia, fibromyalgia-fibromyositis, Goodpassuia syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, hidradenitis suppurativa, idiopathic and / or acute thrombocytopenic purpura, idiopathic pulmonary fibrosis, IgA neuropathy, interstitial cystitis, juvenile arthritis, Kawasaki disease, lichen planus, Lyme disease, Meniere's disease, mixed connective tissue disease, myasthenia gravis, neurogenic myotonia, strabismus-myoclonus syndrome, optic neuritis, Oddi thyroiditis, pemphigus vulgaris, pernicious anemia, polychondritis, polymyositis and dermatomyositis, primary biliary cirrhosis, polyarteritis nodosa, polyglandular syndrome, polymyalgia rheumatica, primary agammaglobulinemia, Raynaud's phenomenon, Reiter's syndrome, rheumatic fever, sarcoidosis, and scleroderma. Syndrome, stiff-person syndrome, pulseless disease, temporal arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, vulvar pain, and Wegener's granulomatosis.

[0053] On the other hand, this document provides a method for treating cancer in human patients, the method comprising administering to the patient a therapeutically effective amount of the antibody, its antigen-binding fragment, or ADC described herein. In some embodiments, the cancer is selected from leukemia, lymphoma, multiple myeloma, and neuroblastoma.

[0054] In some embodiments of any of the foregoing aspects, the effector function of the antibody is reduced, defined as a decrease in binding to the Fcγ receptor (FcγR) relative to the binding of the same antibody containing the unmodified Fc region to the FcγR. In one embodiment, the reduction in binding is a reduction of at least 70%, up to 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% of the antibody binding to the FcγR relative to the binding of the same antibody containing the unmodified Fc region to the FcγR. In some embodiments, the antibody binds to the FcγR undetectably. In some embodiments, the antibody binding to the FcγR is assessed by biolayer interferometry (BLI). In some embodiments, the FcγR is an FcγR1 receptor, an FcγR2 receptor, or an FcγR3 receptor. In some embodiments, the FcγR1 receptor is FcγR1A, FcγR1B, or FcγR1C. In some embodiments, the FcγR1 receptor is FcγR2A, FcγR2B, or FcγR2C. In some embodiments, the FcγR1 receptor is FcγR3A or FcγR3B. In some embodiments, the Fc receptor is a human Fc receptor.

[0055] In some embodiments of any of the foregoing aspects, the IgG isotype is IgG1 isotype, IgG2 isotype, IgG3 isotype or IgG4 isotype.

[0056] In some embodiments of any of the foregoing aspects, the antibody is a human antibody.

[0057] In some embodiments of any of the above aspects, the antibody is a chimeric antibody or a humanized antibody.

[0058] In some embodiments of any of the foregoing aspects, the antibody is a monoclonal antibody.

[0059] In some embodiments of any of the foregoing aspects, the antibody specifically binds to CD117, CD45, CD2, CD5, CD137, or CD252.

[0060] On the other hand, this document provides antibody-drug conjugates (ADCs) comprising any of the antibodies described herein, wherein the antibodies are conjugated to cytotoxins via linkers.

[0061] In some embodiments of the conjugates described herein, the cytotoxin is an RNA polymerase inhibitor. In some embodiments, the RNA polymerase inhibitor is amatoxin.

[0062] In some embodiments, the amatoxin is represented by formula (1A).

[0063]

[0064] Where R1 is H, OH, OR A OR C ;

[0065] R2 represents H, OH, or OR. B OR C ;

[0066] R A and R B Together with the oxygen atoms they are bonded to, they form optionally substituted 5-membered heterocyclic alkyl groups;

[0067] R3 is H, R C Or R D ;

[0068] R4, R5, R6, and R7 are each independently H, OH, and OR. C OR D R C Or R D ;

[0069] R8 represents OH, NH2, and OR. C OR D NHR C or NR C R D ;

[0070] R9 represents H, OH, and OR. C OR D ;

[0071] x is -S-, -S(O-) or -SO2-;

[0072] R C Yes, it's LZ;

[0073] R D It is optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 ynyl, optionally substituted C2-C6 heteroynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

[0074] L is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 alynylene, optionally substituted C2-C6 heteroynylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene; and

[0075] Z is a chemical moiety formed by the coupling reaction between the reactive substituent present on L and the reactive substituent present in the antibody or its antigen-binding fragment.

[0076] Where Am contains exactly one R C Substituents.

[0077] In some embodiments, the amatoxin is represented by formula (IB).

[0078]

[0079] Where R1 is H, OH, OR A OR C ;

[0080] R2 represents H, OH, or OR. B OR C ;

[0081] R A and R B Together with the oxygen atoms they are bonded to, they form optionally substituted 5-membered heterocyclic alkyl groups;

[0082] R3 is H, R C Or R D ;

[0083] R4, R5, R6, and R7 are each independently H, OH, and OR. C OR D R C Or R D ;

[0084] R8 represents OH, NH2, and OR. C OR D NHR C or NR C R D ;

[0085] R9 represents H, OH, and OR. C OR D ;

[0086] X is -S-, -S(O-) or -SO2-;

[0087] R C Yes, it's LZ;

[0088] R D It is optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 ynyl, optionally substituted C2-C6 heteroynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

[0089] L is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 alynylene, optionally substituted C2-C6 heteroynylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene; and

[0090] Z is a chemical moiety formed by the coupling reaction between the reactive substituent present on L and the reactive substituent present in the antibody or its antigen-binding fragment.

[0091] Where Am contains exactly one R C Substituents.

[0092] In some embodiments, the RNA polymerase inhibitor is amanita. In some embodiments, the amanita is selected from α-amanita, β-amanita, γ-amanita, ε-amanita, amanitin, amanitamide, amanita nontoxic cyclic peptide, amanita nontoxic cyclic peptide acid, and pro-amanita nontoxic cyclic peptide.

[0093] In some embodiments, the cytotoxin is selected from Pseudomonas exotoxin A, deBouganin, diphtheria toxin, saponins, maytansine, maytanyl alkaloids, oliguria guanylate, anthracyclines, galizine, irinotecan, SN-38, pyrrolobenzodiazepines, pyrrolobenzodiazepine dimers, indobenzobenzodiazepines, and indobenzobenzodiazepine dimers. In some embodiments, the oliguria guanylate is MMAE or MMAF.

[0094] In some embodiments of the conjugates described herein, the antibody is conjugated to the toxin via a cysteine ​​residue in the Fc domain of the antibody. In some embodiments, the cysteine ​​residue is introduced via an amino acid substitution in the Fc domain of the antibody. In some embodiments, the amino acid substitution is D265C.

[0095] On the other hand, this article provides pharmaceutical compositions comprising the antibody or ADC described herein and a pharmaceutically acceptable carrier.

[0096] In another aspect, this article provides a method for depleting hematopoietic stem cell (HSC) populations in human patients, the method comprising administering an effective amount of the antibody or ADC described herein to the patient.

[0097] In some embodiments of the method described herein, the method further includes administering a graft containing hematopoietic stem cells to a patient. In some embodiments, the graft is heterologous.

[0098] On the other hand, this article provides a method for administering a graft containing hematopoietic stem cells to a human patient, wherein the patient has previously been administered an amount of the antibody or ADC described herein sufficient to deplete the patient's hematopoietic stem cell population.

[0099] In some implementations of the methods described herein, the patient suffers from a blood disorder, metabolic disorder, cancer, or autoimmune disease or severe combined immunodeficiency disease (SCID).

[0100] On the other hand, this article provides a method for treating leukemia in human patients, the method comprising administering the antibody or ADC described herein to a human patient suffering from leukemia.

[0101] In one aspect, this document provides a method for depleting a CD117+ cell population in a patient with this need, the method comprising administering to the patient an effective amount of an anti-CD117 antibody-drug conjugate (ADC), wherein the antibody-drug conjugate (ADC) comprises an anti-CD117 antibody conjugated to amatoxins via a linker and is represented by the formula Ab-ZL-Am, where Ab is an anti-CD117 antibody containing an H435A mutation (EU index) in the Fc region of the antibody, L is a linker, Z is a chemical moiety, and Am is amatoxins. In one embodiment, the ADC is administered before the patient receives a graft containing hematopoietic stem cells. In another embodiment, the ADC is administered concurrently with the patient receiving a graft containing hematopoietic stem cells.

[0102] On the other hand, this document provides a method for administering an anti-CD117 antibody-drug conjugate (ADC) to a human patient in an amount sufficient to deplete the CD117+ cell population, wherein the antibody-drug conjugate (ADC) comprises an anti-CD117 antibody conjugated to amatoxins via a linker and is represented by the formula Ab-ZL-Am, where Ab is an anti-CD117 antibody containing an H435A mutation (EU index) in the Fc region of the antibody, L is a linker, Z is a chemical motif, and Am is amatoxins; and subsequently administering a graft containing hematopoietic stem cells to the patient. In one embodiment, the graft containing hematopoietic stem cells is administered to the patient after the concentration of the ADC has been substantially cleared from the patient's blood. In another embodiment, the hematopoietic stem cells or their progeny retain their functional potential two days or more after transplantation into the patient. In yet another embodiment, the hematopoietic stem cells or their progeny are capable of localizing to hematopoietic tissue and / or reconstructing hematopoiesis after transplantation into the patient. In another implementation, the patient suffers from a condition selected from the following: adenosine deaminase deficiency and severe combined immunodeficiency, hyperimmune globulin M syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, severe thalassemia, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis. In yet another implementation, the patient suffers from an autoimmune disease or a hematologic malignancy.In another implementation, the autoimmune disease is selected from multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, psoriasis, type 1 diabetes, acute disseminated encephalomyelitis, Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune oophoritis, Barlow's disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Crohn's disease, cicatricial pemphigoid, peritoneal inflammatory diarrhea herpetic dermatitis, cold agglutinin disease, CREST syndrome, malignant atrophic papulosis, discoid lupus, and familial autonomic dysfunction. Endometriosis, idiopathic mixed cryoprecipitate globulinemia, fibromyalgia-fibromyositis, Goodpassuia syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, hidradenitis suppurativa, idiopathic and / or acute thrombocytopenic purpura, idiopathic pulmonary fibrosis, IgA neuropathy, interstitial cystitis, juvenile arthritis, Kawasaki disease, lichen planus, Lyme disease, Meniere's disease, mixed connective tissue disease, myasthenia gravis, neurogenic myotonia, strabismus-myoclonus syndrome, optic neuritis, Oddi thyroiditis, pemphigus vulgaris, pernicious anemia, polychondritis, polymyositis and dermatomyositis, primary biliary cirrhosis, polyarteritis nodosa, polyglandular syndrome, polymyalgia rheumatica, primary agammaglobulinemia, Raynaud's phenomenon, Wright's syndrome, rheumatic fever, sarcoidosis, scleroderma. Syndrome, stiff-person syndrome, pulseless disease, temporal arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, vulvar pain, and Wegener's granulomatosis.

[0103] On the other hand, this document provides a method for treating a human subject suffering from a hematologic malignancy, comprising administering to the human subject suffering from a hematologic malignancy an effective amount of an anti-CD117 antibody-drug conjugate (ADC), wherein the antibody-drug conjugate (ADC) comprises an anti-CD117 antibody conjugated to amatoxins via a linker and is represented by the formula Ab-ZL-Am, wherein Ab is an anti-CD117 antibody containing an H435A mutation (EU index) in the Fc region of the antibody, L is a linker, Z is a chemical moiety, and Am is amatoxins. In one embodiment, the hematologic malignancy is leukemia. In another embodiment, the Fc region of the anti-CD117 antibody contains a D265C mutation (EU index). In yet another embodiment, the anti-CD117 antibody comprises a heavy chain variable region comprising CDR1 containing the amino acid sequence described in SEQ ID NO:7, CDR2 containing the amino acid sequence described in SEQ ID NO:8, and CDR3 containing the amino acid sequence described in SEQ ID NO:9; and comprises a light chain variable region comprising CDR1 containing the amino acid sequence described in SEQ ID NO:10, CDR2 containing the amino acid sequence described in SEQ ID NO:11, and CDR3 containing the amino acid sequence described in SEQ ID NO:12. In another embodiment, the anti-CD117 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising the amino acid sequence described in SEQ ID NO:13, and the light chain variable region comprising the amino acid sequence described in SEQ ID NO:14. In another embodiment, after administration to a patient, the ADC is internalized by cancer cells, autoimmune cells, or hematopoietic stem cells. In another embodiment, Am-LZ is represented by formula (I).

[0104]

[0105] Where R1 is H, OH, OR A OR C R2 is H, OH, OR B OR C ;R A and R B When present, they combine with the oxygen atoms they are bonded to to form optionally substituted 5-membered heterocyclic alkyl groups; R3 is H, R C Or R D R4, R5, R6, and R7 are each independently H, OH, and OR. C OR D R C Or R D R8 represents OH, NH2, and OR. C OR D NHRC or NR C R D R9 represents H, OH, and OR. C OR D x is -S-, -S(O-) or -SO2-; R C Yes - LZ; R D Optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 ynyl, optionally substituted C2-C6 heteroyynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; L is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C2-C6 alkenyl, or optionally substituted alkylene. The C2-C6 heteroene group, optionally substituted C2-C6 ynynyl group, optionally substituted C2-C6 heteroynyl group, optionally substituted cycloalkylene group, optionally substituted heterocycloalkylene group, optionally substituted arylene group, optionally substituted heteroarylene group, dipeptide, -(C=O)-, disulfide, peptide, or combinations thereof; and Z is a chemical moiety formed by the coupling reaction between a reactive substituent present on L and a reactive substituent present in an antibody or its antigen-binding fragment, wherein Am specifically contains an R C Substituents. In another embodiment, Am-LZ is represented by formula (IB).

[0106]

[0107] Where R1 is H, OH, OR A OR C R2 is H, OH, OR B OR C ;R A and R B When present, they combine with the oxygen atoms they are bonded to to form optionally substituted 5-membered heterocyclic alkyl groups; R3 is H, R C Or R D R4, R5, R6, and R7 are each independently H, OH, and OR. C OR D R C Or R D R8 represents OH, NH2, and OR. C OR D NHR C or NR C R D R9 represents H, OH, and OR. C OR Dx is -S-, -S(O-) or -SO2-; R C Yes - LZ; R D Optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 ynyl, optionally substituted C2-C6 heteroyneyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; L is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, optionally substituted C2-C6 alkenyl. Optionally substituted C2-C6 heteroeneyl, optionally substituted C2-C6 ynynyl, optionally substituted C2-C6 heteroynyl, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, optionally substituted heteroarylene, dipeptide, -(C=O)-, disulfide, peptide, or combinations thereof; and Z is a chemical moiety formed by the coupling reaction between a reactive substituent present on L and a reactive substituent present in an antibody or its antigen-binding fragment, wherein Am specifically contains an R C Substituents. In another embodiment, the ADC is administered to a human patient at a dose of about 0.1 mg / kg to about 0.3 mg / kg. Attached Figure Description

[0108] Figure 1A-1E The results of a standard biolayer interferometry (BLI) assay are depicted graphically to assess the binding response of antibodies with the indicated amino acid substitutions to the Fcγ receptor shown in the legend. Normalized binding responses of each anti-CD117 antibody variant relative to WT IgG1 binding are shown in the figure. Figure 1A In, and the quantification of the normalized binding response for each anti-CD117 antibody variant is shown in Figure 1B middle. Figure 1C The normalized binding response of antiCD45 antibody variants relative to WT antiCD45 antibody binding was described. Figure 1C (The term "ic" as used in this article refers to an interchain conjugate with natural hinge cysteine.) Normalized binding responses of other anti-CD117 antibody variants relative to WT IgG1 (isotype control) are shown in... Figure 1D In the figure, the normalized binding response quantification of each anti-CD117 antibody variant is shown in Figure 1E middle.

[0109] Figure 2The results of the mast cell degranulation assay are depicted graphically, with β-hexosaminease measured after mast cells were incubated with the antibody shown. β-hexosaminease released from mast cells was measured by monitoring p-nitrophenol produced from the 4-nitrophenyl N-acetyl-β-D-glucosinolate substrate, and the results are given as the absorbance of p-nitrophenol at 405 nm on the y-axis.

[0110] Figure 3A , 3B Figures 3C, 3D, and 3E depict the results of an in vitro cytokine release assay to measure IL-6 (3C) released from human peripheral blood mononuclear cells (PBMCs) after incubation with the antibody shown. Figure 3A ), IL-8 Figure 3B ), TNFα ( Figure 3C ), IL-1B Figure 3D ) and GM-CSF ( Figure 3E ). Figures 3A-3D The human PBMC is derived from one of four donors, as defined in the legend.

[0111] Figure 4A and 4B The results of an in vitro antibody-dependent phagocytosis (ADCP) assay are depicted graphically, showing reduced ADCP activity compared to the control due to Fc effector silencing in certain Fc variants. Figure 4A The results of flow cytometry analysis depicting the co-expression of CFSE and CD134 staining were presented. Figure 4B The results of incubating a mixture of MDM and Kasumi-1 cells (molar ratio 1:2) with increasing concentrations of the indicated antibody at 37°C for 2 hours are described.

[0112] Figure 5A , 5B Chromatograms of the results of the thermal stability assay were plotted at 5C, where the melting temperature of each antibody shown was evaluated.

[0113] Figure 6A and 6B It is a table that shows in Figure 5A (see Figure 6A )and Figure 5B and 5C (see Figure 6B The melting temperatures of Tm1 (CH2 fold) and Tm2 (fab / CH3 fold) for each antibody shown are determined in the thermal stability assay depicted in the figure.

[0114] Figure 7A and 7BChromatograms were plotted, showing the elution curves of antibodies after analysis by hydrophobic interaction chromatography (HIC) at room temperature for time = 0 (non-stress condition) or after incubation at 60°C for 30 minutes (stress condition). Figure 7A Chromatograms were plotted, showing the results after analysis by hydrophobic interaction chromatography (HIC) at room temperature at time = 0 (non-stress conditions); Figure 7A (The image below is a chromatogram) or after incubation at 60°C for 30 minutes (stress conditions); Figure 7A (The above figure is a chromatogram) Elution curves of Ab1 antibody and certain Ab1 Fc variants. Figure 7B Chromatograms were plotted, showing the elution curves of Ab2 antibody and certain Ab2 Fc variants after analysis by hydrophobic interaction chromatography (HIC) at room temperature for time = 0 (non-stress condition) or after incubation at 60°C for 30 minutes (stress condition).

[0115] Figures 8A-8E It is depicted in the form of a diagram. Figure 7A and 7B The results of the HIC assay show the antibody monomer (i.e., "major") peak after exposure to stress or non-stress conditions. Figure 8A and 8D ) or hydrophobic degradation peak ( Figure 8B , 8C The percentage of area (and 8E).

[0116] Figures 9A-9E The results of size exclusion chromatography are depicted graphically, which determines the percentage area of ​​the antibody monomer peak after exposure to room temperature for 0 minutes (non-stress condition) or incubation at 60°C for 30 minutes (stress condition). Figure 9A and 9D ) or percentage of polymer aggregate peaks ( Figure 9B , 9C and 9E).

[0117] Figure 10A and 10B The results of non-human primate drug pharmacokinetic assays are plotted graphically, expressed as the concentration (ng / mL) of genetically engineered fast half-life anti-CD117-amanita toxin ADC at different doses (0.1 mg / kg and 0.3 mg / kg) as the time of action (i.e., hours after administration; x-axis). Figure 10B This demonstrates that the timing of ADC-mediated depletion and clearance provides a window for post-application transplantation pretreatment.

[0118] Figure 11A-11E The use of flow cytometry is depicted in a graphical manner. Figure 11A and Figure 11C) Detection of depletion of phenotypic hematopoietic stem cells (i.e., CD34+CD90+CD45RA-HSC) or assessment of colony-forming units in bone marrow aspirate fluid ( Figure 11B and Figure 11D The results of the assay were presented as a function of different doses of the ADC1 antibody-drug conjugate (ADC) relative to the control (i.e., PBS) (x-axis). Figure 11C and 11D Data corresponding to the unconjugated anti-CD117 antibody (“anti-CD117”) are also shown. Figure 11E Phenotypic analysis of bone marrow hematopoietic stem cells (treated vs. untreated) using flow cytometry (day 7 after dose administration) is shown.

[0119] Figures 12A-12C The detection is depicted graphically. Figure 12A ) Neutrophil count (10 3 / mL) and ( Figure 12B and 12C Lymphocyte count (10) 3 The results of the determination of ( / mL) were presented as a function of the number of days following administration of different doses of ADC1 antibody-drug conjugate (ADC) (relative to the control (i.e., PBS)). Figure 12C Data on lymphocyte counts in cynomolgus monkeys corresponding to administration of unconjugated anti-CD117 antibody (“anti-CD117”) are also shown.

[0120] Figures 13A-13C The detection is depicted graphically. Figure 13A and 13C Plasma alanine aminotransferase (ALT; in U / mL) and ( Figure 13B The results of plasma bilirubin (in U / mL) levels were measured as a function of the number of days following administration of different doses of ADC1 antibody-drug conjugate (ADC) (relative to the control (i.e., PBS)). Figure 13C Data on plasma ALT levels in cynomolgus monkeys corresponding to administration of unconjugated anti-CD117 antibody (“anti-CD117”) are also presented.

[0121] Figure 14 Images of liver and kidney tissues isolated from cynomolgus monkeys 35 days after administration of ADC1 (0.3 mg / kg) or control (PBS) are shown.

[0122] Figure 15 The detection of reticular cell counts (10) is depicted graphically. 9 The results of the determination ( / mL) were presented as a function of the number of days following administration of different doses (0.1 mg / kg or 0.3 mg / kg) of the ADC1 antibody drug conjugate (relative to the control (i.e., PBS) or the unconjugated anti-CD117 antibody). Detailed Implementation

[0123] This article discloses antibodies and their conjugates (antibody-drug conjugates; ADCs) having modified Fc regions, wherein the modifications reduce or substantially eliminate antibody effector function. Modification of the Fc region can also allow antibody-drug conjugation and / or reduce the antibody's half-life. Interactions between antibodies and antibody-antigen complexes with immune system cells can influence a variety of responses, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Binding of the antibody's Fc region to Fc receptors on the cell surface can trigger numerous biological responses, including phagocytosis and disruption of antibody-coated particles, clearance of immune complexes, lysis of antibody-coated target cells via killer cells (i.e., ADCC), release of inflammatory mediators, placental transfer, and control of immunoglobulin production. By reducing or essentially eliminating antibody effector function, currently disclosed antibodies can, for example, advantageously avoid triggering multiple immune system responses that may be harmful in certain therapies (e.g., avoiding cytokine release or mast cell degranulation) and hematopoietic cell depletion (e.g., for the treatment of blood cancers, immune system diseases and conditions, autoimmune diseases, graft-versus-host disease, etc.).

[0124] Therefore, this document includes anti-hematopoietic cell antibodies (also known as anti-HC antibodies) having a modified Fc region that are useful in therapeutics. For example, the antibodies or ADCs described herein can be used in pretreatment procedures where a patient is prepared to receive a graft containing hematopoietic stem cells. Such procedures facilitate the implantation of hematopoietic stem cell grafts. According to the methods described herein, in some embodiments, a patient can be pretreated (e.g., for hematopoietic stem cell transplantation therapy or immune system reset) by administering an ADC, antibody, or antigen-binding fragment thereof to the patient, which is capable of binding to antigens expressed by hematopoietic cells (e.g., hematopoietic stem cells, such as hematopoietic stem cells and / or mature immune cells (e.g., T cells)), such as CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, CD252, and combinations thereof. In some embodiments, the antibodies or ADCs considered herein can be used to treat diseases or conditions of the hematopoietic system. For example, in some embodiments, the antibodies or ADCs considered herein can be used to treat blood cancers. In another non-limiting example, the antibodies or ADCs considered herein can be used to treat graft-versus-host disease (“GvHD”). In some implementations, the antibodies or ADCs considered herein can be used to treat T-cell-mediated diseases or conditions. As described herein, antibodies can covalently bind to cytotoxins to form antibody-drug conjugates (ADCs). Administration of ADCs, antibodies, or antigen-binding fragments thereof capable of binding to one or more of the aforementioned antigens to patients requiring hematopoietic stem cell transplantation therapy can facilitate the engraftment of hematopoietic stem cell transplants, for example, by selectively depleting endogenous hematopoietic stem cells, thereby creating vacancies to be filled by exogenous hematopoietic stem cell transplants.

[0125] In one particular aspect, the present invention provides isolated anti-CD117 antibodies, particularly isolated human anti-CD117 antibodies, which bind to the extracellular domain of human CD117, wherein the isolated anti-CD117 antibody has a modified Fc region, wherein the modification reduces or substantially eliminates the antibody effector function. The binding regions of the isolated anti-CD117 antibodies identified herein are described below.

[0126] The following sections describe antibodies or conjugates thereof that can be administered to patients, such as those suffering from cancer or autoimmune diseases, or those requiring hematopoietic stem cell transplantation therapy to facilitate the implantation of hematopoietic stem cell grafts, and provide methods for administering such therapy to patients (e.g., prior to hematopoietic stem cell transplantation).

[0127] definition

[0128] As used herein, the term “about” means a value that is within 5% above or below the stated value.

[0129] As used herein, the term "heterogeneous," when used in the context of transplantation, defines a cell (or tissue or organ) that is transplanted from a donor to a recipient of the same species but is genetically different. Thus, the term "heterogeneous cell" refers to a genetically different cell type between two individuals belonging to the same species, such as humans. More commonly, the term "heterogeneous" is used to define cells that are transplanted from a donor to an unrelated recipient of the same species, such as stem cells.

[0130] As used in this article, the term "autologous" refers to a cell or graft from the same subject in which the donor and recipient are the same individual.

[0131] As used in this article, the term "heterogeneous" refers to cells in which the donor and recipient species are different.

[0132] As used herein, the term "immune cell" refers to cells of hematopoietic origin that play a role in the immune response, including but not limited to. Immune cells include, but are not limited to, T cells and natural killer (NK) cells. In one embodiment, natural killer cells include cell lines such as NK-92 cells. Other examples of NK cell lines include NKG, YT, NK-YS, HANK-1, YTS cells, and NKL cells. Immune cells can be heterologous or autologous.

[0133] As used herein, the term "antibody" refers to an immunoglobulin molecule that specifically binds to or responds to a particular antigen. Antibodies include, but are not limited to, monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), genetically engineered antibodies, and other modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugated antibodies (e.g., bispecific, trispecific, and tetraspecific antibodies, biantibodies, triantibodies, and tetraantibodies), and antibody fragments (i.e., antigen-binding fragments of antibodies), including, for example, Fab', F(ab')2, Fab, Fv, rlgG, and scFv fragments, provided they exhibit the desired antigen-binding activity.

[0134] The antibodies disclosed herein are typically isolated or recombinant. "Isolated," as used herein, refers to a polypeptide, such as an antibody, that has been identified, isolated, and / or recovered from cells or cell cultures expressing it. Typically, isolated antibodies are prepared through at least one purification step. Therefore, "isolated antibody" means an antibody that is substantially free of other antibodies with different antigen specificities. For example, an isolated antibody that specifically binds to CD117 is substantially free of antibodies that specifically bind to antigens other than CD117.

[0135] As used herein, the term "monoclonal antibody" refers to an antibody derived from a single clone (including any eukaryotic, prokaryotic, or phage clone) by any method available or known in the art, and is not limited to antibodies produced by hybridoma technology. Monoclonal antibodies that can be used in this disclosure can be prepared using a wide variety of techniques known in the art, including hybridoma, recombinant, and phage display technologies, or combinations thereof. Unless otherwise stated, the term "monoclonal antibody" (mAb) means comprising the complete molecule and an antibody fragment (including, for example, Fab and F(ab')2 fragments) capable of specifically binding to a target protein. As used herein, Fab and F(ab')2 fragments refer to antibody fragments lacking the complete Fc fragment of the antibody. In one embodiment, the antibody fragment comprises an Fc region.

[0136] Typically, antibodies consist of a heavy chain and a light chain containing antigen-binding regions. Each heavy chain comprises a heavy chain variable region (abbreviated as HCVR or VH in this document) and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain comprises a light chain variable region (abbreviated as LCVR or VL in this document) and a light chain constant region. The light chain constant region consists of one domain, CL. The VH and VL regions can be further subdivided into highly variable regions called complementarity-determining regions, which are separated by more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen. The constant regions of antibodies can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.

[0137] As used herein, the term "antigen-binding fragment" refers to one or more portions of an antibody that retain the ability to specifically bind to a target antigen. The antigen-binding function of an antibody can be achieved through fragments of a full-length antibody. Antibody fragments can be, for example, Fab, F(ab')2, single-chain antibodies, biantibodies, triantibodies, antibody conjugates, nanobodies, aptamers, or domain antibodies. Examples of binding fragments covered by the term "antigen-binding fragment" of an antibody include, but are not limited to: (i) Fab fragments, monovalent fragments consisting of VL, VH, CL, and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments containing two Fab fragments linked by disulfide bonds in the hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of VL and VH domains of an antibody arm; (v) dAbs including VH and VL domains; (vi) dAb fragments consisting of VH domains (see, for example, Ward et al., Nature 341:544-546, 1989); (vii) dAbs consisting of VH or VL domains; (viii) separate complementarity-determining regions (CDRs); and (ix) combinations of two or more (e.g., two, three, four, five, or six) separate CDRs, which may optionally be linked by synthetic linkers. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by independent genes, they can be linked using recombination methods via adapters to form a single protein chain, where the VL and VH regions pair to form a monovalent molecule (called a single-stranded Fv (scFv); see, for example, Bird et al., Science 242:423-426, 1988 and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988). These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and the applicability of the fragments can be screened in the same manner as for intact antibodies. Antigen-binding fragments can be generated by recombinant DNA technology, enzymatic or chemical cleavage of intact immunoglobulins, or, in some cases, by chemical peptide synthesis procedures known in the art. In one embodiment, the antigen-binding fragment of the antibody comprises an Fc region.

[0138] As used herein, the term "anti-CD117 antibody" or "CD117-binding antibody" refers to an antibody that can bind to CD117 with sufficient affinity, such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD117.

[0139] As used herein, the term "anti-CD45 antibody" or "CD45-binding antibody" refers to an antibody that can bind to CD45 with sufficient affinity, such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD45.

[0140] As used herein, the terms “anti-CD2 antibody” or “CD2-binding antibody” or “anti-CD2 ADC” or “CD2-binding ADC” refer to antibodies or ADCs that specifically bind to human CD2 when CD2 is found on the surface of cells such as T cells.

[0141] As used herein, the terms “anti-CD5 antibody” or “CD5-binding antibody” or “anti-CD5 ADC” or “CD5-binding ADC” refer to antibodies or ADCs that specifically bind to human CD5 when CD5 is found on the surface of cells such as T cells.

[0142] As used herein, the term "anti-CD137 antibody" or "CD137-binding antibody" refers to an antibody that can bind to CD137 with sufficient affinity, such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD137.

[0143] As used herein, the term "anti-CD252 antibody" or "CD252-binding antibody" refers to an antibody capable of binding to CD252 with sufficient affinity, such that the antibody can be used as a diagnostic and / or therapeutic agent targeting CD252. In a preferred embodiment, the antibody specifically binds to human CD252 (hCD252). CD252 is present on antigen-presenting cells.

[0144] As used herein, the term "bispecific antibody" refers to, for example, a monoclonal antibody, such as a human or humanized antibody, that can bind to at least two different antigens or two different epitopes. For example, one binding specificity may target an epitope on the hematopoietic stem cell surface antigen CD117 (e.g., GNNK+CD117), and the other may specifically bind to an epitope on a different hematopoietic stem cell surface antigen or another cell surface protein, such as a receptor or receptor subunit involved in signal transduction pathways that enhance cell growth. In some embodiments, the binding specificity may target unique, non-overlapping epitopes on the same target antigen (i.e., a bispecific antibody).

[0145] As used herein, a “full-length” or “complete” antibody refers to an antibody having two heavy chain (H) polypeptides and two light chain (L) polypeptides interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated as HCVR or VH in this document) and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (abbreviated as LCVR or VL in this document) and a light chain constant region. The light chain constant region consists of one domain CL. The VH and VL regions can be further subdivided into highly variable regions called complementarity-determining regions, which are separated by more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (such as effector cells) and the first component (Clq) of the classical complement system.

[0146] As used herein, the term "complementarity-determining region" (CDR) refers to a highly variable region found in the variable regions of the light and heavy chains of an antibody. More conserved portions of the variable domain are called framework regions (FRs). The amino acid positions describing the highly variable regions of an antibody can vary depending on the context and various definitions known in the art. Some positions within a variable domain can be considered hybridization highly variable positions because, under one set of criteria, these positions can be considered within the highly variable region, while under another set of criteria, they can be considered outside the highly variable region. One or more of these positions can also be found in extended highly variable regions. The antibodies described herein may contain modifications at these hybridization highly variable positions. The variable domains of the natural heavy and light chains each contain four framework regions, predominantly in a β-sheet configuration, linked by three CDRs to form a loop connecting the β-sheet structure, and in some cases, to form part of the β-sheet structure. In each chain, the CDRs are tightly held together by the frame regions in the sequence FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, and together with the CDRs from other antibody chains, they contribute to the formation of antibody target binding sites (see Kabat et al., Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, MD., 1987). In some embodiments, unless otherwise stated, the immunoglobulin amino acid residues are numbered according to the immunoglobulin amino acid residue numbering system of Kabat et al. (although any antibody numbering scheme may be used, including but not limited to IMGT and Chothia).

[0147] As used herein, the term "heat stress" refers to the stress exerted on a molecule (e.g., an antibody, its Fc-containing antigen-binding fragment, or an ADC) by any change in temperature. In one embodiment, heat stress is the incubation of an antibody, its Fc-containing antigen-binding fragment, or an ADC at 60°C for 30 minutes.

[0148] As used herein, the term "specific binding" refers to the ability of an antibody (or ADC) to recognize and bind to a specific protein structure (epitope) rather than a protein in general. If an antibody is specific for epitope "A", in a reaction containing labeled "A" and an antibody, the presence of a molecule containing epitope A (or free, unlabeled A) reduces the amount of labeled A bound to the antibody. By way of example, an antibody "specifically binds" to a target if, when labeled, it can compete with a corresponding unlabeled antibody for its target. In one embodiment, an antibody specifically binds to a target, such as an antigen expressed by hematopoietic stem cells, such as CD117 (e.g., GNNK+CD117) or CD45, or an antigen expressed by mature immune cells (e.g., T cells), such as CD45, CD2, CD5, CD137, or CD252, if the antibody is specific for the target K D For at least about 10 -4 M, 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M or smaller (smaller means less than 10) -12 Numbers, such as 10 -13 In one implementation, the term "specific binding" refers to the antibody binding at a rate of at least about 1 x 10⁻⁶. -6 M, 1x10 -7 M, 1x10 -8 M, 1x10 - 9 M, 1x10 -10 M, 1x10 -11 M, 1x10 -12 M or larger K d The ability to bind antigens and / or bind antigens with an affinity at least twice that of nonspecific antigens. In one embodiment, K is determined according to standard biological layer interferometry (BLI). DHowever, it should be understood that antibodies may be able to specifically bind to two or more sequence-related antigens. For example, in one embodiment, an antibody may specifically bind to human and non-human (e.g., mouse or non-human primate) orthologs of the antigen, such as CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, or CD252.

[0149] As used herein, the term "chimeric" antibody refers to an antibody having a variable sequence derived from a non-human immunoglobulin (e.g., a rat or mouse antibody) and a constant region of a human immunoglobulin (typically selected from a human immunoglobulin template). Methods for generating chimeric antibodies are known in the art. See, for example, Morrison, 1985, Science 229(4719):1202-7; Oi et al., 1986, BioTechniques 4:214-221; Gillies et al., 1985, J. Immunol. Methods 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397.

[0150] As used herein, the terms “Fc,” “Fc region,” “Fc domain,” and “IgG Fc domain” refer to a portion of an immunoglobulin, such as an IgG molecule, associated with the crystallizable fragment obtained by digestion of an IgG molecule with papain. An Fc region comprises the C-terminal half of two IgG molecule heavy chains linked by disulfide bonds. It lacks antigen-binding activity but contains carbohydrate portions and binding sites for complement and Fc receptors, including the FcRn receptor (see below). For example, an Fc domain comprises a second constant domain CH2 (e.g., residues at EU positions 231–340 of human IgG1) and a third constant domain CH3 (e.g., residues at EU positions 341–447 of human IgG1). As used herein, an Fc domain comprises a “lower hinge region” (e.g., residues at EU positions 233–239 of IgG1).

[0151] Fc can refer to the region alone or in the context of an antibody, antibody fragment, or Fc fusion protein. Polymorphism has been observed at multiple locations of the Fc domain, including but not limited to EU positions 270, 272, 312, 315, 356, and 358, and therefore minor differences may exist between the sequences presented in this application and sequences known in the art. Thus, “wild-type IgG Fc domain” or “WT IgG Fc domain” refers to any naturally occurring IgG Fc region (i.e., any allele). The heavy chain sequences of human IgG1, IgG2, IgG3, and IgG4 can be found in many sequence databases, for example, in the Uniprot database (www.uniprot.org) under accessions P01857 (IGHG1_HUMAN), P01859 (IGHG2_HUMAN), P01860 (IGHG3_HUMAN), and P01861 (IGHG1_HUMAN), respectively. An instance of a “WT” Fc region is provided in SEQ ID NO:15 (which provides a heavy chain constant region containing the Fc region).

[0152] As used herein, the term "modified Fc region" or "variant Fc region" refers to an IgG Fc region containing one or more amino acid substitutions, deletions, insertions, or modifications introduced at any position within the Fc region. In some respects, variant IgG Fc domains containing one or more amino acid substitutions result in reduced or absent binding affinity for FcγR and / or C1q compared to wild-type Fc domains that do not contain one or more amino acid substitutions. Furthermore, Fc binding interactions are essential for a variety of effector functions and downstream signaling events, including but not limited to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Therefore, in some respects, antibodies containing variant Fc domains (e.g., antibodies, fusion proteins, or conjugates) may exhibit altered binding affinity for at least one or more Fc ligands (e.g., FcγR) relative to corresponding antibodies having the same amino acid sequence but not containing one or more amino acid substitutions, deletions, insertions, or modifications, such as unmodified Fc regions containing naturally occurring amino acid residues at corresponding positions within the Fc region.

[0153] The variant Fc domains described herein are defined based on the amino acid modifications that compose them. For all amino acid substitutions in the Fc region discussed herein, the numbering is always based on the EU index, as in Kabat. Thus, for example, D265C is an Fc variant in which the aspartic acid (D) at EU position 265 is substituted with cysteine ​​(C) relative to the parental Fc domain. Similarly, for example, D265C / L234A / L235A defines a variant Fc variant with substitutions at EU positions 265 (D to C), 234 (L to A), and 235 (L to A) relative to the parental Fc domain. Variants can also be designated based on their final amino acid composition at the mutated EU amino acid positions. For example, the L234A, L235A mutant could be called "LALA". As another example, the E233P, L234V, L235A, delG236 (deleted 236) mutant could be called "EPLVLAdelG". As yet another example, the I253A, H310A, and H435A mutants can be referred to as "IHH". Note that the order of substitution provided is arbitrary.

[0154] As used herein, the term “Fcγ receptor” or “FcγR” refers to any member of a family of proteins that bind to the Fc region of an IgG antibody and are encoded by the FcγR gene. In humans, this family includes, but is not limited to, FcγRI (CD64), including isotypes FcγRIa, FcγRIb, and FcγRIc; fcγRII (CD32), including isotypes FcγRIIa (including allotypes H131 and R131), FcγRIIb (including FcγRIIb-1 and FcγRIIb-2), and FcγRIIc; and FcγRIII (CD16), including isotypes FcγRIIIa (including allotypes V158 and F158) and FcγRIIIb (including allotypes FcγRIIIb-NA1 and FcγRIIIb-NA2), as well as any undiscovered human FcγRs or FcγR isotypes or allotypes. FcγRs can originate from any organism, including but not limited to humans, mice, rats, rabbits, and monkeys. Mouse FcγRs include, but are not limited to, FcγRI(CD64), FcγRII(CD32), FcγRIII(CD16), and FcγRIII-2(CD16-2), as well as any undiscovered mouse FcγRs or FcγR allotypes or allotypes.

[0155] As used herein, the term "effective function" refers to a biochemical event resulting from the interaction of the Fc domain with the Fc receptor. Effector functions include, but are not limited to, ADCC, ADCP, and CDC. As used herein, "effective cell" means a cell in the immune system that expresses one or more Fc receptors and mediates one or more effector functions. Effector cells include, but are not limited to, monocytes, macrophages, neutrophils, dendritic cells, eosinophils, mast cells, platelets, B cells, large granular lymphocytes, Langerhans cells, natural killer (NK) cells, and γδT cells, and can be derived from any organism, including, but not limited to, humans, mice, rats, rabbits, and monkeys.

[0156] As used herein, the term "silent" ("silenced" or "silencing") refers to an antibody having the modified Fc region described herein, whose binding to the Fcγ receptor (FcγR) is reduced (e.g., as measured by, for example, BLI, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% reduction in binding to the FcγR compared to the binding of the same antibody containing the unmodified Fc region). In some embodiments, the Fc-silenced antibody has no detectable binding to the FcγR. The binding of antibodies with modified Fc regions to FcγR can be determined using a variety of techniques known in the art, such as, but not limited to, equilibration methods (e.g., enzyme-linked immunosorbent assay (ELISA); KinExA, Rathanaswami et al. Analytical Biochemistry, Vol. 373: 52-60, 2008; or radioimmunoassay (RIA)), or kinetic-based assays via surface plasmon resonance assays or other mechanisms (e.g., BIACORE RTM assays or Otecte RTM assays (forteBIO)), and other methods such as indirect binding assays, competitive binding assays, fluorescence resonance energy transfer (FRET), gel electrophoresis, and chromatography (e.g., gel filtration). These and other methods can utilize labeling on one or more components being examined and / or employ multiple detection methods, including but not limited to colorimetric, fluorescent, luminescent, or isotopic labeling. A detailed description of binding affinity and kinetics can be found in Paul, WE, ed., Fundamental Immunology, 4th ed., Lippincott-Raven, Philadelphia (1999) (which focuses on antibody-immunogen interactions). An example of competitive binding assays is radioimmunoassay, which involves incubating a labeled antigen with a target antibody in the presence of incrementally added unlabeled antigens and detecting the antibody that binds to the labeled antigen. The affinity of the target antibody for a specific antigen and the rate of binding deviation can be determined from the data using scatchard plot analysis. Competition with a secondary antibody can also be determined using radioimmunoassay. In this case, the antigen is incubated with a target antibody conjugated to a labeled compound in the presence of incrementally added unlabeled secondary antibody.

[0157] As used herein, the term "identical antibody containing an unmodified Fc region" refers to an antibody that lacks the said amino acid substitutions (e.g., D265C, L234A, L235A and / or H435A), but otherwise has the same amino acid sequence as the Fc-modified antibody to which it is compared.

[0158] The term "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which a polypeptide containing an Fc domain (e.g., an antibody) binds to an Fc receptor (FcR) present on certain cytotoxic cells (e.g., primarily NK cells, neutrophils, and macrophages), causing these cytotoxic effector cells to specifically bind to "target cells" carrying antigens, and subsequently kill the target cells with cytotoxins (Hogarth et al., Nature review DrugDiscovery 2012, 11:313). It is anticipated that other polypeptides containing an Fc domain, such as Fc fusion proteins and Fc conjugate proteins, with the ability to specifically bind to target cells carrying antigens, besides antibodies and their fragments, could enable cell-mediated cytotoxicity.

[0159] For simplicity, cell-mediated cytotoxicity resulting from the activity of peptides containing Fc domains is also referred to herein as ADCC activity. The ability of any specific peptide of this disclosure to mediate ADCC lysis of target cells can be tested. To assess ADCC activity, a target peptide (e.g., an antibody) is combined with immune effector cells and added to target cells, resulting in cell lysis of the target cells. Cell lysis is typically detected by releasing a marker (e.g., a radioactive substrate, a fluorescent dye, or a native intracellular protein) from the lysed cells. Effector cells used for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Specific examples of in vitro ADCC assays are described in Bruggemann et al., J. Exp. Med. 166:1351 (1987); Wilkinson et al., J. Immunol. Methods 258:183 (2001); Patel et al., J. Immunol. Methods 184:29 (1995). Alternatively or otherwise, the ADCC activity of the target antibody can be evaluated in vivo, for example, in animal models, as disclosed in Clynes et al., Proc. Natl. Acad. Sci. USA 95:652 (1998).

[0160] As used herein, the terms “condition” and “conditioning” refer to the process by which a patient is prepared to receive a transplant, such as a graft containing hematopoietic stem cells. Such procedures facilitate the engraftment of hematopoietic stem cell grafts (e.g., inferred from a sustained increase in the number of viable hematopoietic stem cells in blood samples isolated from the patient after the conditionation procedure and subsequent hematopoietic stem cell transplantation). According to the methods described herein, patients can be pretreated for hematopoietic stem cell transplantation therapy by administering an ADC, antibody, or antigen-binding fragment thereof capable of binding antigens expressed by hematopoietic stem cells (e.g., CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, or CD252). As described herein, antibodies can be covalently conjugated with cytotoxins to form ADCs. Administering an antibody, antigen-binding fragment thereof, or ADC capable of binding one or more of the aforementioned antigens to patients requiring hematopoietic stem cell transplantation therapy can facilitate the engraftment of hematopoietic stem cell grafts, for example, by selectively depleting endogenous hematopoietic stem cells, thereby creating a vacancy to be filled by an exogenous hematopoietic stem cell graft.

[0161] As used in this article, the term "effective amount" or "therapeutic effective amount" refers to an amount sufficient to achieve the desired outcome or to be effective against autoimmune diseases or cancer.

[0162] As used herein, the term "half-life" refers to the time required for the plasma concentration of an antibody drug in the body to decrease by half or 50%. A 50% decrease in serum concentration reflects the amount of drug circulating.

[0163] As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced through random or site-specific mutations in vitro, during gene rearrangement, or through somatic mutations in vivo). However, as used herein, the term "human antibody" is not intended to include antibodies in which a CDR sequence derived from another mammalian species (e.g., mouse) has been transplanted into a human frame sequence. Human antibodies can be produced in human cells (e.g., through recombinant expression) or by non-human animal or prokaryotic or eukaryotic cells capable of expressing functionally rearranged human immunoglobulin (e.g., heavy chain and / or light chain) genes. When a human antibody is a single-chain antibody, it may include adaptor peptides not present in naturally occurring human antibodies. For example, an Fv may contain adaptor peptides linking the heavy chain variable region and the light chain variable region, such as 2 to approximately 8 glycine or other amino acid residues. Such adaptor peptides are considered to be of human origin. Human antibodies can be prepared by a variety of methods known in the art, including phage display methods using antibody libraries derived from human immunoglobulin sequences. Human antibodies can also be generated using transgenic mice that do not express functional endogenous immunoglobulins but can express human immunoglobulin genes (see, for example, PCT Publications WO1998 / 24893; WO1992 / 01047; WO1996 / 34096; WO1996 / 33735; U.S. Patents 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598).

[0164] A “humanized” form of a non-human (e.g., mouse) antibody is a chimeric immunoglobulin that contains a minimal sequence derived from a non-human immunoglobulin. Typically, a humanized antibody contains substantially all of at least one (usually two) variable domains, wherein all or substantially all of the CDR regions correspond to those of the non-human immunoglobulin, and all or substantially all of the FR regions are those of the human immunoglobulin sequence. Humanized antibodies may also contain at least a portion of the immunoglobulin constant region (Fc), typically a portion of the common sequence of human immunoglobulins. Methods for antibody humanization are known in the art. See, for example, Riechmann et al., 1988, Nature 332:323-7; U.S. Patent Nos. 5,530,101, 5,585,089, 5,693,761, 5,693,762, and 6,180,370 to Queen et al.; EP239400; PCT Publication WO 91 / 09967; U.S. Patent Nos. 5,225,539, EP592106, EP519596; Padlan, 1991, Mol. Immunol., 28:489-498; Studnicka et al., 1994, Prot. Eng. 7:805-814; Roguska et al., 1994, Proc. Natl. Acad. Sci. 91:969-973; and U.S. Patent No. 5,565,332.

[0165] As used herein, the term "engrafting potential" refers to the ability of hematopoietic stem cells and progenitor cells to re-enter tissue, whether such cells are naturally circulating or provided by transplantation. The term encompasses all events surrounding or leading to engraftment, such as tissue homing and colonization of cells within the target tissue. Engrafting efficiency or engraftment rate can be evaluated or quantified using any clinically acceptable parameters known to those skilled in the art and may include, for example, assessment of competitive re-implantation units (CRUs); incorporation or expression of markers in tissues where stem cells have been homegrown, colonized, or transplanted; or assessment of subject progression by disease progression, survival of hematopoietic stem cells and progenitor cells, or survival of the recipient. Engraftment can also be determined by measuring the white blood cell count in peripheral blood during the post-transplantation period. Engraftment can also be assessed by measuring the bone marrow cell recovery rate of donor cells in bone marrow aspirate samples.

[0166] As used herein, the term "hematopoietic stem cell" ("HSC") refers to immature blood cells capable of self-renewal and differentiation into mature blood cells, which comprise various lineages, including but not limited to granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), coagulation cells (e.g., megakaryocytes, platelet-producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B cells, and T cells). Such cells may include CD34+ cells. CD34+ cells are immature cells expressing the CD34 cell surface marker. In humans, CD34+ cells are considered to include a subset of cells possessing the stem cell characteristics defined above, while in mice, HSCs are CD34-. Furthermore, HSC also refers to long-term replantable HSCs (LT-HSCs) and short-term replantable HSCs (ST-HSCs). LT-HSCs and ST-HSCs differ based on their functional potential and expression of cell surface markers. For example, human HSCs are CD34+, CD38-, CD45RA-, CD90+, CD49F+, and lin- (negative for maturation lineage markers including CD2, CD3, CD4, CD7, CD8, CD10, CD11B, CD19, CD20, CD56, and CD235A). In mice, bone marrow LT-HSCs were CD34-, SCA-1+, C-kit+, CD135-, Slamfl / CD150+, CD48-, and lin- (negative for maturation lineage markers including Ter119, CD11b, Gr1, CD3, CD4, CD8, B220, and IL7ra), while ST-HSCs were also CD34+, SCA-1+, C-kit+, CD135-, Slamfl / CD150+, and lin- (negative for maturation lineage markers including Ter11, CD11b, Gr1, CD3, CD4, CD8, B220, and IL7ra). Furthermore, under homeostatic conditions, ST-HSCs were less quiescent and more proliferative than LT-HSCs. However, LT-HSCs have a greater self-renewal potential (i.e., they survive throughout adulthood and can be continuously transplanted through successive recipients), while ST-HSCs have limited self-renewal (i.e., they survive only for a limited time and do not have the potential for continuous transplantation). Either of these HSCs can be used in the methods described herein. ST-HSCs are particularly useful because they are highly proliferative and therefore can produce differentiated offspring more quickly.

[0167] As used herein, the term “anti-hematopoietic cell antibody” or “anti-HC antibody” refers to an antibody that specifically binds to antigens expressed by hematopoietic stem cells, such as CD117 (e.g., GNNK+CD117) or CD45; or antigens expressed by mature immune cells (e.g., T cells), such as CD45, CD2, CD5, CD137, or CD252.

[0168] As used herein, the term “functional potential of hematopoietic stem cells” refers to the functional characteristics of hematopoietic stem cells, including 1) pluripotency (which refers to the ability of hematopoietic stem cells to differentiate into multiple different lineages, including but not limited to granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), coagulating cells (e.g., megakaryocytes, platelet-producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B cells, and T cells), 2) self-renewal (which refers to the ability of hematopoietic stem cells to produce daughter cells that have the same potential as the parent cells, and this ability can be repeated throughout an individual’s lifespan without depletion), and 3) the ability of hematopoietic stem cells or their progeny to be reintroduced into a transplant recipient, where they return to the hematopoietic stem cell niche and restore productivity and continuous hematopoiesis.

[0169] As used herein, the terms “subject” and “patient” refer to an organism, such as a human being, that receives treatment for the specific disease or condition described herein. For example, a patient, such as a human patient, may receive treatment prior to hematopoietic stem cell transplantation therapy to facilitate the engraftment of exogenous hematopoietic stem cells.

[0170] As used herein, the term "donor" refers to a person or animal from which one or more types of cells are isolated prior to the administration of the cells or their progeny to a recipient. One or more types of cells may be, for example, a population of hematopoietic stem cells.

[0171] As used herein, the term "double-chain antibody" refers to a bivalent antibody containing two polypeptide chains, each of which contains V proteins linked by a linker (e.g., a linker consisting of five amino acids). H and V L The structural domain, the joint is too short to allow V to... H and V L The domains associate intramolecularly on the same peptide chain. This configuration forces each domain to pair with a complementary domain on another peptide chain, thus forming a homodimeric structure. Therefore, the term "trivalent antibody" refers to a trivalent antibody containing three peptide chains, each of which contains a V-type peptide linked by a linker. H A structural domain and a V L The linker has a structural domain that is extremely short (e.g., a linker consisting of 1-2 amino acids) to allow V within the same peptide chain.H and V L Intramolecular association of structural domains. Peptides configured in this way typically trimerize to fold into their native structures, causing the Vo of adjacent peptide chains to... H and V L The domains are spatially close to each other (see, for example, Holliger et al., Proc. Natl. Acad. Sci. USA 90:6444-48, 1993).

[0172] As used herein, the term "endogenous" describes substances, such as molecules, cells, tissues, or organs (e.g., hematopoietic stem cells or hematopoietic lineage cells, such as megakaryocytes, coagulating cells, platelets, erythrocytes, mast cells, medulloblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, or B lymphocytes), that are naturally present in a particular organism (e.g., a human patient).

[0173] As used herein, the term "recipient" refers to a patient receiving a transplant, such as a graft containing a population of hematopoietic stem cells. The transplanted cells administered to the recipient can be, for example, autologous, syngeneic, or xenologous cells.

[0174] As used herein, the term “sample” refers to a sample taken from a subject (e.g., blood, blood components (e.g., serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g., placenta or skin), pancreatic juice, chorionic villus sampling, and cells).

[0175] As used herein, the term "scFv" refers to a single-chain Fv antibody in which the variable domains of the antibody's heavy and light chains are linked together to form a single chain. An scFv fragment comprises a single polypeptide chain containing variable regions (V regions) of the antibody light chain separated by linkers. L (e.g., CDR-L1, CDR-L2 and / or CDR-L3) and antibody heavy chain variable regions (V H (e.g., CDR-H1, CDR-H2, and / or CDR-H3). Connect the V segments of the scFv file. L and V HThe linkers in the regions can be peptide linkers composed of amino acids from the proteoglycan. Alternative linkers can be used to increase the resistance of scFv fragments to proteolytic degradation (e.g., linkers containing D-amino acids), enhance the solubility of scFv fragments (e.g., hydrophilic linkers such as linkers containing polyethylene glycol or polypeptides containing repeating glycine and serine residues), improve the biophysical stability of the molecule (e.g., linkers containing cysteine ​​residues that form intramolecular or intermolecular disulfide bonds), or reduce the immunogenicity of scFv fragments (e.g., linkers containing glycosylation sites). Those skilled in the art will also understand that the variable regions of the scFv molecules described herein can be modified so that they differ in amino acid sequence from those of the antibody molecules from which they originate. For example, nucleotide or amino acid substitutions that result in conserved substitutions or alterations at amino acid residues (e.g., in CDRs and / or framework residues) can be made to maintain or enhance the ability of the scFv to bind to the antigen recognized by the corresponding antibody.

[0176] As used herein, the phrase "substantially cleared from the blood" refers to the time point after administration of a therapeutic agent (e.g., an anti-CD117 antibody or its antigen-binding fragment) to a patient when the concentration of the therapeutic agent in a blood sample separated from the patient is such that the therapeutic agent is undetectable by conventional means (e.g., such that the therapeutic agent is undetectable above the noise threshold of the device or assay used to detect the therapeutic agent). Various techniques known in the art can be used to detect antibodies, antibody fragments, and protein ligands, such as ELISA-based assays known in the art or described herein. Other assays that can be used to detect antibodies or antibody fragments include immunoprecipitation techniques and immunoblotting assays, as well as other assays known in the art.

[0177] As used in this article, the term "transfection" refers to any of the various techniques commonly used to introduce exogenous DNA into prokaryotic or eukaryotic host cells, such as electroporation, lipid transfection, calcium phosphate precipitation, DEAE-glucan transfection, etc.

[0178] As used herein, “treatment” means reducing the severity and / or frequency of disease symptoms, eliminating disease symptoms and / or the underlying cause of said symptoms, reducing the frequency or likelihood of disease symptoms and / or their underlying cause, and improving or remedying harm directly or indirectly caused by the disease, any improvement in any consequence of the disease, such as prolonging survival, reducing morbidity, and / or mitigating side effects as a byproduct of alternative treatments; as readily understood in the art, complete eradication of the disease is preferred but not required for treatment. Beneficial or desired clinical outcomes include, but are not limited to, promoting the engraftment of exogenous hematopoietic cells in a patient following antibody pretreatment therapy and subsequent hematopoietic stem cell transplantation therapy as described herein. Additional beneficial outcomes include an increase in the cell count or relative concentration of hematopoietic stem cells in patients requiring hematopoietic stem cell transplantation following pretreatment therapy and subsequent administration of an exogenous hematopoietic stem cell graft. Beneficial outcomes of the therapies described herein may also include an increase in the cell count or relative concentration of one or more cell types of hematopoietic lineages, such as megakaryocytes, coagulating cells, platelets, erythrocytes, mast cells, myeloid cells, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, or B lymphocytes, following pretreatment and subsequent hematopoietic stem cell transplantation. Additional beneficial outcomes may include a reduction in the number of pathogenic cell populations, such as cancer cell populations (e.g., CD117+ leukemia cells) or autoimmune cells (e.g., CD117+ autoimmune lymphocytes, such as CD117+ T cells expressing T cell receptors that cross-react with self-antigens). With respect to the methods of this disclosure relating to disease prevention, it should be understood that the term "prevention" does not require the complete interruption of the disease state. Rather, as used herein, the term prevention refers to the ability of a person skilled in the art to identify susceptible populations so that the administration of the compounds of the invention can be carried out before the onset of disease. This term does not mean that the disease state is completely avoided.

[0179] As used herein, patients who “need” hematopoietic stem cell transplantation include those who exhibit defects or deficiencies in one or more blood cell types, and those with stem cell disorders, autoimmune diseases, cancer, or other pathologies described herein. Hematopoietic stem cells typically exhibit 1) pluripotency and thus can differentiate into a variety of distinct blood lineages, including but not limited to granulocytes (e.g., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), coagulating cells (e.g., megakaryocytes, platelet-producing megakaryocytes, platelets), monocytes (e.g., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B cells, and T cells), 2) self-renewal and thus can produce daughter cells with the same potential as the mother cell, and 3) the ability to reintroduce into the recipient, where they return to the hematopoietic stem cell niche and restore productivity and sustained hematopoiesis. Therefore, hematopoietic stem cells can be administered to patients who are deficient or deficient in one or more hematopoietic lineage cell types to rebuild the deficient or deficient cell population in vivo. For example, the patient may have cancer, and the deficiency may be due to the administration of chemotherapy agents or other drugs that selectively or nonspecifically deplete the cancer cell population. Alternatively or alternatively, the patient may have hemoglobinopathies (e.g., non-malignant hemoglobinopathies) such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome. Subjects may be subjects suffering from severe combined immunodeficiency of adenosine deaminase (ADA SCID), HIV / AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome. Subjects may have or be affected by inherited blood disorders (e.g., sickle cell anemia) or autoimmune diseases. Alternatively or alternatively, subjects may have or be affected by malignancies (e.g., neuroblastoma or hematologic cancers). For example, the subject may have leukemia, lymphoma, or myeloma. In some implementations, the subject has acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma. In some implementations, the subject has myelodysplastic syndrome. In some implementations, the subject has an autoimmune disease, such as scleroderma, multiple sclerosis, ulcerative colitis, Crohn's disease, type 1 diabetes, or another autoimmune disease described herein. In some implementations, the subject requires chimeric antigen receptor T-cell therapy. In some implementations, the subject has or is otherwise affected by metabolic storage disorders.Subjects may suffer from or otherwise be affected by metabolic disorders selected from glycogen storage diseases, mucopolysaccharidosis, Gaucher disease, Hurlers disease, sphingolipid metabolism disorders, metachromatic leukodystrophy, or any other disease or condition that may benefit from the treatments and therapies disclosed herein, including but not limited to severe combined immunodeficiency, Wiscott-Aldrich syndrome, hyperimmunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteosclerosis, osteogenesis imperfecta, storage disease, thalassemia, sickle cell anemia, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis, and those diseases or conditions described in "Bone Marrow Transplantation for Non-Malignant Disease," ASH Education Book, 1:319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety because it relates to pathologies that can be treated with hematopoietic stem cell transplantation therapy. Alternatively or concurrently, patients "in need" hematopoietic stem cell transplantation may be those who have or do not suffer from one of the aforementioned pathologies, but still exhibit reduced levels of one or more endogenous cell types in the hematopoietic lineage (e.g., compared to other healthy subjects). These endogenous cell types include megakaryocytes, coagulating cells, platelets, erythrocytes, mast cells, medulloblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T lymphocytes, and B lymphocytes. Those skilled in the art can readily determine whether the levels of one or more of the aforementioned cell types or other blood cell types are reduced relative to other healthy subjects, for example, by flow cytometry and fluorescence-activated cell sorting (FACS) methods, as well as other procedures known in the art.

[0180] As used herein, the terms “variant” and “derivative” are used interchangeably and refer to naturally occurring, synthetic, and semi-synthetic analogs of the compounds, peptides, proteins, or other substances described herein. Variants or derivatives of the compounds, peptides, proteins, or other substances described herein may retain or improve the biological activity of the original material.

[0181] As used herein, the phrase “stem cell disease” broadly refers to any disease, condition, or symptom that can be treated or cured by pretreatment of a subject’s target tissue and / or by ablation of endogenous stem cell populations in the target tissue (e.g., ablation of endogenous hematopoietic stem cells or progenitor cell populations from a subject’s bone marrow tissue) and / or by transplantation or implantation of stem cells into a subject’s target tissue. For example, type 1 diabetes has been shown to be cured by hematopoietic stem cell transplantation and can benefit from pretreatment according to the compositions and methods described herein. Other diseases that can be treated with the compositions and methods described herein include, but are not limited to, sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, Wiskott-Aldrich syndrome, ADA SCID, HIV / AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome. Other conditions that can be treated using the patient preconditioning and / or hematopoietic stem cell transplantation methods described herein include inherited blood disorders (e.g., sickle cell anemia) and autoimmune disorders such as scleroderma, multiple sclerosis, ulcerative colitis, and Crohn's disease. Other conditions that can be treated using the preconditioning and / or transplantation methods described herein include malignancies such as neuroblastoma or hematologic cancers such as leukemia, lymphoma, and myeloma. For example, cancer could be acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin's lymphoma. Other conditions that can be treated using the preconditioning and / or transplantation methods described herein include myelodysplastic syndromes. In some embodiments, the subject has or is otherwise affected by metabolic storage disorders. For example, subjects may have or be otherwise affected by metabolic disorders selected from glycogen storage diseases, mucopolysaccharidosis, Gaucher disease, Hurlers disease, sphingolipid metabolism disorders, metachromatic leukodystrophy, or any other disease or condition that may benefit from the treatments and therapies disclosed herein, including but not limited to severe combined immunodeficiency, Wiscott-Aldrich syndrome, hyperimmunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteosclerosis, osteogenesis imperfecta, storage disease, thalassemia, sickle cell anemia, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis, and those diseases or conditions described in "Bone Marrow Transplantation for Non-Malignant Disease," ASH Education Book, 1:319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety as it relates to pathologies that can be treated by administration of hematopoietic stem cell transplantation therapy.

[0182] As used herein, the term "vector" includes nucleic acid vectors, such as plasmids, DNA vectors, RNA vectors, viruses, or other suitable replicons. Expression vectors described herein may contain polynucleotide sequences and additional sequence elements, such as those for protein expression and / or integration of these polynucleotide sequences into the genome of mammalian cells. Some vectors that can be used to express the antibodies and antibody fragments of the present invention include plasmids containing regulatory sequences, such as promoter and enhancer regions, that direct gene transcription. Other useful vectors for expressing antibodies and antibody fragments contain polynucleotide sequences that enhance the translation rate of these genes or improve the stability or nuclear export of mRNA transcribed from the genes. These sequence elements may include, for example, 5' and 3' untranslated regions and polyadenylation signal sites to guide efficient transcription of the genes carried on the expression vector. Expression vectors described herein may also contain polynucleotides encoding markers for selecting cells containing such vectors. Examples of suitable markers include genes encoding antibiotic resistance (e.g., ampicillin, chloramphenicol, kanamycin, and norsinolytics).

[0183] As used herein, the terms “conjugate” or “antibody-drug conjugate” or “ADC” refer to an antibody linked to a cytotoxin. An ADC is formed by the chemical bonding of a reactive functional group of one molecule (e.g., an antibody or its antigen-binding fragment) to a suitable reactive functional group of another molecule (e.g., a cytotoxin as described herein). Conjugates may contain a linker between two mutually bound molecules, such as a linker between an antibody and a cytotoxin. Examples of linkers that can be used to form conjugates include peptide-containing linkers, such as linkers containing naturally occurring or non-naturally occurring amino acids, such as D-amino acids. These linkers can be prepared using a variety of strategies described herein or known in the art. Depending on the reactive components, the linker can be cleaved, for example by enzymatic hydrolysis, photolysis, hydrolysis under acidic conditions, hydrolysis under alkaline conditions, oxidation, disulfide reduction, nucleophilic cleavage, or organometallic cleavage (see, for example, Leriche et al., Bioorg. Med. Chem., 20:571-582, 2012).

[0184] As used herein, the term "microtubule binder" refers to a compound that acts by disrupting the microtubule network essential for mitosis and interphase cell function. Examples of microtubule binders include, but are not limited to, maytansine, maytanyl and its derivatives, such as those described herein or known in the art; vinca alkaloids, such as vincaine, vinca sulfate, vincristine, vinblastine sulfate, vinorelbine, and vinorelbine; taxanes, such as docetaxel and paclitaxel; macrolides, such as spongiol, colchicine, and epothilone; and their derivatives, such as epothilone B or its derivatives.

[0185] As used herein, the term "amanita phalloides" refers to a member of the amanita phalloides family of peptides produced by the death cap (Amanita phalloides), or a variant or derivative thereof, such as a variant or derivative thereof capable of inhibiting RNA polymerase II activity. Amanita phalloids used in conjunction with the compositions and methods described herein include compounds such as, but not limited to, compounds of formulas (III), (IIIA), (IIIB), and (IIIC), each described below (e.g., α-amanitaine, β-amanitaine, γ-amanitaine, ε-amanitaine, amanitin, amanitamide, amanita nontoxic cyclic peptide, amanita nontoxic cyclic peptide acid, and proamanita nontoxic cyclic peptide). As described herein, amanita phalloids can, for example, be conjugated to an antibody or its antigen-binding fragment via a linker portion (L) (thereby forming an ADC). Exemplary methods for amanita phalloid conjugation and linkerization for such processes are described below. Exemplary linker-containing amanita toxins that can be conjugated to antibody or antigen-binding fragments, depending on the composition and method, are also described herein.

[0186] As used herein, the term "acyl" refers to -C(=O)R, where R is hydrogen ("aldehyde"), C1-C 12 Alkyl, C2-C 12 alkenyl, C2-C 12 Alkyne group, C3-C7 carbon cyclo group, C6-C 20 Aryl, 5-10 membered heteroaryl, or 5-10 membered heterocyclic group, as defined herein. Non-limiting examples include formyl, acetyl, propionyl, benzoyl, and acryloyl.

[0187] As used in this article, the term "C1-C" 12 "Alkyl" refers to a straight-chain or branched saturated hydrocarbon having 1 to 12 carbon atoms. A representative C1-C... 12 Alkyl groups include, but are not limited to, -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl; while branched C1-C 12 Alkyl groups include, but are not limited to, -isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, and 2-methylbutyl. Branched alkyl groups may be unsubstituted or substituted.

[0188] As used herein, the term "alkenyl" refers to a C2-C group containing an ortho-, secondary, or tertiary carbon atom with at least one unsaturated site. 12 Hydrocarbons, i.e., carbon-carbon sp2 double bonds. Examples include, but are not limited to: ethylene or vinyl groups, -allyl, -1-butenyl, -2-butenyl, -isobutenyl, -1-pentenyl, -2-pentenyl, -3-methyl-1-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, etc. Alkenyl groups can be unsubstituted or substituted.

[0189] As used herein, "alkynyl" refers to a C2-C group containing a normal, secondary, or tertiary carbon atom with at least one unsaturated site. 12 Hydrocarbons, i.e., carbon-carbon sp triple bonds. Examples include, but are not limited to, acetylene and propyne. The alkynyl group can be unsubstituted or substituted.

[0190] As used in this article, "aryl" refers to C6-C 20 A carbocyclic aromatic group. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthracene. Aryl groups can be unsubstituted or substituted.

[0191] As used herein, "arylalkyl" refers to an acyclic alkyl group in which the alkyl group is bonded to a carbon atom (usually terminal or sp). 3 One of the hydrogen atoms on a carbon atom is replaced by an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethyl-1-yl, 2-phenylethyl-1-yl, naphthylmethyl, 2-naphthylethyl-1-yl, 2-naphthylethyl-1-yl, naphthalenebenzyl, 2-naphthylethyl-1-yl, etc. Arylalkyl groups contain 6 to 20 carbon atoms; for example, the alkyl portion (including alkyl, alkenyl, or ynyl) of an arylalkyl group has 1 to 6 carbon atoms, and the aryl portion has 5 to 14 carbon atoms. The alkylaryl group can be unsubstituted or substituted.

[0192] As used herein, “cycloalkyl” refers to a saturated carbocyclic group, which can be monocyclic or bicyclic. Cycloalkyl groups include monocyclic rings having 3-7 carbon atoms or bicyclic rings having 7-12 carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups can be unsubstituted or substituted.

[0193] As used herein, "cycloalkenyl" refers to an unsaturated carbocyclic group, which can be monocyclic or bicyclic. Cycloalkenyl groups include monocyclic rings having 3 to 6 carbon atoms or bicyclic rings having 7 to 12 carbon atoms. Examples of monocyclic cycloalkenyl groups include 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, and 1-cyclohex-3-enyl. Cycloalkenyl groups can be unsubstituted or substituted.

[0194] As used herein, “heteroaryl” refers to an acyclic alkyl group in which the alkyl group is bonded to a carbon atom (usually terminal or sp). 3One of the hydrogen atoms on a carbon atom is replaced by a heteroaryl group. Typical heteroarylalkyl groups include, but are not limited to, 2-benzimidazolylmethyl, 2-furanylethyl, etc. Heteroarylalkyl groups contain 6 to 20 carbon atoms, for example, the alkyl part (including alkyl, alkenyl, or ynyl) of a heteroarylalkyl group has 1 to 6 carbon atoms, and the heteroaryl part has 5 to 14 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S. The heteroaryl part of a heteroarylalkyl group can be a monocyclic ring with 3 to 7 ring members (2 to 6 carbon atoms) or a bicyclic ring with 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example: bicyclic [4,5], [5,5], [5,6], or [6,6] systems.

[0195] As used herein, “heteroaryl” and “heterocyclic alkyl” refer to aromatic or non-aromatic ring systems in which one or more ring atoms are heteroatoms, such as nitrogen, oxygen, and sulfur. Heteroaryl or heterocyclic alkyl groups contain 2 to 20 carbon atoms and 1 to 3 heteroatoms selected from nitrogen, oxygen, phosphorus, and sulfur. Heteroaryl or heterocyclic alkyl groups can be monocyclic with 3 to 7 ring members (2 to 6 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S) or bicyclic with 7 to 10 ring members (4 to 9 carbon atoms and 1 to 3 heteroatoms selected from N, O, P, and S), for example, bicyclic [4,5], [5,5], [5,6], or [6,6] systems. Heteroaryl and heterocyclic aryl groups can be unsubstituted or substituted.

[0196] Heteroaryl and heterocyclic alkyl groups are described in Paquette, Leo A.; "Principles of Modern Heterocyclic Chemistry" (WA Benjamin, New York, 1968), especially Chapters 1, 3, 4, 6, 7 and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), especially Volumes 13, 14, 16, 19 and 28; and J. Am. Chem. Soc. (1960) 82:5566.

[0197] Examples of heteroaryl groups include, by way of example and not limitation, pyridyl, thiazolyl, tetrahydrothiophene, pyrimidinyl, furanyl, thiophene, pyrroleyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthyl, indoleyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indoleazinyl, isoindoleyl, 3H-indoleyl, 1H-indazolyl, and purineyl. 4H-quinolinyl, phthalazinyl, naphridinyl, quinoxolinyl, quinazolinyl, cinnamolinyl, pteridinyl, 4aH-carbazoyl, carbazoyl, phenanthridineyl, acridineyl, pyrimidinyl, phenanthridineyl, phenazinyl, phenothiazinyl, furazinyl, phenotoxazinyl, isochromyl, chromanyl, imidazoalkyl, imidazolinyl, pyrazolyl, benzotriazolyl, benzisoxazolyl, and isatinoyl.

[0198] Examples of heterocyclic alkyl groups include, by way of example and not limitation, dihydropyridyl, tetrahydropyridyl (piperidinyl), tetrahydrothiophenyl, piperidyl, 4-piperidinyl, pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, bis-tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, piperazineyl, quininecycloyl, and morpholinyl.

[0199] As examples and not limitations, carbon-bonded heteroaryl and heterocycloalkyl groups are bonded at the 2, 3, 4, 5, or 6 positions of pyridine, at the 3, 4, 5, or 6 positions of pyridazine, at the 2, 4, 5, or 6 positions of pyrimidine, at the 2, 3, 5, or 6 positions of pyrazine, at the 2, 3, 4, or 5 positions of furan, tetrahydrofuran, thiofuran, thiophene, pyrrole, or tetrahydropyrrole, at the 2, 4, or 5 positions of oxazole, imidazole, or thiazole, at the 3, 4, or 5 positions of isoxazole, pyrazole, or isothiazole, at the 2 or 3 positions of aziridine, at the 2, 3, or 4 positions of azircyclic butane, at the 2, 3, 4, 5, 6, 7, or 8 positions of quinoline, or at the 1, 3, 4, 5, 6, 7, or 8 positions of isoquinoline. More typically, carbon-bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.

[0200] By way of example and not limitation, nitrogen-bonded heteroaryl and heterocyclic alkyl groups are bonded at the 1-position of aziridinium, aziridine, pyrrole, pyrrolidine, 2-pyrrololine, 3-pyrroleoline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, and 1H-indazole, at the 2-position of isoindole or isoindoline, at the 4-position of morpholine, and at the 9-position of carbazole or β-carbline. More generally, nitrogen-bonded heterocycles include 1-aziridinium, 1-aziridine, 1-pyrrole, 1-imidazolyl, 1-pyrazolium, and 1-piperidinium.

[0201] As used herein and applied to any of the aforementioned alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heterocyclic, etc., "substituted" means that one or more hydrogen atoms are each independently substituted by a substituent. Unless otherwise limited by the definition of a single substituent, the aforementioned chemical part, such as "alkyl," "heteroalkyl," "alkenyl," "heteroalkenyl," "alkynyl," "heteroalkynyl," "cycloalkyl," "heterocycloalkyl," "aryl," and "heteroaryl," may optionally be substituted by, for example, one to five substituents selected from the following: alkyl, alkynyl, cycloalkyl, heterocycloalkyl, alkylaryl, alkylheteroaryl, alkylcycloalkyl, alkylheterocycloalkyl, amino, ammonium, acyl, acoxy, amide, aminocarbonyl, alkoxycarbonyl, urea, carbamate, aryl, heteroaryl, sulfinyl, sulfonyl, alkoxy, thioalkyl, halogen, carboxyl, trihalomethyl, cyano, hydroxyl, mercapto, nitro, etc. Typical substituents include, but are not limited to, -X, -R, -OH, -OR, -SH, -SR, NH2, -NHR, -N(R)2, and -N. + (R)3, -CX3, -CN, -OCN, -SCN, -NCO, -NCS, -NO, -NO2, -N3, -NC(=O)H, -NC(=O)R, -C(=O)H, -C(=O)R, -C(=O)NH2, -C(=O)N (R)2, -SO3-, -SO3H, -S(=O)2R, -OS(=O)2OR, -S(=O)2NH2, -S(=O)2N(R)2, -S(=O)R, -OP(=O)(OH)2, -OP(=O)(OR)2, -P( =O)(OR)2, -PO3, -PO3H2, -C(=O)X, -C(=S)R, -CO2H, -CO2R, -CO2-, -C(=S)OR, -C(=O)SR, -C(=S)SR, -C(=O)NH2, -C(=O)N(R)2, -C(=S)NH2, -C(=S)N(R)2, -C(=NH)NH2 and -C(=NR)N(R)2; wherein each X is independently selected from F, Cl, Br and I in each case; and each R is independently selected from Cl-C in each case.12 Alkyl, C6-C 20 Aryl, C3-C 14 Heterocyclic alkyl or heteroaryl, protecting group, and prodrug moiety. When the group is described as "optionally substituted," the group may be independently substituted by one or more of the aforementioned substituents in each case. Substitution may include cases where adjacent substituents undergo ring closure, such as ring closure of an ortho-functional substituent, to form, for example, lactams, lactones, cyclic anhydrides, acetals, hemiacetals, thioacetals, acetalamines, and hemiacetalamines formed by ring closure, for example, to provide a protecting group.

[0202] It should be understood that, depending on the context, certain group naming conventions may include mono- or bi-groups. For example, when a substituent requires two attachment sites with the rest of the molecule, the substituent should be understood to be bi-group. For instance, substituents of alkyl groups identified as requiring two attachment sites include bi-groups, such as -CH2-, -CH2CH2-, -CH2CH(CH3)CH2-, etc. Other group naming conventions clearly indicate that the group is bi-group, such as "alkylene", "alkenyl", "arylene", "heterocyclic alkylene", etc.

[0203] As used herein, the term "coupling reaction" refers to a chemical reaction in which two or more substituents suitably adapted to react with each other react to form a chemical portion of a molecular fragment linked (e.g., covalently) to each substituent. Coupling reactions include those in which a reactive substituent bound to a cytotoxic fragment (e.g., a cytotoxic substance known in the art or described herein) reacts with a suitable reactive substituent bound to an antibody fragment or its antigen-binding fragment (e.g., an antibody known in the art or described herein that is specific to CD117 (e.g., GNNK+CD117) or its antigen-binding fragment). Examples of suitable reactive substituents include nucleophile / electrophile pairs (e.g., thiol / haloalkyl pairs, amine / carbonyl pairs, or thiol / α,β-unsaturated carbonyl pairs, etc.), diene / dien affinity pairs (e.g., azide / alkyne pairs, etc.), etc. Coupling reactions include, but are not limited to, thiol alkylation, hydroxyl alkylation, amine alkylation, amine condensation, amidation, esterification, disulfide formation, cycloaddition (e.g., [4+2]Diels-Alder cycloaddition, [3+2]Huisen cycloaddition, etc.), nucleophilic aromatic substitution, electrophilic aromatic substitution, and other reaction forms known in the art or described herein.

[0204] As used in this article, “CRU (Competitive Replantation Unit)” refers to a unit of measurement for long-term transplanted stem cells, which can be detected after transplantation in vivo.

[0205] As used herein, the “drug-to-antibody ratio” or “DAR” refers to the amount of cytotoxicant (e.g., amatoxin) attached to the antibody of an ADC. While higher loadings are possible depending on the number of binding sites on the antibody, the DAR of an ADC can range from 1 to 8. Thus, in some embodiments, the DAR of the ADC described herein is 1, 2, 3, 4, 5, 6, 7, or 8.

[0206] Where all substituents are described as bigroups (i.e., having two attachment sites with the rest of the molecule), it should be understood that substituents may be attached in any oriented configuration unless otherwise stated.

[0207] Fc-modified antibodies

[0208] This disclosure is partly based on the finding that antibodies or antigen-binding fragments thereof having Fc modifications that allow Fc silencing and are capable of binding antigens expressed by hematopoietic cells can be used as therapeutic agents. For example, this disclosure is partly based on the finding that antibodies or antigen-binding fragments thereof having Fc modifications that allow Fc silencing and are capable of binding (i) antigens expressed by hematopoietic cells, including but not limited to CD117 (e.g., GNNK+CD117) or CD45; or antigens expressed by mature immune cells (e.g., T cells), including but not limited to CD45, CD2, CD5, CD137, or CD252, can be used as therapeutic agents (e.g., as “naked” antibodies or as ADCs) to (i) treat cancers and autoimmune diseases characterized by CD117+ (e.g., GNNK+CD117) or CD45+ hematopoietic stem cells; or CD45+, CD2+, CD5+, CD137+, or CD252+ immune cells (e.g., T cells) and (ii) promote the engraftment of transplanted hematopoietic stem cells in patients requiring transplant therapy. These therapeutic activities can be induced, for example, by the binding of anti-hematopoietic cell (HC) antibodies (e.g., anti-CD117, anti-CD45, anti-CD2, anti-CD5, anti-CD137, anti-CD252, etc.) or their antigen-binding fragments, which bind to antigens (e.g., CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, CD252, etc.) expressed by hematopoietic cells (e.g., hematopoietic stem cells, leukocytes, immune cells, such as mature immune cells (e.g., T cells)) (e.g., cancer cells, autoimmune cells, or hematopoietic stem cells), and subsequently induce cell death. The depletion of endogenous hematopoietic stem cells can provide a niche where transplanted hematopoietic stem cells can settle and subsequently establish productive hematopoiesis. In this way, transplanted hematopoietic stem cells can be successfully engrafted into patients, such as those suffering from the stem cell disease described herein.

[0209] The antibodies or their antigen-binding fragments described herein may also include modifications and / or mutations that alter the properties of the antibody and / or fragment, such as those that increase half-life or increase or decrease ADCC.

[0210] In one embodiment, an antibody comprising one or more radiolabeled amino acids is provided. The radiolabeled antibody can be used for diagnostic and therapeutic purposes (conjugation to a radiolabeled molecule is another possible feature). Non-limiting examples of peptide labeling include, but are not limited to, 3H, 14C, 15N, 35S, 90Y, 99Tc, and 125I, 131I, and 186Re. Methods for preparing radiolabeled amino acids and related peptide derivatives are known in the art (see, for example, Junghans et al., in Cancer Chemotherapy and Biotherapy 655-686 (2nd edition edited by Chafner and Longo, edited by Lippincott Raven (1996)) and U.S. Patent Nos. 4,681,581, 4,735,210, 5,101,827, 5,102,990 (US RE35,500), 5,648,471, and 5,697,902). For example, radioisotopes can be conjugated using the chloramine-T method.

[0211] In one embodiment, the anti-HC antibody (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) or its antigen-binding fragment comprises a modified Fc region, wherein the modified Fc region comprises at least one amino acid modification relative to the wild-type Fc region, such that the molecule's affinity for or binding to FcgammaR (FcγR) is altered. Certain amino acid positions within the Fc region are known by crystallographic studies to be in direct contact with FcγR. Specifically, amino acids 234-239 (hinge region), 265-269 (B / C ring), 297-299 (C' / E ring), and 327-332 (F / G ring). (See Sondermann et al., 2000 Nature, 406:267-273). In some embodiments, the antibodies described herein may include a variant Fc region containing a modification of at least one residue that, based on structural and crystallographic analysis, directly contacts FcγR. In one embodiment, according to the EU index as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NH1, MD (1991), the Fc region of an anti-HC antibody (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, anti-CD252 antibody, etc.) or its antigenic fragment contains an amino acid substitution at amino acid 265, which is expressly incorporated herein by reference. "EU index as in Kabat" refers to the number of the human IgG1 EU antibody. In one embodiment, the Fc region contains a D265A mutation. In one embodiment, the Fc region contains a D265C mutation. In some embodiments, according to the EU index as in Kabat, the Fc region of the antibody (or a fragment thereof) contains an amino acid substitution at amino acid 234. In one embodiment, the Fc region contains an L234A mutation. In some embodiments, according to the EU index as described in Kabat, the Fc region of an anti-HC antibody (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) or its antigen fragment contains an amino acid substitution at amino acid 235. In one embodiment, the Fc region contains an L235A mutation. In yet another embodiment, the Fc region contains both L234A and L235A mutations (also referred to herein as “L234A.L235A” or “LALA”). In yet another embodiment, the Fc region contains both L234A and L235A mutations, wherein the Fc region does not contain a P329G mutation.In another embodiment, the Fc region contains the D265C, L234A, and L235A mutations (also referred to herein as "D265C.L234A.L235A"). In yet another embodiment, the Fc region contains the D265C, L234A, and L235A mutations, wherein the Fc region does not contain the P329G mutation. In still another embodiment, the Fc region contains the D265C, L234A, L235A, and H435A mutations (also referred to herein as "D265C.L234A.L235A.H435A"). In yet another embodiment, the Fc region contains the D265C, L234A, L235A, and H435A mutations, wherein the Fc region does not contain the P329G mutation. In yet another embodiment, the Fc region contains the D265C and H435A mutations (also referred to herein as "D265C.H435A"). In yet another embodiment, the Fc region contains the D265A, S239C, L234A, and L235A mutations (also referred to herein as "D265A.S239C.L234A.L235A"). In yet another embodiment, the Fc region contains the D265A, S239C, L234A, and L235A mutations, wherein the Fc region does not contain the P329G mutation. In yet another embodiment, the Fc region contains the D265C, N297G, and H435A mutations (also referred to herein as "D265C.N297G.H435A"). In yet another embodiment, the Fc region contains the D265C, N297Q, and H435A mutations (also referred to herein as "D265C.N297Q.H435A"). In another embodiment, the Fc region contains the E233P, L234V, L235A, and delG236 (deletion 236) mutations (also referred to herein as "E233P.L234V.L235A.delG236" or "EPLVLAdelG"). In another embodiment, the Fc region contains the E233P, L234V, L235A, and delG236 (deletion 236) mutations, wherein the Fc region does not contain the P329G mutation. In another embodiment, the Fc region contains the E233P, L234V, L235A, delG236 (deletion 236), and H435A mutations (also referred to herein as "E233P.L234V.L235A.delG236.H435A" or "EPLVLAdelG.H435A"). In another embodiment, the Fc region contains the E233P, L234V, L235A, delG236 (deletion 236), and H435A mutations, wherein the Fc region does not contain the P329G mutation. In another embodiment, the Fc region contains the L234A, L235A, S239C, and D265A mutations.In another embodiment, the Fc region contains L234A, L235A, S239C, and D265A mutations, wherein the Fc region does not contain the P329G mutation. In another embodiment, the Fc region contains H435A, L234A, L235A, and D265C mutations. In yet another embodiment, the Fc region contains H435A, L234A, L235A, and D265C mutations, wherein the Fc region does not contain the P329G mutation.

[0212] In some embodiments, the antibody has a modified Fc region such that, in in vitro effector function assays, the antibody reduces effector function by decreasing binding to the Fc receptor (FcR) compared to the binding of the same antibody containing an unmodified Fc region to the FcR. In some embodiments, the antibody has a modified Fc region such that, in in vitro effector function assays, the antibody reduces effector function by decreasing binding to the Fcγ receptor (FcR) compared to the binding of the same antibody containing an unmodified Fc region to the FcγR. In some embodiments, FcγR is FcγR1. In some embodiments, FcγR is FcγR2A. In some embodiments, FcγR is FcγR2B. In other embodiments, FcγR is FcγR2C. In some embodiments, FcγR is FcγR3A. In some embodiments, FcγR is FcγR3B. In other embodiments, the reduction in binding is relative to the binding of the same antibody containing the unmodified Fc region to FcγR, with a reduction of at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100% of the antibody binding to FcγR. In still other embodiments, the reduction in binding is relative to the binding of the same antibody containing the unmodified Fc region to FcγR, with a reduction of at least 70% to 100%, at least 80% to 100%, at least 90% to 100%, at least 95% to 100%, or at least 98% to 100% of the antibody binding to FcγR.

[0213] In some embodiments, the antibody has a modified Fc region such that, in an in vitro cytokine release assay, the antibody reduces cytokine release by at least 50% compared to the cytokine release of the same antibody containing an unmodified Fc region. In some embodiments, the reduction in cytokine release is relative to the cytokine release of the same antibody containing an unmodified Fc region, with a reduction of at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100%. In some embodiments, the reduction in cytokine release is relative to the cytokine release of the same antibody containing an unmodified Fc region, with a reduction of at least 70% to 100%, at least 80% to 100%, at least 90% to 100%, or at least 95% to 100%. In some preferred embodiments, cytokine release is achieved via immune cells.

[0214] In some embodiments, the antibody has a modified Fc region such that, in an in vitro mast cell degranulation assay, the antibody reduces mast cell degranulation by at least 50% compared to mast cell degranulation with the same antibody containing an unmodified Fc region. In some embodiments, the reduction in mast cell degranulation is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100% compared to mast cell degranulation with the same antibody containing an unmodified Fc region. In some embodiments, the reduction in mast cell degranulation is at least 70% to 100%, at least 80% to 100%, at least 90% to 100%, or at least 95% to 100% compared to mast cell degranulation with the same antibody containing an unmodified Fc region.

[0215] In some embodiments, the antibody has a modified Fc region such that, in an in vitro antibody-dependent phagocytosis assay, the antibody reduces or prevents antibody-dependent phagocytosis (ADCP) by at least 50% relative to ADCP of the same antibody containing an unmodified Fc region. In some embodiments, the reduction in ADCP is at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or at least 100% relative to antibody-dependent phagocytosis of the same antibody containing an unmodified Fc region.

[0216] In some embodiments, the anti-HC antibodies described herein (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) comprise an Fc region containing one or a combination of the following modifications: D265A, D265C, D265C / H435A, D265C / LALA, D265C / LALA / H435A, D265A / S239C / L234A / L235A / H435A,D265A / S239C / L234A / L235A,D265C / N297G,D265C / N297G / H435A,D265C(EPLVLAdelG*),D265C(EPLVLAdelG) / H435A,D265C / N297Q / H435A,D265C / N297Q,EPLVLAdelG / H435A,EPLVLAdelG / D265C,EPLVLAdelG / D265A,N297A,N297G orN297Q.

[0217] The binding or affinity between the modified Fc region and the Fcγ receptor can be determined using a variety of techniques known in the art, such as, but not limited to, equilibrium methods (e.g., enzyme-linked immunosorbent assay (ELISA); KinExA, Rathanaswami et al. Analytical Biochemistry, Vol. 373: 52-60, 2008; or radioimmunoassay (RIA)), or other mechanisms by surface plasmon resonance assays or kinetic-based assays (e.g., BIACORE.RTM analysis or Octet.RTM analysis (forteBIO)), and other methods such as indirect binding assays, competitive binding assays, fluorescence resonance energy transfer (FRET), gel electrophoresis, and chromatography (e.g., gel filtration). These and other methods can utilize labeling on one or more components being examined and / or employ multiple detection methods, including but not limited to colorimetric, fluorescent, luminescent, or isotopic labeling. A detailed description of binding affinity and kinetics can be found in Paul, WE, ed., Fundamental Immunology, 4th ed., Lippincott-Raven, Philadelphia (1999), which focuses on antibody-immunogen interactions. An example of competitive binding assays is radioimmunoassay, which involves incubating a labeled antigen with a target antibody in the presence of incrementally added unlabeled antigen and detecting the antibody binding to the labeled antigen. The affinity of the target antibody for a specific antigen and the rate of binding deviation can be determined from the data using scatchard plot analysis. Competition with a secondary antibody can also be determined using radioimmunoassay. In this case, the antigen is incubated with a target antibody conjugated to a labeled compound in the presence of incrementally added unlabeled secondary antibody.

[0218] In one embodiment, the binding of an antibody with the Fc modification described herein (e.g., D265C, L234A, L235A, and / or H435A) to the Fcγ receptor is reduced by at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% (e.g., as assessed by biological layer interferometry (BLI), for example, as described in Example 1) relative to the binding of the same antibody containing the unmodified Fc region to the Fcγ receptor.

[0219] Without being bound by any theory, it is believed that the binding interaction between the Fc region and the Fcγ receptor is essential for a variety of effector functions and downstream signaling events, including but not limited to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Therefore, in some respects, antibodies containing modified Fc regions (e.g., containing L234A, L235A, and / or D265C mutations) exhibit significantly reduced or eliminated effector functions. Effector functions can be determined using a variety of methods known in the art, for example, by measuring cellular responses to the target antibody (e.g., mast cell degranulation or cytokine release). For example, using standard methods in the art, the ability of an Fc-modified antibody to trigger mast cell degranulation in vitro (e.g., as described in Example 2) or to trigger cytokine release, for example, by human peripheral blood mononuclear cells (e.g., as described in Example 3).

[0220] Therefore, in one embodiment, the Fc region contains a mutation that results in a reduced half-life (e.g., relative to an antibody having an unmodified Fc region). In certain situations where the antibody is expected to act as a short-lived therapeutic agent (e.g., the pretreatment steps described herein, where HSCs are administered after antibody administration), antibodies with a short half-life may be advantageous. Ideally, the antibody is substantially cleared before HSC delivery, and the HSCs typically also express target antigens (e.g., CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, or CD252), but are not targets of anti-HC antibodies (e.g., anti-CD117 antibodies, anti-CD45 antibodies, anti-CD2 antibodies, anti-CD5 antibodies, anti-CD137 antibodies, or anti-CD252 antibodies), unlike endogenous stem cells. In one embodiment, the Fc region contains a mutation at position 435 (according to Kabat's EU index). In one embodiment, the mutation is the H435A mutation.

[0221] In one embodiment, the half-life (e.g., in humans) of the anti-HC antibody described herein (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) is equal to or less than about 24 hours, equal to or less than about 23 hours, equal to or less than about 22 hours, equal to or less than about 21 hours, equal to or less than about 20 hours, equal to or less than about 19 hours, equal to or less than about 18 hours, equal to or less than about 17 hours, equal to or less than about 16 hours, equal to or less than about 15 hours, equal to or less than about 14 hours, equal to or less than about 13 hours, equal to or less than about 12 hours, or equal to or less than about 11 hours.

[0222] In one embodiment, the half-life (e.g., in humans) of the anti-HC antibodies described herein (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) is about 1-5 hours, about 5-10 hours, about 10-15 hours, about 15-20 hours, or about 20-25 hours.

[0223] In some aspects, the Fc region contains two or more mutations that confer a reduced half-life and diminished effector function to the antibody. In some embodiments, the Fc region contains mutations that reduce the half-life and at least one mutation of a residue that can directly contact FcγR (e.g., based on structural and crystallographic analysis). In one embodiment, the Fc region contains H435A, L234A, and L235A mutations. In one embodiment, the Fc region contains H435A and D265C mutations. In one embodiment, the Fc region contains H435A, L234A, L235A, and D265C mutations.

[0224] In some embodiments, the antibody or its antigen-binding fragment is conjugated to a cytotoxin (e.g., amatoxins) via a cysteine ​​residue in the Fc domain of the antibody or its antigen-binding fragment. In some embodiments, the cysteine ​​residue is introduced via a mutation in the Fc domain of the antibody or its antigen-binding fragment. For example, the cysteine ​​residue may be selected from Cys118, Cys239, and Cys265. In one embodiment, the Fc region of an anti-HC antibody (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) or its antigen-binding fragment contains an amino acid substitution at amino acid 265 (according to Kabat's EU index). In one embodiment, the Fc region contains a D265C mutation. In one embodiment, the Fc region contains both D265C and H435A mutations. In one embodiment, the Fc region contains D265C, L234A, and L235A mutations. In one embodiment, the Fc region contains mutations of D265C, L234A, L235A, and H435A. In one embodiment, the Fc region of an anti-HC antibody (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) or its antigen-binding fragment contains an amino acid substitution at amino acid 239 (according to Kabat's EU index). In one embodiment, the Fc region contains the S239C mutation. In one embodiment, the Fc region contains the L234A mutation, L235A mutation, S239C mutation, and D265A mutation. In another embodiment, the Fc region contains the S239C and H435A mutations. In another embodiment, the Fc region contains the L234A mutation, L235A mutation, and S239C mutation. In yet another embodiment, the Fc region contains the H435A mutation, L234A mutation, L235A mutation, and S239C mutation. In yet another implementation, the Fc region contains H435A mutation, L234A mutation, L235A mutation, S239C mutation, and D265A mutation.

[0225] It is worth noting that, unless otherwise stated, the Fc amino acid positions refer to the EU number index.

[0226] Methods for genetically engineering antibodies to include any Fc modifications described herein are well known in the art. These methods include, but are not limited to, preparation by site-directed (or oligonucleotide-mediated) mutagenesis, PCR mutagenesis, and cassette mutagenesis of DNA molecules encoding antibodies or at least antibody constant regions. Site-directed mutagenesis is well known in the art (see, for example, Carter et al., Nucleic Acids Res., 13:4431-4443 (1985) and Kunkel et al., Proc. Natl. Acad. Sci. USA, 82:488 (1987)). PCR mutagenesis is also suitable for preparing amino acid sequence variants of starting peptides. See Higuchi, In PCR Protocols, pp. 177-183 (Academic Press, 1990); and Vallette et al., Nuc. Acids Res. 17:723-733 (1989). Another method for preparing sequence variants, box mutagenesis, is based on the technique described by Wells et al., Gene, 34:315-323 (1985).

[0227] Anti-CD117 antibody

[0228] This disclosure is also based in part on the finding that antibodies or antigen-binding fragments thereof capable of binding to CD117 (e.g., GNNK+CD117) can be used alone or as an ADC to (i) treat cancers characterized by CD117+ cells (e.g., acute myeloid leukemia or myelodysplastic syndromes) and autoimmune diseases, and (ii) promote the engraftment of transplanted hematopoietic stem cells in patients requiring transplant therapy. These therapeutic activities can be induced, for example, by the binding of anti-CD117 antibodies or antigen-binding fragments thereof to CD117 (e.g., GNNK+CD117) expressed on the surface of cells (e.g., cancer cells, autoimmune cells, or hematopoietic stem cells), and subsequently induce cell death. The depletion of endogenous hematopoietic stem cells can provide a niche where transplanted hematopoietic stem cells can settle and subsequently establish productive hematopoiesis. In this way, transplanted hematopoietic stem cells can be successfully engrafted into patients, such as those with the stem cell disease described herein.

[0229] Antibodies and antigen-binding fragments capable of binding to human CD117 (also known as c-Kit, mRNA NCBI reference sequence: NM_000222.2, protein NCBI reference sequence: NP_000213.1), including those capable of binding GNNK+CD117, can be used in conjunction with the compositions and methods described herein to pretreat patients undergoing hematopoietic stem cell transplantation therapy. In a significant proportion of the population, polymorphisms affecting the CD117 coding region or extracellular domain are currently unknown in non-oncology indications. At least four isoforms of CD117 have been identified, with the potential to express additional isoforms in tumor cells. Two CD117 isoforms are located in the intracellular domain of the protein, and two are present in the external juxtamembranous region. The two extracellular isoforms, GNNK+ and GNNK-, differ in the presence (GNNK+) or absence (GNNK-) of a four-amino acid sequence. These isotypes have reportedly the same affinity for the ligand (SCF), but ligand binding to the GNNK- isotype has been reported to increase internalization and degradation. The GNNK+ isotype can be used as an immunogen to generate antibodies capable of binding to CD117, as antibodies generated against this isotype include both GNNK+ and GNNK- proteins.

[0230] In one embodiment, the anti-CD117 antibody or its antigen-binding portion comprises a heavy chain variable region as described in the amino acid sequence of SEQ ID NO:13 and a light chain variable region as described in the amino acid sequence of SEQ ID NO:14.

[0231] In another embodiment, the anti-CD117 antibody or its antigen-binding portion comprises three CDR sequences of the heavy chain variable region (VH) amino acid sequence and three CDR sequences of the light chain variable region (LH) amino acid sequence of Ab85.

[0232] In another embodiment, the anti-CD117 antibody or its antigen-binding portion comprises the heavy chain variable region (VH) amino acid sequence and the light chain variable region (LH) amino acid sequence of Ab85 (which may also be referred to interchangeably as Ab2 herein).

[0233] The amino acid sequence of the heavy chain variable region is provided below as SEQ ID NO:13. The VH CDR amino acid sequence of Ab85 is underlined below and is as follows: NYWIG (VH CDR 1; SEQ ID NO:7); IINPRDSDTRYRPSFQG (VH CDR2; SEQ ID NO:8); and HGRGYEGYEGAFDI (VH CDR3; SEQ ID NO:9).

[0234] Ab85 VH sequence

[0235] EVQLVQSGAEVKKPGESLKISCKGSGYSFT NYWIG WVRQMPGKGLEWMA IINPRDSDTRYRPSFQG QVTISADKSISTAYLQWSSLKASDTAMYYCAR HGRGYEGYEGAFDI WGQGTLVTVSS(SEQ ID NO:13)

[0236] The light chain variable region (VL) amino acid sequence of Ab85 is provided below as SEQ ID NO:14. The VL CDR amino acid sequences of Ab85 are underlined below and are as follows: RSSQGIRSDLG (VLCDR1; SEQ ID NO:10); DASNLET (VLCDR2; SEQ ID NO:11); and QQANGFPLT (VL CDR3; SEQ ID NO:12).

[0237] Ab85 VL sequence

[0238] DIQMTQSPSSLSASVGDRVTITC RSSQGIRSDLG WYQQKPGKAPKLLIY DASNLET GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQANGFPLT FGGGTKVEIK(SEQ ID NO:14).

[0239] In another embodiment, the anti-CD117 antibody or its antigen-binding portion comprises the heavy chain variable region (VH) amino acid sequence and the light chain variable region (LH) amino acid sequence of Ab249 (which may also be referred to interchangeably as Ab3 herein).

[0240] The heavy chain variable region (VH) amino acid sequence of Ab249 is provided below as SEQ ID NO:346. The VHCDR amino acid sequences of Ab249 are underlined below and are as follows: TSWIG (VHCDR1; SEQ ID NO:340); IIYPGDSDTRYSPSFQG (VH CDR2; SEQ ID NO:341); and HGLGYNGYEGAFDI (VH CDR3; SEQ ID NO:342).

[0241] Ab249 VH sequence

[0242] EVQLVQSGAEVKKPGESLKISCKGSGYRFT TSWIG WVRQMPGKGLEWMG IIYPGDSDTRYSPSFQG QVTISADKSISTAYLQWSSLKASDTAMYYCAR HGLGYNGYEGAFDI WGQGTLVTVSS (SEQ ID NO:346).

[0243] The light chain variable region (VL) amino acid sequence of Ab249 is provided below as SEQ ID NO:347. The VLCDR amino acid sequences of Ab249 are underlined below and are as follows: RASQGIGSALA (VL CDR1; SEQ ID NO:343); DASNLET (VL CDR2; SEQ ID NO:344); and QQLNGYPLT (VL CDR3; SEQ ID NO:345).

[0244] Ab249 VL sequence

[0245] DIQMTQSPSSLSASVGDRVTITC RASQGIGSALA WYQQKPGKAPKLLIY DASNLET GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQLNGYPLT FGQGTRLEIK (SEQ ID NO:347)

[0246] Human antibodies Ab85 and Ab249 are both derived from antibody CK6, which is an antagonist of anti-CD117 antibody. Compared with CK6, Ab85 and Ab249 have improved properties, such as improved binding characteristics.

[0247] Therefore, in some embodiments, the anti-CD117 antibody comprises a heavy chain containing the CDR group (CDR1, CDR2, and CDR3) as described in SEQ ID NO:7, 8, and 9, and a light chain containing the CDR group as described in SEQ ID NO:10, 11, and 12. In other embodiments, the anti-CD117 antibody comprises a heavy chain containing the CDR group (CDR1, CDR2, and CDR3) as described in SEQ ID NO:340, 341, and 342, and a light chain containing the CDR group as described in SEQ ID NO:343, 344, and 345.

[0248] In another embodiment, the anti-CD117 antibody or its antigen-binding portion comprises the heavy chain variable region (VH) amino acid sequence and the light chain variable region (LH) amino acid sequence of Ab67 (a neutral antibody; which may also be referred to herein as Ab1 interchangeably).

[0249] The heavy chain variable region (VH) amino acid sequence of Ab67 is provided below as SEQ ID NO:354. The VHCDR amino acid sequences of Ab67 are underlined below and are as follows: FTFSDADMD (VHCDR1; SEQ ID NO:348); RTRNKAGSYTTEYAASVKG (VH CDR2; SEQ ID NO:349); and AREPKYWIDFDL (VH CDR3; SEQ ID NO:350).

[0250] Ab67VH sequence

[0251] EVQLVESGGGLVQPGGSLRLSCAASGFTFSDADMDWVRQAPGKGLEWVGRTRNKAGSYTTEYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCAREPKYWIDFDLWGRGTLVTVSS(SEQ ID NO:354)

[0252] The light chain variable region (VL) amino acid sequence of Ab67 is provided below as SEQ ID NO:355. The VLCDR amino acid sequences of Ab67 are underlined below and are as follows: RASQSISSYLN (VLCDR 1; SEQ ID NO:351); AASSLQS (VL CDR 2; SEQ ID NO:352); and QQSYIAPYT (VL CDR 3; SEQ ID NO:353).

[0253] Ab67 VL sequence

[0254] DIQMTQSPSSSLSASVGDRVTITCRASQSISLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYIAPYTFGGGTKVEIK(SEQ ID NO:355)

[0255] Therefore, in some embodiments, the anti-CD117 antibody comprises a heavy chain containing the CDR group (CDR1, CDR2 and CDR3) as described in SEQ ID NO348, 349 and 350 and a light chain containing the CDR group as described in SEQ ID NO351, 352 and 353.

[0256] Additional sequences of the anti-CD117 antibody or binding fragment described herein are provided in Table 5.

[0257] The anti-CD117 antibodies or binding fragments described herein may also include modifications and / or mutations that alter the properties of the antibody and / or fragment, such as those that increase half-life, increase or decrease ADCC, as known in the art.

[0258] In one embodiment, the anti-CD117 antibody or its binding fragment comprises a variant Fc region, wherein the variant Fc region contains at least one amino acid modification relative to the wild-type Fc region, such that the molecule's affinity for FcγR is altered. Certain amino acid positions within the Fc region are known by crystallographic studies to be in direct contact with FcγR. Specifically, amino acids 234-239 (hinge region), 265-269 (B / C ring), 297-299 (C' / E ring), and 327-332 (F / G ring) (see Sondermann et al., 2000 Nature, 406:267-273). For example, amino acid substitutions at positions 234 and 235 in the Fc region have been identified as reducing the affinity of IgG antibodies for Fc receptors, particularly the Fcγ receptor (FcγR). In one embodiment, the anti-CD117 antibody described herein comprises an Fc region containing amino acid substitutions at L234 and / or L235, such as L234A and L235A (EU index). Therefore, the anti-CD117 antibody described herein may contain a variant Fc region containing a modification of at least one residue that, based on structural and crystallographic analysis, is in direct contact with FcγR. In one embodiment, the Fc region of the anti-CD117 antibody (or a fragment thereof containing Fc) contains an amino acid substitution at amino acid 265, according to the EU index as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition, Public Health Service, NH1, MD (1991), which is expressly incorporated herein by reference. Unless otherwise stated, “EU index as in Kabat” or “EU index” refers to the number of the human IgG1 EU antibody and is used herein with respect to the Fc amino acid position.

[0259] In one embodiment, the Fc region contains the D265A mutation. In another embodiment, the Fc region contains the D265C mutation.

[0260] In some embodiments, according to the EU index as in Kabat, the Fc region of the anti-CD117 antibody (or a fragment thereof) contains an amino acid substitution at amino acid 234. In one embodiment, the Fc region contains an L234A mutation. In some embodiments, according to the EU index as in Kabat, the Fc region of the anti-CD117 antibody (or a fragment thereof) contains an amino acid substitution at amino acid 235. In one embodiment, the Fc region contains an L235A mutation. In yet another embodiment, the Fc region contains both L234A and L235A mutations. In yet another embodiment, the Fc region contains D265C, L234A, and L235A mutations.

[0261] In some respects, variant IgG Fc domains contain one or more amino acid substitutions that result in reduced or absent binding affinity for FcγR and / or C1q, compared to wild-type Fc domains that do not contain one or more amino acid substitutions. Fc binding interactions are essential for a variety of effector functions and downstream signaling events, including but not limited to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Therefore, in some respects, antibodies containing modified Fc regions (e.g., those containing L234A, L235A, and D265C mutations) exhibit significantly reduced or eliminated effector functions.

[0262] Affinity to the Fc region can be determined using a variety of techniques known in the art, such as, but not limited to, equilibrium methods (e.g., enzyme-linked immunosorbent assay (ELISA); KinExA, Rathanaswami et al. Analytical Biochemistry, Vol. 373: 52-60, 2008; or radioimmunoassay (RIA)), or kinetic-based assays via surface plasmon resonance or other mechanisms (e.g., BIACORE). TM Analysis or Octet TMAnalysis (forteBIO) and other methods, such as indirect binding assays, competitive binding assays, fluorescence resonance energy transfer (FRET), gel electrophoresis, and chromatography (e.g., gel filtration), can be used. These and other methods may utilize labeling on one or more components being examined and / or employ multiple detection methods, including but not limited to colorimetric, fluorescence, luminescence, or isotopic labeling. Detailed descriptions of binding affinity and kinetics can be found in Paul, WE, ed., Fundamental Immunology, 4th ed., Lippincott-Raven, Philadelphia (1999) (which focuses on antibody-immunogen interactions). An example of a competitive binding assay is radioimmunoassay, which involves incubating a labeled antigen with a target antibody in the presence of incrementally added unlabeled antigen and detecting the antibody that binds to the labeled antigen. The affinity of the target antibody for a specific antigen and the rate of binding deviation can be determined from the data using scatchard plot analysis. Competition with a secondary antibody can also be determined using radioimmunoassay. In this case, the antigen is incubated with the target antibody conjugated with the labeled compound in the presence of incremental, unlabeled second antibody.

[0263] In one embodiment, the anti-CD117 antibody described herein includes an Fc region comprising L235A, L235A, and D265C (EU index). The antibodies of this invention can be further genetically engineered by introducing additional Fc mutations to further adjust the antibody half-life, for example in (Dall'Acqua et al. (2006) J Biol Chem 281:23514-24), (Zalevsky et al. (2010) Nat Biotechnol 28:157-9), (Hinton et al. (2004) J Biol Chem 279:6213-6), (Hinton et al. (2006) J Immunol 176:346-56), (Shields et al. (2001) J Biol Chem 276:6591-604), (Petkova et al. (2006) Int Immunol 18:1759-69), (Datta-Mannan et al. (2007) Drug Metab Dispos 35:86-94), (Vaccaro et al. (2005) Nat Biotechnol Those described in (23:1283-8), (Yeung et al. (2010) Cancer Res 70:3269-77), and (Kim et al. (1999) Eur J Immunol 29:2819-25), and including positions 250, 252, 253, 254, 256, 257, 307, 376, 380, 428, 434, and 435. Exemplary mutations that can be prepared alone or in combination are T250Q, M252Y, 1253A, S254T, T256E, P2571, T307A, D376V, E380A, M428L, H433K, N434S, N434A, N434H, N434F, H435A, and H435R mutations.

[0264] Therefore, in one embodiment, the Fc region contains a mutation that results in a reduced half-life. In certain situations where the antibody is expected to act as a short-lived therapeutic agent (e.g., the pretreatment steps described herein, where HSCs are administered after antibody administration), antibodies with a short half-life (also referred to herein as a “rapid” half-life) may be advantageous. Ideally, the antibody is substantially cleared before HSC delivery, and HSCs typically also express CD117, but are not a target of anti-CD117 antibodies, unlike endogenous stem cells. In one embodiment, the Fc region contains a mutation at position 435 (according to Kabat’s EU index). In one embodiment, the mutation is the H435A mutation. In another embodiment, the mutation is the D265C mutation. In yet another embodiment, the mutation is both the H435A and D265C mutations.

[0265] In one embodiment, the half-life of the anti-CD117 antibody described herein is equal to or less than 24 hours, equal to or less than 22 hours, equal to or less than 20 hours, equal to or less than 18 hours, equal to or less than 16 hours, equal to or less than 14 hours, equal to or less than 13 hours, equal to or less than 12 hours, equal to or less than 11 hours, equal to or less than 10 hours, equal to or less than 9 hours, equal to or less than 8 hours, equal to or less than 7 hours, equal to or less than 6 hours, or equal to or less than 5 hours. In one embodiment, the half-life of the antibody is 5 to 7 hours; 5 to 9 hours; 15 to 11 hours; 5 to 13 hours; 5 to 15 hours; 5 to 20 hours; 5 to 24 hours; 7 to 24 hours; 9 to 24 hours; 11 to 24 hours; 12 to 22 hours; 10 to 20 hours; 8 to 18 hours; or 14 to 24 hours.

[0266] Anti-CD117 antibodies that can be used in conjunction with the patient pretreatment methods described herein include, for example, antibodies generated and released from ATCC accession number 10716 (deposited as BA7.3C.9), such as SR-1 antibodies, which are described, for example, in U.S. Patent No. 5,489,516, the disclosure of which is incorporated herein by reference because it relates to anti-CD117 antibodies.

[0267] In one embodiment, the anti-CD117 antibody described herein comprises an Fc region containing L235A, L235A, D265C, and H435A (EU index).

[0268] Other anti-CD117 antibodies that can be used in conjunction with the patient pretreatment methods described herein include those described in U.S. Patent No. 7,915,391, which describes, for example, a humanized SR-1 antibody; U.S. Patent No. 5,808,002, which describes, for example, an anti-CD117 A3C6E2 antibody; and those described, for example, in WO 2015 / 050959, which describes an anti-CD117 antibody that binds to epitopes comprising Pro317, Asn320, Glu329, Val331, Asp332, Lus358, Glue360, Glue376, His378, and / or Thr380 of human CD117; and US 2012 / 0288506 (also disclosed as U.S. Patent No. 8,552,157), which describes, for example, an anti-CD117 antibody CK6 (which may also be referred to herein interchangeably as Ab4), having the following CDR sequence:

[0269] CDR-H1 (SEQ ID NO:1) with the amino acid sequence SYWIG;

[0270] CDR-H2 (SEQ ID NO:2) with the amino acid sequence IIYPGDSDTRYSPSFQG;

[0271] CDR-H3 (SEQ ID NO:3) with the amino acid sequence HGRGYNGYEGAFDI;

[0272] CDR-L1 (SEQ ID NO:4) with the amino acid sequence RASQGISSALA;

[0273] CDR-L2 (SEQ ID NO:5) with the amino acid sequence DASSLES; and

[0274] CDR-L3 (SEQ ID NO:6) has the amino acid sequence CQQFNSYPLT.

[0275] The amino acid sequence of the heavy chain variable region of CK6 is provided in SEQ ID NO 27: CDR text is underlined and in bold.

[0276] The variable sequence of the light chain amino acid of CK6 is provided in SEQ ID NO28:

[0277] CDR text is underlined and in bold.

[0278] Additional anti-CD117 antibodies and their antigen-binding fragments that can be used in conjunction with the compositions and methods described herein include those described in US 2015 / 0320880, such as clone 9P3, NEG024, NEG027, NEG085, NEG086, and 20376.

[0279] The disclosure of each of the aforementioned publications is incorporated herein by reference because they relate to anti-CD117 antibodies. Antibody and antigen-binding fragments that can be used in conjunction with the compositions and methods described herein include the antibodies and their antigen-binding fragments described above, as well as humanized variants of those non-human antibody and antigen-binding fragments described above and antibodies or antigen-binding fragments that bind to the same epitopes as those described above (e.g., as assessed by a competitive CD117 binding assay).

[0280] Exemplary antigen-binding fragments of the aforementioned antibodies include dual variable immunoglobulin domains, single-chain Fv molecules (scFv), double-chain antibodies, triple-chain antibodies, nanobodies, antibody-like protein scaffolds, Fv fragments, Fab fragments, F(ab')2 molecules, and tandem double scFv, etc.

[0281] Antibodies can be produced using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567. In one embodiment, an isolated nucleic acid encoding the anti-CD117 antibody described herein is provided. This nucleic acid may encode an amino acid sequence comprising VL and / or an amino acid sequence comprising VH of the antibody (e.g., the light chain and / or heavy chain of the antibody). In another embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In another embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, the host cell comprises (e.g., has been transformed): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VL and an amino acid sequence comprising an antibody VH, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VL, and a second vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VH. In one embodiment, the host cell is a eukaryotic cell, such as Chinese hamster ovary (CHO) cells or lymphocytes (e.g., Y0, NSO, Sp20 cells). In one embodiment, a method for preparing an anti-CLL-1 antibody is provided, wherein the method includes culturing a host cell containing a nucleic acid encoding the antibody under conditions suitable for antibody expression, as provided above, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0282] To recombinantly generate anti-CD117 antibodies, the nucleic acid encoding the antibody (e.g., as described above) is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. This nucleic acid can be readily isolated and sequenced using conventional methods (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the antibody heavy and light chains).

[0283] Host cells suitable for cloning or expressing vectors encoding antibodies include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be generated in bacteria, particularly when glycosylation and Fc effector function are not required. For information on the expression of antibody fragments and peptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523 (see also Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo, editor, Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in *E. coli*). Following expression, the antibody can be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0284] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted for suspension growth can be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 cell lines transformed with SV40 (COS-7); human embryonic kidney lines (293 or 293 cells, as described, for example, in Graham et al., J. Gen Virol. 36:59 (1977)); young hamster kidney cells (BHK); mouse podocytes (TM4 cells, as described, for example, in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumors (MMT 060562); TRI cells, as described, for example, in Mather et al., Annals As described in NYAcad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NSO, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).

[0285] In one embodiment, the anti-CD117 antibody or its antigen-binding fragment comprises a variable region having an amino acid sequence that is at least 95%, 96%, 97%, or 99% identical to that of the SEQ ID NO disclosed herein. Alternatively, the anti-CD117 antibody or its antigen-binding fragment comprises a CDR containing the SEQ ID NO disclosed herein, wherein the frame region of the variable region described herein has an amino acid sequence that is at least 95%, 96%, 97%, or 99% identical to that of the SEQ ID NO disclosed herein.

[0286] In one embodiment, the anti-CD117 antibody or its antigen-binding fragment comprises a heavy chain variable region and a heavy chain constant region having the amino acid sequences disclosed herein. In another embodiment, the anti-CD117 antibody or its antigen-binding fragment comprises a light chain variable region and a light chain constant region having the amino acid sequences disclosed herein. In yet another embodiment, the anti-CD117 antibody or its antigen-binding fragment comprises a heavy chain variable region, a light chain variable region, a heavy chain constant region, and a light chain constant region having the amino acid sequences disclosed herein.

[0287] Other anti-CD117 antibodies are described in US 2019 / 0153114 A1 and US 2019 / 0144558 A1, the contents of which are hereby expressly incorporated in their entirety by reference.

[0288] The anti-CD117 antibody and ADC described herein can be used to treat a variety of conditions, such as cell type diseases in the hematopoietic lineage, cancer, autoimmune diseases, metabolic disorders, and stem cell diseases. The compositions and methods described herein can (I) directly deplete pathological cell populations, such as cancer cells (e.g., leukemia cells) and autoimmune cell populations (e.g., autoreactive T cells), and / or (ii) deplete endogenous hematopoietic stem cell populations, thereby facilitating the engraftment of transplanted hematopoietic stem cells by providing a niche where transplanted cells can settle. The aforementioned activities can be achieved by administering an ADC, antibody, or antigen-binding fragment thereof capable of binding to antigens expressed by endogenous pathogenic cells, autoimmune cells, or hematopoietic stem cells. In the case of directly treating a disease, this administration can result in a reduction in the number of cells causing the target pathology. In the case of preparing a patient for hematopoietic stem cell transplantation therapy, this administration can result in selective depletion of the endogenous hematopoietic stem cell population, thereby creating a vacancy in hematopoietic tissue, such as bone marrow, which can then be filled by transplanted exogenous hematopoietic stem cells. This invention is partly based on the discovery that ADCs, antibodies, or antigen-binding fragments thereof capable of binding to CD117 (e.g., GNNK+CD117) can be administered to patients to influence both of these activities. CD117-binding ADCs, antibodies, or antigen-binding fragments thereof can be administered to patients suffering from cancer or autoimmune diseases to directly deplete cancer cells or autoimmune cell populations, and can be administered to patients requiring hematopoietic stem cell transplantation therapy to promote the survival and engraftment potential of transplanted hematopoietic stem cells.

[0289] Engraftment of hematopoietic stem cell transplants resulting from the administration of anti-CD117 ADCs, antibodies, or their antigen-binding fragments can be observed in a variety of empirical measurements. For example, after administration of an ADC, antibody, or its antigen-binding fragment capable of binding to CD117, followed by the administration of a hematopoietic stem cell transplant, engraftment can be evaluated by assessing the number of competing reimplantation units (CRUs) present in the patient's bone marrow. Alternatively, engraftment can be observed by incorporating a reporter gene (e.g., an enzyme that catalyzes a chemical reaction that produces fluorescence, chromophores, or luminescent products) into a vector transfected with donor hematopoietic stem cells, followed by monitoring the corresponding signal in the tissue where the hematopoietic stem cells have settled (e.g., bone marrow). Engraftment can also be observed by evaluating the number and viability of hematopoietic stem cells and progenitor cells, for example, as determined by fluorescence-activated cell sorting (FACS) analysis methods known in the art. Engraftment can also be determined by measuring the white blood cell count in peripheral blood during the post-transplant period and / or by measuring the recovery of donor cells from bone marrow cells in a bone marrow aspirate sample.

[0290] anti-CD2 antibody

[0291] Human CD2 is also known as T cell surface antigen T11 / Leu-5, T11, CD2 antigen (p50), and sheep erythrocyte receptor (SRBC). CD2 is expressed on T cells. Two isotypes of human CD2 have been identified. Isotype 1, containing 351 amino acids, is described in Seed, B. et al. (1987) 84:3365-69 (see also Sewell et al. (1986) 83:8718-22) and below (NCBI reference sequence: NP_001758.2):

[0292] msfpckfvas flllifnvssk gavskeitna letwgalgqd inldipsfqm sddiddikwe

[0293] ktsdkkkiaq frkeketfke kdtyklfkng tlkikhlktd dqdiykvsiy dtkgknvlek

[0294] ifdlkiqerv skpkiswtci nttltcevmn gtdpelnlyq dgkhlklsqr vithkwttsl

[0295] sakfkctagn kvskessvep vscpekgldi yliigicggg sllmvfvall vfyitkrkkq

[0296] rsrrndeele trahrvatee rgrkphqipa stpqnpatsq hpppppghrs qapshrpppp

[0297] ghrvqhqpqk rppapsgtqv hqqkgpplpr prvqpkpphg aaenslspss n(SEQ ID NO:29)

[0298] The second isoform of CD2 is 377 amino acids and was identified in this paper as the NCBI reference sequence: NP_001315538.1.

[0299] In one embodiment, anti-CD2 antibodies that can be used in conjunction with the compositions and methods described herein include those having one or more or all of the following CDRs:

[0300] a. CDR-H1 (SEQ ID NO:30) with the amino acid sequence EYYMY;

[0301] b. CDR-H2 (SEQ ID NO:31) having the amino acid sequence RIDPEDGSIDYVEKFKK;

[0302] c. CDR-H3 (SEQ ID NO:32) having the amino acid sequence GKFNYRFAY;

[0303] d. CDR-L1 (SEQ ID NO:33) having the amino acid sequence RSSQSLLHSSGNTYLN;

[0304] e. CDR-L2 (SEQ ID NO:34) having the amino acid sequence LVSKLES; and

[0305] f. CDR-L3 (SEQ ID NO:35) having the amino acid sequence MQFTHYPYT.

[0306] In one embodiment, the anti-CD2 antibody or its antigen-binding portion comprises a heavy chain variable region as described in the amino acid sequence of SEQ ID NO: 36 and a light chain variable region as described in the amino acid sequence of SEQ ID NO: 37.

[0307] In one embodiment, anti-CD2 antibodies that can be used in conjunction with the compositions and methods described herein include those having one or more or all of the following CDRs:

[0308] a. CDR-H1 (SEQ ID NO:38) with the amino acid sequence GFTFSSY;

[0309] b. CDR-H2 (SEQ ID NO:39) having the amino acid sequence SGGGF;

[0310] c. CDR-H3 (SEQ ID NO:40) having the amino acid sequence SSYGEIMDY;

[0311] d. CDR-L1 (SEQ ID NO:42) having the amino acid sequence RASQRIGTSIH;

[0312] e. CDR-L2 (SEQ ID NO:43) with the amino acid sequence YASESIS; and

[0313] f. CDR-L3 (SEQ ID NO:44) having the amino acid sequence QQSHGWPFTF.

[0314] In one embodiment, the anti-CD2 antibody or its antigen-binding portion comprises a heavy chain variable region as described in the amino acid sequence of SEQ ID NO45 and a light chain variable region as described in the amino acid sequence of SEQ ID NO47.

[0315] In another embodiment, anti-CD2 antibodies that can be used in conjunction with the compositions and methods described herein include those having one or more or all of the following CDRs:

[0316] a. CDR-H1 (SEQ ID NO:38) with the amino acid sequence GFTFSSY;

[0317] b. CDR-H2 (SEQ ID NO:39) having the amino acid sequence SGGGF;

[0318] c. CDR-H3 (SEQ ID NO:41) having the amino acid sequence SSYGELMDY;

[0319] d. CDR-L1 (SEQ ID NO:42) having the amino acid sequence RASQRIGTSIH;

[0320] e. CDR-L2 (SEQ ID NO:43) with the amino acid sequence YASESIS; and

[0321] f. CDR-L3 (SEQ ID NO:44) having the amino acid sequence QQSHGWPFTF.

[0322] In one embodiment, the anti-CD2 antibody or its antigen-binding portion comprises a heavy chain variable region as described in the amino acid sequence of SEQ ID NO46 and a light chain variable region as described in the amino acid sequence of SEQ ID NO47.

[0323] Antibodies containing the aforementioned CDR sequence and their antigen-binding fragments are described, for example, in U.S. Patent No. 6,849,258, the disclosure of which is incorporated herein by reference because it relates to anti-CD2 antibodies and their antigen-binding fragments.

[0324] In addition, in some implementations, the serum half-life of the anti-CD2 antibody in human subjects is 3 days or less.

[0325] Additional sequences of the anti-CD2 antibody or binding fragment described herein are provided in Table 5.

[0326] Additional anti-CD2 antibodies, their antigen-binding fragments, or their ADCs that can be used in the compositions and methods described herein can be identified using techniques known in the art, such as hybridoma generation. Hybridomas can be prepared using a mouse system. Protocols for immunization and subsequent isolation of spleen cells for fusion are known in the art. Fusion partners and procedures for hybridoma generation are also known. Alternatively, anti-CD2 antibodies can be used with HuMAb- Or XenoMouse TM The CD2 antigen is isolated and / or purified during the preparation of additional anti-CD2 antibodies. The CD2 antigen may be a fragment of the CD2 extracellular domain. Animal immunization can be performed by any method known in the art. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual, New York: Cold Spring Harbor Press, 1990. Methods for immunizing animals (e.g., mice, rats, sheep, goats, pigs, cattle, and horses) are well known in the art. See Harlow and Lane, as above, and U.S. Patent No. 5,994,619. The CD2 antigen may be administered with an adjuvant to stimulate an immune response. Adjuvants known in the art include complete or incomplete Freund's adjuvant, RIBI (muramicyl dipeptide), or ISCOM (immunostimulatory complex). After immunization of the animal with the CD2 antigen, immortalized cell lines producing antibodies are prepared from cells isolated from the immunized animal. Following immunization, the animals are euthanized, and the lymph nodes and / or spleen B cells are immortalized using methods known in the art (e.g., oncogene transfer, oncoviral transduction, exposure to oncogenes or mutagenic compounds, fusion with immortalized cells such as myeloma cells, and inactivation of tumor suppressor genes). See, for example, Harlow and Lane, as above. Desired characteristics of the hybridoma can be selected, cloned, and further screened, including robust growth, high antibody production, and desired antibody signatures.

[0327] Anti-CD2 antibodies used in the anti-CD2 ADCs described herein can also be identified using high-throughput screening of libraries of antibodies or antibody fragments against molecules capable of binding to CD2. Such methods include in vitro display techniques known in the art, such as phage display, bacterial display, yeast display, mammalian cell display, ribosome display, mRNA display, and cDNA display. The use of phage display to isolate antibodies, antigen-binding fragments, or ligands that bind to biologically relevant molecules has been outlined in, for example, Felici et al., Biotechnol. Annual Rev. 1:149-183, 1995; Katz, Annual Rev. Biophys. Biomol. Struct. 26:27-45, 1997; and Hoogenboom et al., Immunotechnology 4:1-20, 1998, the disclosures of which are incorporated herein by reference because they relate to in vitro display techniques. Randomly combinable peptide libraries have been constructed to select peptides that bind to cell surface antigens, as described in Kay, Perspect. Drug Discovery Des. 2:251-268, 1995 and Kay et al., Mol. Divers. 1:139-140, 1996, the contents of each of which are incorporated herein by reference because they relate to the discovery of antigen-binding molecules. Proteins, such as multimeric proteins, have been successfully displayed as functional molecules in phages (see, e.g., EP 0349578; EP4527839; and EP 0589877, and Chiswell and McCafferty, Trends Biotechnol. 10:80-84, 1992, the contents of which are incorporated herein by reference because they relate to the use of in vitro display techniques to discover antigen-binding molecules). Additionally, functional antibody fragments, such as Fab and scFv fragments, have been expressed in in vitro display forms (see, e.g., McCafferty et al., Nature 348:552-554, 1990; Barbas et al., Proc. Natl. Acad. Sci. USA). 88:7978-7982, 1991; and Clackson et al., Nature 352:624-628, 1991, the contents of each of which are incorporated herein by reference because they relate to in vitro display platforms for the discovery of antigen-binding molecules).

[0328] In addition to in vitro display techniques, computational modeling techniques can be used in computers to design and identify anti-CD2 antibodies or antibody fragments, for example, using the procedures described in US 2013 / 0288373, the disclosure of which is incorporated herein by reference as it relates to molecular modeling methods for identifying anti-CD2 antibodies. For instance, using computational modeling techniques, those skilled in the art can screen a library of antibodies or antibody fragments in a computer for molecules capable of binding to specific epitopes on CD2 (e.g., extracellular epitopes of CD2).

[0329] In one embodiment, the anti-CD2 antibody used in the ADC described herein is capable of internalization into cells. In identifying anti-CD2 antibodies (or fragments thereof), additional techniques can be used to identify antibodies or antigen-binding fragments that bind to CD2 on the surface of cells (e.g., T cells) and are also capable of being internalized by the cells (e.g., via receptor-mediated endocytosis). For example, the in vitro display techniques described above are suitable for screening antibodies or antigen-binding fragments thereof that bind to CD2 on the surface of hematopoietic stem cells and subsequently become internalized. Phage display represents a technique that can be used in conjunction with this screening modality. To identify anti-CD2 antibodies or fragments thereof that bind to CD2 and subsequently become internalized into CD2+ cells, those skilled in the art can use the phage display techniques described in Williams et al., Leukemia 19:1432-1438, 2005, the disclosure of which is incorporated herein by reference in its entirety.

[0330] The internalization capability of anti-CD2 antibodies or fragments thereof can be assessed, for example, using radionuclide internalization assays known in the art. For instance, anti-CD2 antibodies or fragments thereof identified using in vitro display techniques described herein or known in the art can be functionalized by incorporating a radioisotope, for example... 18 F, 75 Br、 77 Br、 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At、 67 Ga、 111 In、 99 Tc, 169 Yb、 186 Re、 64 Cu、 67 Cu、 177 Lu、 77 As、 72 As、 86 Y、 90 Y、 89 Zr、 212Bi、 213 Bior 225 Ac. For example, radioactive halogens, for example 18 F, 75 Br、 77 Br、 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At this stage, beads (e.g., polystyrene beads) containing an electrophilic halogen reagent (e.g., iodide beads, Thermo Fisher Scientific, Inc., Cambridge, MA) can be incorporated into the antibody, its fragment, or ligand. The radiolabeled antibody or its fragment can be incubated with hematopoietic stem cells for a time sufficient to allow internalization. The internalized antibody or its fragment can be identified by detecting radiation emitted by the resulting hematopoietic stem cells (e.g., gamma radiation) and comparing it with radiation emitted by the recovered wash buffer (e.g., gamma radiation). The aforementioned internalization assay can also be used to characterize the ADC.

[0331] In some embodiments, the anti-CD2 antibody (or a fragment thereof) has a defined serum half-life. For example, the serum half-life of an anti-CD2 antibody (or a fragment thereof) in a human patient may be about 1-24 hours. Similarly, an ADC containing such an anti-CD2 antibody may also have a serum half-life of about 1-24 hours in a human patient. Pharmacokinetic analysis by measuring serum levels can be performed using assays known in the art.

[0332] To recombinantly generate anti-CD2 antibodies, the nucleic acid encoding the antibody (e.g., as described above) is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. This nucleic acid can be readily isolated and sequenced using standard procedures, such as by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of the antibody.

[0333] Host cells suitable for cloning or expressing vectors encoding antibodies include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be generated in bacteria, particularly when glycosylation and Fc effector function are not required. For information on the expression of antibody fragments and peptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523 (see also Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo, editor, Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in *E. coli*). Following expression, the antibody can be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0334] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted for suspension growth can be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 cell lines transformed with SV40 (COS-7); human embryonic kidney lines (293 or 293 cells, as described, for example, in Graham et al., J. Gen Virol. 36:59 (1977)); young hamster kidney cells (BHK); mouse podocytes (TM4 cells, as described, for example, in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumors (MMT 060562); TRI cells, as described, for example, in Mather et al., Annals As described in NYAcad.Sci.383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NSO, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, editor, HumanaPress, Totowa, NJ), pp. 255-268 (2003). In one embodiment, the host cell is a eukaryotic cell, such as Chinese hamster ovary (CHO) cells or lymphocytes (e.g., Y0, NSO, Sp20 cells).

[0335] anti-CD5 antibody

[0336] Human CD5 is also known as lymphocyte antigen T1, T1, Leu-1, and LEU1. CD5 is expressed on human T cells. Two isotypes of human CD5 have been identified. Isotype 1 contains 495 amino acids and has been described in Gladkikh et al. (2017) Cancer Med. 6(12):2984 and Jones et al. (1986) Nature 323(6086):346. The amino acid sequence of CD5 (isotype 1) is provided below (NCBI reference sequence: NP_055022.2):

[0337]

[0338] The second isoform of human CD5 (SEQ ID NO:339) is 438 amino acids (see the underlined portion above) and has been identified as the NCBI reference sequence: NP_001333385.1. Unlike isoform 1, CD5 isoform 2 is an intracellular protein. Compared to isoform 1, isoform 2 contains a different 5' UTR and lacks the in-frame portion of the 5' coding region. Compared to isoform 1, the resulting isoform 2 has a shorter N-terminus. Compared to isoform 1, CD5 isoform 2 lacks a leader peptide and represents the intracellular isoform found in B lymphocyte subsets. The ADC described herein is specific for human CD5 isoform 1, representing the extracellular form of human CD5.

[0339] In one embodiment, the anti-CD5 antibody that can be used in the methods and compositions described herein is antibody 5D7v (Ab5D7v). The amino acid sequence of the heavy chain variable region (VH) of Ab5D7v is provided below as SEQ ID NO:49.

[0340] QVTLKESGPVLVKPTETLTLTCTFSG FSLSTSGMG VGWIRQAPGKGLEWVAHI WWDDD VYYNPSLKSRLTITKDASKDQVSLKLSSVTAADTAVYYCVR RRATGTGFDY WGQGTLVTVSS(SEQ ID NO:49)

[0341] The VH CDR amino acid sequences of Ab5D7v are underlined above and are as follows: FSLTSGMG (VH CDR1; SEQ ID NO:51); WWDDD (VH CDR2; SEQ ID NO:52); and RRATGTGFDY (VH CDR3; SEQ ID NO:53).

[0342] The amino acid sequence of the light chain variable region (VL) of Ab5D7v is provided below as SEQ ID NO:50.

[0343] NIVMTQSPSSLSASVGDRVTITCQAS QDVGTA VAWYQQKPDQSPKLLIY WTSTRHT GVPDRFTGSGSGTDFTLTISSLQPEDIATYFCHQ YNSYNT FGSGTKLEIK(SEQ ID NO:50)

[0344] The VL CDR amino acid sequences of Ab5D7v are underlined above and are as follows: QDVGTA (VL CDR1; SEQ ID NO: 54); WTSTRHT (VL CDR2; SEQ ID NO: 55); and YNSYNT (VL CDR3; SEQ ID NO: 56).

[0345] In one embodiment, the anti-CD5 ADC comprises an anti-CD5 antibody comprising a heavy chain containing a CDR1 domain containing the amino acid sequence described in SEQ ID NO:51, a CDR2 domain containing the amino acid sequence described in SEQ ID NO:52, and a CDR3 domain containing the amino acid sequence described in SEQ ID NO:53; and a light chain containing a CDR1 domain containing the amino acid sequence described in SEQ ID NO:54, a CDR2 domain containing the amino acid sequence described in SEQ ID NO:55, and a CDR3 domain containing the amino acid sequence described in SEQ ID NO:56, wherein the antibody is conjugated to a cytotoxin via a linker.

[0346] In one embodiment, the anti-CD5 ADC comprises an anti-CD5 antibody comprising a heavy chain containing a variable region comprising an amino acid sequence as described in SEQ ID NO:49; and a light chain containing a variable region comprising an amino acid sequence as described in SEQ ID NO:50, wherein the antibody is conjugated to a cytotoxin via a linker.

[0347] In another embodiment, the anti-CD5 antibody used in the ADCs described herein is a 5D7 antibody (see, for example, US20080254027, the disclosure of which is incorporated herein by reference). In another embodiment, the anti-CD5 antibody used in the methods and compositions (including ADCs) described herein is a variant of the 5D7 antibody (see, for example, US 20080254027, the disclosure of which is incorporated herein by reference).

[0348] Furthermore, in some embodiments, the serum half-life of the anti-CD5 ADC in human subjects is 3 days or less. Additional sequences of the anti-CD5 antibody or binding fragment described herein are provided in Table 5.

[0349] Additional anti-CD5 antibodies that can be used with the ADC described herein can be identified using techniques known in the art, such as hybridoma generation. Hybridomas can be prepared using a mouse system. Protocols for immunization and subsequent isolation of spleen cells for fusion are known in the art. Fusion partners and procedures for hybridoma generation are also known. Alternatively, the anti-CD5 antibody can be HuMAb- Or XenoMouse TM The CD5 antigen is isolated and / or purified during the preparation of additional anti-CD5 antibodies. The CD5 antigen may be a fragment of the CD5 extracellular domain. Animal immunization can be performed by any method known in the art. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual, New York: Cold Spring Harbor Press, 1990. Methods for immunizing animals (e.g., mice, rats, sheep, goats, pigs, cattle, and horses) are well known in the art. See Harlow and Lane, as above, and U.S. Patent No. 5,994,619. The CD5 antigen may be administered with an adjuvant to stimulate an immune response. Adjuvants known in the art include complete or incomplete Freund's adjuvant, RIBI (muramicyl dipeptide), or ISCOM (immunostimulatory complex). After immunization of animals with the CD5 antigen, immortalized cell lines producing antibodies are prepared from cells isolated from the immunized animals. Following immunization, the animals are euthanized, and the lymph nodes and / or spleen B cells are immortalized using methods known in the art (e.g., oncogene transfer, oncoviral transduction, exposure to oncogenes or mutagenic compounds, fusion with immortalized cells such as myeloma cells, and inactivation of tumor suppressor genes). See, for example, Harlow and Lane, as above. Desired characteristics of the hybridoma can be selected, cloned, and further screened, including robust growth, high antibody production, and desired antibody signatures.

[0350] Anti-CD5 antibodies used in the anti-CD5 ADCs described herein can also be identified using high-throughput screening of libraries of antibodies or antibody fragments against molecules capable of binding to CD5. Such methods include in vitro display techniques known in the art, such as phage display, bacterial display, yeast display, mammalian cell display, ribosome display, mRNA display, and cDNA display. The use of phage display to isolate antibodies, antigen-binding fragments, or ligands that bind to biologically relevant molecules has been outlined in, for example, Felici et al., Biotechnol. Annual Rev. 1:149-183, 1995; Katz, Annual Rev. Biophys. Biomol. Struct. 26:27-45, 1997; and Hoogenboom et al., Immunotechnology 4:1-20, 1998, the disclosures of which are incorporated herein by reference because they relate to in vitro display techniques. Randomly combinable peptide libraries have been constructed to select peptides that bind to cell surface antigens, as described in Kay, Perspect. Drug Discovery Des. 2:251-268, 1995 and Kay et al., Mol. Divers. 1:139-140, 1996, the contents of each of which are incorporated herein by reference because they relate to the discovery of antigen-binding molecules. Proteins, such as multimeric proteins, have been successfully displayed as functional molecules in phages (see, e.g., EP 0349578; EP4527839; and EP 0589877, and Chiswell and McCafferty, Trends Biotechnol. 10:80-84, 1992, the contents of which are incorporated herein by reference because they relate to the use of in vitro display techniques to discover antigen-binding molecules). Additionally, functional antibody fragments, such as Fab and scFv fragments, have been expressed in in vitro display forms (see, e.g., McCafferty et al., Nature 348:552-554, 1990; Barbas et al., Proc. Natl. Acad. Sci. USA). 88:7978-7982, 1991; and Clackson et al., Nature 352:624-628, 1991, the contents of each of which are incorporated herein by reference because they relate to in vitro display platforms for the discovery of antigen-binding molecules).

[0351] In addition to in vitro display techniques, computational modeling techniques can be used in computers to design and identify anti-CD5 antibodies or antibody fragments, for example, using the procedures described in US 2013 / 0288373, the disclosure of which is incorporated herein by reference as it relates to molecular modeling methods for identifying anti-CD2 antibodies. For example, using computational modeling techniques, those skilled in the art can screen a library of antibodies or antibody fragments in a computer for molecules capable of binding to specific epitopes on CD5 (e.g., extracellular epitopes of CD5).

[0352] In one embodiment, the anti-CD5 antibody used in the ADC described herein is capable of internalization into cells. In identifying anti-CD5 antibodies (or fragments thereof), additional techniques can be used to identify antibodies or antigen-binding fragments that bind to CD5 on the surface of cells (e.g., T cells) and are also capable of being internalized by the cells (e.g., via receptor-mediated endocytosis). For example, the in vitro display techniques described above are suitable for screening antibodies or antigen-binding fragments thereof that bind to CD5 on the surface of hematopoietic stem cells and subsequently become internalized. Phage display represents a technique that can be used in conjunction with this screening modality. To identify anti-CD5 antibodies or fragments thereof that bind to CD5 and subsequently become internalized into CD5+ cells, those skilled in the art can use the phage display techniques described in Williams et al., Leukemia 19:1432-1438, 2005, the disclosure of which is incorporated herein by reference in its entirety.

[0353] The internalization capability of anti-CD5 antibodies or fragments thereof can be assessed, for example, using radionuclide internalization assays known in the art. For instance, anti-CD5 antibodies or fragments thereof identified using in vitro display techniques described herein or known in the art can be functionalized by incorporating a radioisotope, for example... 18 F, 75 Br、 77 Br、 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At、 67 Ga、 111 In、 99 Tc, 169 Yb、 186 Re、 64 Cu、 67 Cu、 177 Lu、 77 As、 72 As、 86 Y、 90 Y、 89 Zr、 212Bi、 213 Bior 225 Ac. For example, radioactive halogens, for example 18 F, 75 Br、 77 Br、 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At this stage, beads (e.g., polystyrene beads) containing an electrophilic halogen reagent (e.g., iodide beads, Thermo Fisher Scientific, Inc., Cambridge, MA) can be incorporated into the antibody, its fragment, or ligand. The radiolabeled antibody or its fragment can be incubated with hematopoietic stem cells for a time sufficient to allow internalization. The internalized antibody or its fragment can be identified by detecting radiation emitted by the resulting hematopoietic stem cells (e.g., gamma radiation) and comparing it with radiation emitted by the recovered wash buffer (e.g., gamma radiation). The aforementioned internalization assay can also be used to characterize the ADC.

[0354] In some embodiments, the anti-CD5 antibody (or a fragment thereof) has a defined serum half-life. For example, the serum half-life of an anti-CD5 antibody (or a fragment thereof) in a human patient may be about 1-24 hours. Similarly, an ADC containing such an anti-CD5 antibody may also have a serum half-life of about 1-24 hours in a human patient. Pharmacokinetic analysis by measuring serum levels can be performed using assays known in the art.

[0355] To recombinantly generate anti-CD5 antibodies, the nucleic acid encoding the antibody (e.g., as described above) is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. This nucleic acid can be readily isolated and sequenced using standard procedures, such as by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of the antibody.

[0356] Host cells suitable for cloning or expressing vectors encoding antibodies include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be generated in bacteria, particularly when glycosylation and Fc effector function are not required. For information on the expression of antibody fragments and peptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523 (see also Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo, editor, Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in *E. coli*). Following expression, the antibody can be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0357] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted for suspension growth can be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 cell lines transformed with SV40 (COS-7); human embryonic kidney lines (293 or 293 cells, as described, for example, in Graham et al., J. Gen Virol. 36:59 (1977)); young hamster kidney cells (BHK); mouse podocytes (TM4 cells, as described, for example, in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumors (MMT 060562); TRI cells, as described, for example, in Mather et al., Annals As described in NYAcad.Sci.383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NSO, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, editor, HumanaPress, Totowa, NJ), pp. 255-268 (2003). In one embodiment, the host cell is a eukaryotic cell, such as Chinese hamster ovary (CHO) cells or lymphocytes (e.g., Y0, NSO, Sp20 cells).

[0358] In some embodiments, anti-CD5 antibodies that can be used in conjunction with the compositions and methods described herein include antibodies containing a combination of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3 regions as described in Tables 1 and 2 below.

[0359] Table 1

[0360]

[0361]

[0362] Table 2

[0363]

[0364]

[0365] Anti-CD137 antibody

[0366] CD137 is also known as CDw137, TNFRSF9, 4-1BB, and ILA. Anti-CD137 antibodies, their antigen-binding fragments, and their antibody-drug conjugates (ADCs) are available as therapeutic agents to prevent and treat GVHD derived from hematopoietic stem cells in patients suffering from or at risk of GVHD or autoimmune diseases. Additionally, ligands that bind to CD137, such as human CD137L, have been found to be available as therapeutic agents to prevent or treat patients suffering from or at risk of GVHD. These ligands, such as soluble human CD137, can covalently bind to effector domains, such as the Fc domain, to promote antibody-dependent cell-mediated cytotoxicity (ADCC).

[0367] T cells have been shown to express CD137 because this antigen is a transmembrane TNF receptor superfamily of co-stimulatory molecules and is expressed on a variety of hematopoietic cells, promoting T cell activation and regulating T cell proliferation and survival (see, for example, Cannons et al., J. Immunol. 167:1313-1324, 2001, the disclosure of which is incorporated herein by reference because it relates to the expression of CD137 via T cells). Antibodies and their antigen-binding fragments can be identified using techniques known in the art and described herein, such as by immunology, computational modeling techniques and in vitro selection methods, such as phage display and cell-based display platforms described below.

[0368] Anti-CD137 antibodies that can be used for the prevention and treatment of GVHD or autoimmune diseases using the methods disclosed herein include those having one or more or all of the following CDRs:

[0369] a. CDR-H1 (SEQ ID NO:278) with the amino acid sequence STYWIS;

[0370] b. CDR-H2 (SEQ ID NO:279) having the amino acid sequence KIYPGDSYTNYSPSFQG;

[0371] c. CDR-H3 (SEQ ID NO:280) having the amino acid sequence RGYGIFDY;

[0372] d. CDR-L1 (SEQ ID NO:281) with the amino acid sequence SGDNIGDQYAH;

[0373] e. CDR-L2 (SEQ ID NO:282) having the amino acid sequence QDKNRPS; and

[0374] f. CDR-L3 (SEQ ID NO:283) having the amino acid sequence ATYTGFGSLAV

[0375] Additional anti-CD137 antibodies that can be used for the prevention and treatment of GVHD and autoimmune diseases using the methods disclosed herein include those having one or more or all of the following CDRs:

[0376] a. CDR-H1 (SEQ ID NO:278) with the amino acid sequence STYWIS;

[0377] b. CDR-H2 (SEQ ID NO:279) having the amino acid sequence KIYPGDSYTNYSPSFQG;

[0378] c. CDR-H3 (SEQ ID NO:280) having the amino acid sequence RGYGIFDY;

[0379] d. CDR-L1 (SEQ ID NO:281) with the amino acid sequence SGDNIGDQYAH;

[0380] e. CDR-L2 (SEQ ID NO:282) having the amino acid sequence QDKNRPS; and

[0381] f. CDR-L3 (SEQ ID NO:284) with the amino acid sequence STYTFVGFTTV

[0382] Other anti-CD137 antibodies include those with one or more or all of the following CDRs:

[0383] a. CDR-H1 (SEQ ID NO:285) with the amino acid sequence NSYAIS;

[0384] b. CDR-H2 (SEQ ID NO:286) having the amino acid sequence GIIPGFGTANYAQKFQG;

[0385] c. CDR-H3 (SEQ ID NO:287) having the amino acid sequence RKNEEDGGFDH;

[0386] d. CDR-L1 (SEQ ID NO:288) with the amino acid sequence SGDNLGDYYAS;

[0387] e. CDR-L2 (SEQ ID NO:289) with the amino acid sequence DDSNRPS; and

[0388] f. CDR-L3 (SEQ ID NO:290) having the amino acid sequence QTWDGTLHFV.

[0389] Other anti-CD137 antibodies or ADCs include those with one or more or all of the following CDRs:

[0390] a. CDR-H1 (SEQ ID NO:291) with the amino acid sequence SDYYMH;

[0391] b. CDR-H2 (SEQ ID NO:292) having the amino acid sequence VISGSGSNTYYADSVKG;

[0392] c. CDR-H3 (SEQ ID NO:293) having the amino acid sequence RLYAQFEGDF;

[0393] d. CDR-L1 (SEQ ID NO:294) with the amino acid sequence SGDNIGSKYVS

[0394] e. CDR-L2 (SEQ ID NO:295) with the amino acid sequence SDSERPS; and

[0395] f. CDR-L3 (SEQ ID NO:296) having the amino acid sequence QSWDGSISRV.

[0396] The aforementioned antibodies are described, for example, in U.S. Patent No. 9,468,678, the disclosure of which is incorporated herein by reference because it relates to anti-CD137 antibodies and their antigen-binding fragments. The antibodies and fragments disclosed in U.S. Patent No. 9,468,678 can be used in conjunction with the methods disclosed herein.

[0397] In another embodiment, the anti-CD137 antibody that can be used in the methods and compositions (including ADCs) described herein is a mouse anti-CD137 antibody BBK2 (Thermo Fisher; MS621PABX) or an anti-CD137 antibody containing an antigen-binding region corresponding to the BBK2 antibody. The BBK2 antibody (also referred to as BBK-2 antibody or anti-4-1BB antibody) is a mouse monoclonal antibody (IgG1, κ) that binds to the extracellular domain of a human 4-1BB recombinant protein (4-1BB is also referred to as CD137). In some embodiments, the methods and compositions of this disclosure include an anti-CD137 antibody containing a binding region (e.g., CDR) of the BBK2 antibody. In another embodiment, the methods and compositions of this disclosure include an antibody that competitively inhibits the binding of the BBK2 antibody to its epitope on CD137. In some embodiments, the anti-CD137 antibody is humanized BBK2 or chimeric BBK2.

[0398] In one embodiment, the methods and compositions described herein comprise a chimeric anti-CD137 (ch-BBK2) antibody containing a variable heavy chain region and a variable light chain region of BBK2. In some embodiments, the chimeric BBK2 antibody is an IgG1 antibody containing a human constant region. The heavy chain amino acid sequence of ch-BBK2 is described in SEQ ID NO:297, and the light chain amino acid sequence of ch-BBK2 is described in SEQ ID NO:298. The CDR regions (CDR1, CDR2, and CDR3) of each heavy and light chain sequence are described in bold below. Variable regions are in italics.

[0399]

[0400]

[0401] The aforementioned CDR regions (and BBK2 antibody) are described in Lee et al. (2002) European J of Immunogenetics 29(5):449-452. Therefore, in one embodiment, the VH CDR amino acid sequences of the anti-CD137 antibody BBK2 (including ch-BBK2) are as follows: SGYTFTSYW (VH CDR 1; SEQ ID NO:299); NIYPSDSYT (VH cdr 2; SEQ ID NO:300) and TRNGVEGYPHYYAME (VH CDR3; SEQ ID NO:301). The VLCDR amino acid sequences of the anti-CD137 antibody BBK2 (including ch-BBK2) are as follows: SQDLSNH (VL CDR 1; SEQ ID NO:302); YYTS (VL CDR 2; SEQ ID NO:303) and CQQGYTLPY (VL CDR3; SEQ ID NO:304).

[0402] Alternatively, the CDR regions of BBK2 can be defined according to the Kabat number. The CDRs defined by the Kabat number are described below for each heavy and light chain sequence (described in bold). The variable regions of BBK2 are in italics.

[0403]

[0404]

[0405] Therefore, in one embodiment, the VH CDR amino acid sequences of the anti-CD137 antibody BBK2 (including ch-BBK2) are as follows: SYWIN (VH CDR 1; SEQ ID NO:305); NIYPSDSYTNYNQKFKD (VH CDR2; SEQ ID NO:306) and NGVEYPHYYAMEY (CDR3; SEQ ID NO:307), and the VL CDR amino acid sequences of the anti-CD137 antibody BBK2 (including ch-BBK2) are as follows: RASQDLSNHLY (VL CDR 1; SEQ ID NO:308); YTSRLHS (VL CDR 2; SEQ ID NO:309) and QQGYTLPYT (VL CDR3; SEQ ID NO:310).

[0406] The heavy chain variable region of BBK2 is described in SEQ ID NO:311 as follows

[0407] The light chain variable region of BBK2 is described in SEQ ID NO:312 as follows:

[0408] Anti-CD137 antibodies (including anti-CD137 antibodies) may contain heavy and light chain variable region amino acid sequences as described in SEQ ID NO:311 and 312, respectively.

[0409] In one embodiment, the anti-CD137 antibody, such as a chimeric (ch-BBK2) antibody or a humanized BBK2 antibody, comprises a heavy chain variable region containing a CDR1 containing the amino acid sequence of SEQ ID NO:305, a CDR2 containing the amino acid sequence of SEQ ID NO:306, and a CDR3 containing the amino acid sequence of SEQ ID NO:307; and a light chain variable region containing a CDR1 containing the amino acid sequence of SEQ ID NO:308, a CDR2 containing the amino acid sequence of SEQ ID NO:309, and a CDR3 containing the amino acid sequence of SEQ ID NO:310.

[0410] In one embodiment, the anti-CD137 antibody, such as a chimeric (ch-BBK2) antibody or a humanized BBK2 antibody, comprises a heavy chain variable region containing a CDR1 containing the amino acid sequence of SEQ ID NO:299, a CDR2 containing the amino acid sequence of SEQ ID NO:300, and a CDR3 containing the amino acid sequence of SEQ ID NO:301; and a light chain variable region containing a CDR1 containing the amino acid sequence of SEQ ID NO:302, a CDR2 containing the amino acid sequence of SEQ ID NO:303, and a CDR3 containing the amino acid sequence of SEQ ID NO:304.

[0411] Therefore, BBK2, humanized BBK2, or chimeric BBK2 antibodies can be used in the anti-CD137 ADCs and methods described herein. Each of these antibodies can be conjugated with any of the cytotoxicants described below using methods known in the art and those described herein.

[0412] Additional sequences of the anti-CD137 antibody or binding fragment described herein are provided in Table 5.

[0413] Other anti-CD137 antibodies that can be conjugated with the cytotoxins described herein can be identified using techniques known in the art, such as hybridoma generation. Hybridomas can be prepared using a mouse system. Protocols for immunization and subsequent isolation of spleen cells for fusion are known in the art. Fusion partners and procedures for hybridoma generation are also known. Human anti-CD137 antibodies can be generated using HuMAb- Or XenoMouse TM The CD137 antigen is generated during the preparation of anti-CD137 antibodies. In preparing anti-CD137 antibodies, the CD137 antigen is isolated and / or purified. The CD137 antigen may be a fragment of the CD137 extracellular domain. Animal immunization can be performed by any method known in the art. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual, New York: Cold Spring Harbor Press, 1990. Methods for immunizing animals (e.g., mice, rats, sheep, goats, pigs, cattle, and horses) are well known in the art. See, for example, Harlow and Lane, as above, and U.S. Patent No. 5,994,619. The CD137 antigen may be administered with an adjuvant to stimulate an immune response. Adjuvants known in the art include complete or incomplete Freund's adjuvant, RIBI (muramicyl dipeptide), or ISCOM (immunostimulatory complex). After immunizing animals with the CD137 antigen, immortalized cell lines producing antibodies are prepared from cells isolated from the immunized animals. Following immunization, the animals are euthanized, and the lymph nodes and / or spleen B cells are immortalized using methods known in the art (e.g., oncogene transfer, oncoviral transduction, exposure to oncogenes or mutagenic compounds, fusion with immortalized cells such as myeloma cells, and inactivation of tumor suppressor genes). See, for example, Harlow and Lane, as above. Desired characteristics of the hybridoma can be selected, cloned, and further screened, including robust growth, high antibody production, and desired antibody signatures.

[0414] Anti-CD137 antibodies can be produced from isolated nucleic acid molecules containing a nucleotide sequence encoding an amino acid sequence of the CD137-binding molecule provided in this disclosure. The amino acid sequence encoded by the nucleotide sequence can be any part of the antibody, such as a CDR, a sequence containing one, two, or three CDRs, a variable region of the heavy chain, a variable region of the light chain, or can be a full-length heavy chain or a full-length light chain. The nucleic acid in this disclosure can be, for example, DNA or RNA, and may or may not contain intron sequences. Typically, the nucleic acid is a cDNA molecule.

[0415] In addition to antibody and antigen-binding fragments, soluble CD137 ligands, such as human CD137 ligands, can be administered to patients according to the methods described herein to pretreat patients prior to hematopoietic stem cell transplantation therapy. For example, CD137 ligands, such as human CD137 ligands, can be conjugated to cytotoxins (e.g., according to the methods described below or methods known in the art) or another effector molecule (e.g., an Fc domain). Maytansine cytotoxins used in the methods described herein include, for example, human CD137 ligand-IgG1 Fc conjugates, human CD137 ligand-IgG2 Fc conjugates, human CD137 ligand-IgG3 Fc conjugates, human CD137 ligand-IgG4 Fc conjugates, human CD137 ligand-IgA Fc conjugates, human CD137 ligand-IgE Fc conjugates, human CD137 ligand-IgM Fc conjugates, and human CD137 ligand-IgD Fc conjugates.

[0416] The antibodies and ligands used in conjunction with the compositions and methods described herein include variants of the antibodies described above, such as antibody fragments containing or lacking an Fc domain, as well as humanized variants of the nonhuman antibodies described herein and antibody-like protein scaffolds (e.g. 10 The Fn3 domain contains one or more or all of the CDRs or equivalent regions of the antibody, antibody fragment or soluble ligand described herein.

[0417] Anti-CD252 antibody

[0418] This invention also provides antibodies or antigen-binding fragments thereof capable of binding to CD252 (also known as OX40 ligands (OX40L), protein NCBI reference sequence: NP_003317.1; Uniprot accession number: P23510; SEQ ID NO: 313 or 314), which can be used as therapeutic agents for the prevention and treatment of GVHD. Such antibodies can be used alone or as antibody-drug conjugates (ADCs) conjugated with cytotoxic agents.

[0419] In one embodiment, the methods and compositions described herein (e.g., ADCs) comprise an anti-CD252 antibody whose heavy and light chain amino acid sequences are set forth in SEQ ID NO: 315 and 316, respectively. In one embodiment, the anti-CD252 antibody or its antigen-binding portion comprises a heavy chain variable region as described in the amino acid sequence of SEQ ID NO: 315 and a light chain variable region as described in the amino acid sequence of SEQ ID NO: 316. In one embodiment, the anti-CD252 antibody or its antigen-binding portion comprises a heavy chain variable region containing a CDR as described in the amino acid sequence of SEQ ID NO: 315 and a light chain variable region containing a CDR as described in the amino acid sequence of SEQ ID NO: 316. The amino acid sequences of SEQ ID NO: 315 and 316 are provided below.

[0420] In some embodiments, the anti-CD252 antibody or its antigen-binding portion comprises a heavy chain variable region containing a CDR as described in the amino acid sequences of SEQ ID NO:317-319 and a light chain variable region containing a CDR as described in the amino acid sequences of SEQ ID NO:320-322. The amino acid sequences of SEQ ID NO:3-8 are provided below.

[0421] Anti-CD252 VH amino acid sequence (the following CDR sequences are defined by IMGT)

[0422] EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWVSTISGSGGATRYADSVKGRFTISRDNSRNTVYLQMNSLRVEDTAVFYCTKDRLIMATVRGPYYYGMDVWGQGTTVTVSS(SEQ ID NO:315)

[0423] CDR-H1:GTFFSNYA(SEQ ID NO:317)

[0424] CDR-H2:ISGSGGAT(SEQ ID NO:318)

[0425] CDR-H3:TKDRLIMATVRGPYYYGMDV(SEQ ID NO:319)

[0426] Anti-CD252 VL amino acid sequence (the following CDR sequences are defined by IMGT)

[0427] DIQMTQSPSSSLSASVGDRVTITCRASQSISLNWYQQKPGKAPNLLIYAASSLQSGVPSRFSGSGSETDFTLTISSLQPEDFATYYCQQSHSVSFTFGPGTKVDIK(SEQ ID NO:316)

[0428] CDR-L1:QSISSY(SEQ ID NO:320)

[0429] CDR-L2:AAS(SEQ ID NO:321)

[0430] CDR-L3:QQSHSVSFT(SEQ ID NO:322)

[0431] In one embodiment, the anti-CD252 antibody used in the methods and compositions disclosed herein is a complete antibody comprising a heavy chain variable region as described in the amino acid sequence of SEQ ID NO:315 and a light chain variable region as described in the amino acid sequence of SEQ ID NO:316. In one embodiment, the anti-CD252 antibody is genetically engineered to have a short half-life.

[0432] In one embodiment, the anti-CD252 antibody that can be used in the methods and compositions (including ADCs) described herein is an antibody selected from 11c3.1 (Biologend, catalog #326302), 159403 (R&D system, catalog #MAB10541), 159408 (R&D system, catalog #MAB1054), MM0505-8S23 (Novus, catalog #NBP2-11969) or oxelumab (Novus catalog #NBP2).

[0433] In one embodiment, the anti-CD252 antibody that can be used in the methods and compositions (including ADCs) described herein is mouse monoclonal anti-CD252 antibody 11C3.1 or an anti-CD252 antibody containing an antigen-binding region corresponding to antibody 11C3.1. 11C3.1 (sold by Biolegend Cat, Cat. No. 326302 (dated February 27, 2019)).

[0434] In one embodiment, the anti-CD252 antibody comprises heavy chains of CDR1, CDR2, and CDR3 containing anti-CD252 antibody 11C3.1 and a light chain variable region containing CDR1, CDR2, and CDR3 of anti-CD252 antibody 11C3.1. In another embodiment, the anti-CD252 antibody used in the compositions and methods described herein is a humanized anti-CD252 antibody.

[0435] In one embodiment, the anti-CD252 antibody that can be used in the methods and compositions (including ADCs) described herein is mouse monoclonal anti-CD252 antibody 159403 or an anti-CD252 antibody containing an antigen-binding region corresponding to antibody 159403. 159403 (sold by R&D Systems, catalog #MAB10541 (dated February 27, 2019)).

[0436] In one embodiment, the anti-CD252 antibody comprises a heavy chain containing CDR1, CDR2, and CDR3 of anti-CD252 antibody 159403 and a light chain variable region containing CDR1, CDR2, and CDR3 of anti-CD252 antibody 159403. In another embodiment, the anti-CD252 antibody used in the compositions and methods disclosed herein is a humanized 159403 antibody.

[0437] In one embodiment, the anti-CD252 antibody that can be used in the methods and compositions (including ADCs) described herein is mouse monoclonal anti-CD252 antibody 159408 or an anti-CD252 antibody containing an antigen-binding region corresponding to antibody 159408. 159408 (sold by R&D Systems, catalog #MAB1054 (dated February 27, 2019)).

[0438] In one embodiment, the anti-CD252 antibody comprises a heavy chain containing CDR1, CDR2, and CDR3 of anti-CD252 antibody 159408 and a light chain variable region containing CDR1, CDR2, and CDR3 of anti-CD252 antibody 159408. In another embodiment, the anti-CD252 antibody used in the compositions and methods disclosed herein is a humanized 159408 antibody.

[0439] In one embodiment, the anti-CD252 antibody that can be used in the methods and compositions (including ADCs) described herein is the mouse monoclonal anti-CD252 antibody MM0505-8S23 or an anti-CD252 antibody containing an antigen-binding region corresponding to the MM0505-8S23 antibody. MM0505-8S23 (sold by Novus, catalog #NBP2-11969 (dated February 27, 2019)). This antibody is produced from a hybridoma (a mouse myeloma fused with spleen cells from mice immunized with human TNFSF4, also known as an OX40 ligand).

[0440] In one embodiment, the anti-CD252 antibody comprises a heavy chain containing CDR1, CDR2, and CDR3 of anti-CD252 antibody MM0505-8S23 and a light chain variable region containing CDR1, CDR2, and CDR3 of anti-CD252 antibody MM0505-8S23. In another embodiment, the anti-CD252 antibody used in the compositions and methods disclosed herein is a humanized MM0505-8S23 antibody.

[0441] In one embodiment, the anti-CD252 antibody that can be used in the methods and compositions (including ADCs) described herein is a rabbit monoclonal anti-CD252 antibody oxeluromab or an anti-CD252 antibody containing an antigen-binding region corresponding to the oxeluromab antibody. Oxeluromab (sold by Novus, catalog #NBP2-52687-0.1 (dated February 27, 2019)).

[0442] In one embodiment, the anti-CD252 antibody comprises a heavy chain of CDR1, CDR2, and CDR3 containing the anti-CD252 antibody oxeluromumab and a light chain variable region containing the CDR1, CDR2, and CDR3 of the anti-CD252 antibody oxeluromumab. In another embodiment, the anti-CD252 antibody used in the compositions and methods disclosed herein is a humanized oxeluromumab antibody. In some embodiments, the anti-CD252 antibody or its antigen-binding moiety comprises a heavy chain as described in the amino acid sequence of SEQ ID NO:323 and a light chain as described in the amino acid sequence of SEQ ID NO:324. In some embodiments, the anti-CD252 antibody or its antigen-binding moiety comprises a heavy chain variable region as described in the amino acid sequence of SEQ ID NO:331 and a light chain variable region as described in the amino acid sequence of SEQ ID NO:332. In one embodiment, the anti-CD252 antibody or its antigen-binding portion comprises a heavy chain variable region containing a CDR as described in the amino acid sequences of SEQ ID NO:325-327 and a light chain variable region containing a CDR as described in the amino acid sequences of SEQ ID NO:328-330. In one embodiment, the antibody is a complete antibody comprising a heavy chain variable region as described in the amino acid sequence of SEQ ID NO:331 and a light chain variable region as described in the amino acid sequence of SEQ ID NO:332. The amino acid sequences of SEQ ID NO:323-330 are provided below.

[0443] Ocelurumab full-length heavy chain sequence (CDR sequences are defined by IMGT; the heavy chain variable region (SEQ number: 331) is underlined):

[0444] EVQLLESGGGLVQPGGSLRLSCAASGFTFNSYAMSWVRQAPGKGLEWVSIISGSGGFTYYADSVKGRF TISRDNSRTTLYLQMNSLRAEDTAVYYCAKDRLVAPGTFDYWGQGALVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG(SEQ ID NO:323)

[0445] CDR-H1:GFTFNSYA(SEQ ID NO:325)

[0446] CDR-H2:ISGSGGFT(SEQ ID NO:326)

[0447] CDR-H3:AKDRLVAPGTFDY(SEQ ID NO:327)

[0448] The full-length light chain sequence of oxeluroximab (the following CDR sequences are defined by IMGT; the light chain variable region (SEQ number: 332) is underlined):

[0449] DIQMTQSPSSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCQQYNSYPYTFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:324)

[0450] CDR-L1:QGISSW(SEQ ID NO:328)

[0451] CDR-L2:AAS(SEQ ID NO:329)

[0452] CDR-L3:QQYNSYPYT(SEQ ID NO:330)

[0453] The anti-CD252 antibodies or binding fragments described herein may also contain modifications and / or mutations that alter the properties of the antibody and / or fragment, such as those that increase half-life, increase or decrease ADCC, as known in the art.

[0454] In one embodiment, an anti-CD252 antibody or its binding fragment for use in the methods and compositions disclosed herein comprises a variant Fc region, wherein the variant Fc region contains at least one amino acid modification relative to the wild-type Fc region, such that the molecule has an altered affinity for FcγR. Certain amino acid positions within the Fc region are known by crystallographic studies to be in direct contact with FcγR. Specifically, amino acids 234-239 (hinge region), amino acids 265-269 (B / C ring), amino acids 297-299 (C' / E ring), and amino acids 327-332 (F / G ring) (see Sondermann et al., 2000 Nature, 406:267-273). Therefore, the antibodies described herein may comprise a variant Fc region containing a modification of at least one residue that, based on structural and crystallographic analysis, is in direct contact with FcγR. In one embodiment, according to the EU index as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, NH1, MD (1991), the Fc region of the anti-CD252 antibody (or a fragment thereof) contains an amino acid substitution at amino acid 265, which is expressly incorporated herein by reference. “EU index as described in Kabat” refers to the number of the human IgG1 EU antibody. In one embodiment, the Fc region contains the D265A mutation. In one embodiment, the Fc region contains the D265C mutation. In some embodiments, the Fc region of the anti-CD252 antibody (or a fragment thereof) contains an amino acid substitution at amino acid 234 (according to the EU index as described in Kabat). In one embodiment, the Fc region contains the L234A mutation. In some embodiments, the Fc region of the anti-CD252 antibody (or a fragment thereof) contains an amino acid substitution at amino acid 235 (according to the EU index as described in Kabat). In one embodiment, the Fc region contains the L235A mutation. In yet another embodiment, the Fc region contains both L234A and L235A mutations. In another implementation, the Fc region contains D265C, L234A, and L235A mutations.

[0455] In some respects, variant IgG Fc domains containing one or more amino acid substitutions, compared to wild-type Fc domains without one or more amino acid substitutions, result in reduced or absent binding affinity for FcγR and / or C1q. Fc binding interactions are essential for a variety of effector functions and downstream signaling events, including but not limited to antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Therefore, in some respects, anti-CD252 antibodies containing modified Fc regions (e.g., containing L234A, L235A, and D265C mutations) exhibit significantly reduced or eliminated effector functions.

[0456] Affinity to the Fc region can be determined using a variety of techniques known in the art, such as, but not limited to, equilibrium methods (e.g., enzyme-linked immunosorbent assay (ELISA); KinExA, Rathanaswami et al. Analytical Biochemistry, Vol. 373: 52-60, 2008; or radioimmunoassay (RIA)), or other mechanisms by means of surface plasmon resonance assays or kinetic-based assays (e.g., BIACORE). TM Analysis or Octet TM Analysis (forteBIO) and other methods, such as indirect binding assays, competitive binding assays, fluorescence resonance energy transfer (FRET), gel electrophoresis, and chromatography (e.g., gel filtration), can be used. These and other methods can utilize labeling on one or more components being examined and / or employ multiple detection methods, including but not limited to colorimetric, fluorescent, luminescent, or isotopic labeling. A detailed description of binding affinity and kinetics can be found in Paul, WE, ed., Fundamental Immunology, 4th ed., Lippincott-Raven, Philadelphia (1999), which focuses on antibody-immunogen interactions. An example of a competitive binding assay is radioimmunoassay, which involves incubating a labeled antigen with a target antibody in the presence of incrementally added unlabeled antigen and detecting the antibody that binds to the labeled antigen. The affinity of the target antibody for a specific antigen and the rate of binding deviation can be determined from the data using scatchard plot analysis. Competition with a secondary antibody can also be determined using radioimmunoassay. In this case, the antigen is incubated with the target antibody conjugated with the labeled compound in the presence of incrementally added unlabeled second antibody.

[0457] The antibodies of this invention can be further genetically engineered by introducing additional Fc mutations to further adjust the antibody half-life, for example in (Dall'Acqua et al. (2006) J Biol Chem 281:23514-24), (Zalevsky et al. (2010) Nat Biotechnol 28:157-9), (Hinton et al. (2004) J Biol Chem 279:6213-6), (Hinton et al. (2006) J Immunol 176:346-56), (Shields et al. (2001) J Biol Chem 276:6591-604), (Petkova et al. (2006) Int Immunol 18:1759-69), (Datta-Mannan et al. (2007) Drug MetabDispos 35:86-94), (Vaccaro et al. (2005) Nat Biotechnol Those described in (23:1283-8), (Yeung et al. (2010) Cancer Res 70:3269-77), and (Kim et al. (1999) Eur J Immunol 29:2819-25), and including positions 250, 252, 253, 254, 256, 257, 307, 376, 380, 428, 434, and 435. Exemplary mutations that can be prepared alone or in combination are T250Q, M252Y, 1253A, S254T, T256E, P2571, T307A, D376V, E380A, M428L, H433K, N434S, N434A, N434H, N434F, H435A, and H435R mutations.

[0458] Therefore, in one embodiment, the Fc region contains a mutation that results in a reduced half-life. Antibodies with short half-lives may be advantageous in certain situations where the antibody is expected to act as a short-lived therapeutic agent (e.g., the pretreatment steps described herein, where HSCs are administered after antibody administration). Ideally, the antibody is substantially cleared before HSC delivery, and HSCs typically also express CD117, but are not a target of anti-CD117 antibodies, unlike endogenous stem cells. In one embodiment, the Fc region contains a mutation at position 435 (according to Kabat's EU index). In one embodiment, the mutation is the H435A mutation.

[0459] In one embodiment, the half-life of the anti-CD252 antibody described herein is equal to or less than 14 hours, equal to or less than 13 hours, equal to or less than 12 hours, or equal to or less than 11 hours. In another embodiment, the half-life of the anti-CD252 antibody described herein is equal to or less than 24 hours, equal to or less than 22 hours, equal to or less than 20 hours, or equal to or less than 18 hours, equal to or less than 16 hours, equal to or less than 14 hours, equal to or less than 13 hours, equal to or less than 12 hours, or equal to or less than 11 hours. In one embodiment, the half-life of the antibody is about 1 hour to about 20 hours, about 2 hours to about 18 hours, about 4 hours to about 16 hours, about 6 hours to about 14 hours, about 8 hours to about 12 hours, about 11 hours to about 12 hours, about 11 hours to about 24 hours, about 12 hours to about 22 hours, about 10 hours to about 20 hours, about 8 hours to about 18 hours, about 1 hour to about 6 hours, about 2 hours to about 5 hours, about 3 hours to about 4 hours, or about 14 hours to about 24 hours.

[0460] In some aspects, the Fc region contains two or more mutations that confer a reduced half-life and significantly reduce or completely eliminate the effector function of the antibody. In some embodiments, the Fc region contains a mutation that reduces the half-life and a mutation of at least one residue that can directly contact FcγR (e.g., based on structural and crystallographic analysis). In one embodiment, the Fc region contains the H435A mutation, the L234A mutation, and the L235A mutation. In one embodiment, the Fc region contains the H435A mutation and the D265C mutation. In one embodiment, the Fc region contains the H435A mutation, the L234A mutation, the L235A mutation, and the D265C mutation.

[0461] In some embodiments, the antibody or its antigen-binding fragment is conjugated to a cytotoxin (e.g., amatoxins) via a cysteine ​​residue in the Fc domain of the antibody or its antigen-binding fragment. In some embodiments, the cysteine ​​residue is introduced via a mutation in the Fc domain of the antibody or its antigen-binding fragment. For example, the cysteine ​​residue may be selected from Cys118, Cys239, and Cys265. In one embodiment, the Fc region of the anti-CD252 antibody (or a fragment thereof) contains an amino acid substitution at amino acid 265 (according to the EU index in Kabat, as shown). In one embodiment, the Fc region contains a D265C mutation. In one embodiment, the Fc region contains both D265C and H435A mutations. In one embodiment, the Fc region contains D265C, L234A, and L235A mutations. In one embodiment, the Fc region contains D265C, L234A, L235A, and H435A mutations.

[0462] In some embodiments of these aspects, a cysteine ​​residue is naturally present in the Fc domain of the antibody or its antigen-binding fragment. For example, the Fc domain may be an IgG Fc domain, such as the human IgG1 Fc domain, and the cysteine ​​residue may be selected from Cys261, Csy321, Cys367, and Cys425.

[0463] The variant Fc domains described herein are defined according to the amino acid modifications that compose them. For all amino acid substitutions associated with the Fc region discussed herein, the numbering is always based on the EU index. Thus, for example, D265C is an Fc variant in which aspartic acid (D) at EU position 265 is substituted with cysteine ​​(C) relative to the parental Fc domain. Similarly, for example, D265C / L234A / L235A defines variant Fc variants that have substitutions at EU positions 265 (D to C), 234 (L to A), and 235 (L to A) relative to the parental Fc domain. Variants can also be designated according to their final amino acid composition at the mutated EU amino acid positions. For example, the L234A / L235A mutant could be called LALA. Note that the order of substitutions provided is arbitrary.

[0464] In one embodiment, the anti-CD252 antibody or its antigen-binding fragment comprises a variable region having an amino acid sequence that is at least 95%, 96%, 97%, or 99% identical to that of the SEQ ID NO disclosed herein. Alternatively, the anti-CD252 antibody or its antigen-binding fragment comprises a CDR containing the SEQ ID NO disclosed herein, wherein the frame region of the variable region described herein has an amino acid sequence that is at least 95%, 96%, 97%, or 99% identical to that of the SEQ ID NO disclosed herein.

[0465] In some embodiments, the anti-CD252 antibody or its antigen-binding fragment has a specific dissociation rate, which is particularly advantageous when used as part of a conjugate. For example, in some embodiments, the dissociation rate constant (Koff) of the anti-CD252 antibody against human CD252 and / or rhesus monkey CD252 is 1 x 10⁻⁶. -2 Up to 1x10 -3 1x10 -3 Up to 1x10 -4 1x10 -5 Up to 1x10 -6 1x10 -6 Up to 1x10 -7 or 1x10 -7 Up to 1x10 -8As measured by biolayer interferometry (BLI). In some embodiments, the antibody or its antigen-binding fragment is expressed in Kc at a concentration of approximately 100 nM or less, approximately 90 nM or less, approximately 80 nM or less, approximately 70 nM or less, approximately 60 nM or less, approximately 50 nM or less, approximately 40 nM or less, approximately 30 nM or less, approximately 20 nM or less, approximately 10 nM or less, approximately 8 nM or less, approximately 6 nM or less, approximately 4 nM or less, approximately 2 nM or less, or approximately 1 nM or less, as determined by biolayer interferometry (BLI). D Binding to CD252 (e.g., human CD252 and / or rhesus monkey CD252). In some embodiments, the antibody or its antigen-binding fragment is expressed in KJ values ​​of approximately 90 nM–100 nM, approximately 80 nM–90 nM, approximately 70 nM–80 nM, approximately 60 nM–70 nM, approximately 50 nM–60 nM, approximately 40 nM–50 nM, approximately 30 nM–40 nM, approximately 20 nM–30 nM, approximately 10 nM–20 nM, approximately 8 nM–10 nM, approximately 6 nM–8 nM, approximately 4 nM–6 nM, approximately 2 nM–4 nM, approximately 1 nM–2 nM, or approximately 1 nM or less, as determined by biological layer interferometry (BLI). D Combined with CD252 (e.g., human CD252 and / or rhesus monkey CD252).

[0466] The antibodies and their binding fragments disclosed herein can be used in conjugates, as described in more detail below.

[0467] Exemplary antigen-binding fragments of the aforementioned antibodies include dual-variable immunoglobulin domains, single-chain Fv molecules (scFv), double-chain antibodies, triple-chain antibodies, nanobodies, antibody-like protein scaffolds, Fv fragments, Fab fragments, F(ab')2 molecules, and tandem dual scFvs, etc. The anti-CD252 antibodies described herein can be in the form of full-length antibodies, bispecific antibodies, dual-variable domain antibodies, multi-chain or single-chain antibodies, and / or binding fragments that specifically bind to human CD252, including but not limited to Fab, Fab', (Fab')2, Fv, scFv (single-chain Fv), alternative antibodies (including alternative light chain constructs), single-domain antibodies, camel-derived antibodies, etc. They can also be or derived from any isotype, including, for example, IgA (e.g., IgA1 or IgA2), IgD, IgE, IgG (e.g., IgG1, IgG2, IgG3, or IgG4), or IgM. In some embodiments, the anti-CD252 antibody is IgG (e.g., IG1, IG2, IG3, or IG4).

[0468] In one embodiment, the anti-CD252 antibody or its antigen-binding fragment comprises a variable region having an amino acid sequence that is at least 95%, 96%, 97%, or 99% identical to that of the SEQ ID NO disclosed herein. Alternatively, the anti-CD252 antibody or its antigen-binding fragment comprises a CDR containing the SEQ ID NO disclosed herein, wherein the frame region of the variable region described herein has an amino acid sequence that is at least 95%, 96%, 97%, or 99% identical to that of the SEQ ID NO disclosed herein.

[0469] Anti-CD45 antibody

[0470] Antibodies and antigen-binding fragments capable of binding human CD45 (NCBI gene reference sequence: NM_080921.3, NCBI protein reference sequence: NP_563578.2), including those capable of binding CD45RO isoforms, can be used in conjunction with the compositions and methods disclosed herein, for example, to facilitate hematopoietic stem cell grafts in patients requiring hematopoietic stem cell transplantation therapy. In one embodiment, the compositions and methods disclosed herein comprise an anti-CD45 antibody or ADC binding human CD45RO, as described in the amino acid sequence of SEQ ID NO: 336. Antibodies binding multiple isoforms of CD45 disclosed herein are also contemplated for use in the methods and compositions disclosed herein. The multiple isoforms of CD45 arise from the alternative splicing of 34 exons in the primary transcript. Splicing of exons 4, 5, 6, and possibly 7 results in multiple CD45 variants. Alternative exon expression has been observed in the CD45 isoforms described in Table 3 below.

[0471] Table 3. Exon expression of multiple CD45 isotypes

[0472] CD45 (same type) Exon expression patterns CD45RA (SEQ ID NO:333) Only exon 4 is expressed CD45RB (SEQ ID NO:334) Only exon 5 is expressed CD45RC (SEQ ID NO:335) Only exon 6 is expressed CD45RO (SEQ ID NO:336) Exons 4-6 are not expressed.

[0473] Alternative splicing can produce single exons or combinations of exons expressed in multiple isoforms of the CD45 protein (e.g., CD45RA, CD45RAB, CD45RABC). Conversely, CD45RO lacks expression of exons 4-6 and is produced by combinations of exons 1-3 and 7-34. There is evidence that exon 7 can also be excluded from the protein, resulting in the splicing of exons 1-3 and 8-34 together. This protein, designated E3-8, has been detected at the mRNA level but has not yet been identified by flow cytometry.

[0474] CD45RO is currently the only known CD45 isotype expressed on hematopoietic stem cells. CD45RA and CD45RABC are either undetectable or excluded from the hematopoietic stem cell phenotype. Studies in mice have shown that CD45RB is expressed on fetal hematopoietic stem cells but not on adult bone marrow hematopoietic stem cells. Notably, a high rate of polymorphism in exon 6 of CD45RC has been found in Asian populations (exon 6 polymorphism of CD45RC is found in approximately 25% of the Japanese population). This polymorphism leads to high expression of CD45RO and reduced levels of CD45RA, CD45RB, and CD45RC. Additionally, CD45RA variants (e.g., CD45RAB and CD45RAC) exhibit polymorphism in exon 4, which is associated with autoimmune diseases.

[0475] The presence of CD45RO on hematopoietic stem cells and its relatively limited expression on other immune cells (such as T and B lymphocyte subsets and various myeloid cells) make CD45RO particularly suitable as a target for pretreatment therapy in patients requiring hematopoietic stem cell transplantation. Because CD45RO lacks expression only in exons 4, 5, and 6, its use as an immunogen allows for the screening of pan CD45 Abs and CD45RO-specific antibodies.

[0476] Anti-CD45 antibodies that can be used in conjunction with the patient modulation methods described herein include anti-CD45 antibodies and their antigen-binding portions. The antigen-binding portions of antibodies are well known in the art and can be readily constructed based on the antigen-binding regions of antibodies. In some exemplary embodiments, the anti-CD45 antibody used in conjunction with the pretreatment methods described herein can be a monoclonal antibody or its antigen-binding fragment, a polyclonal antibody or its antigen-binding fragment, a humanized antibody or its antigen-binding fragment, a fully human antibody or its antigen-binding fragment, a chimeric antibody or its antigen-binding fragment, a bispecific antibody or its antigen-binding fragment, a bivariate immunoglobulin domain, a single-chain Fv molecule (scFv), a double-chain antibody, a triple-chain antibody, a nanobody, an antibody-like protein scaffold, an Fv fragment, a Fab fragment, an F(ab')2 molecule, or a tandem double scFv. Exemplary anti-CD45 antibodies that can be used in whole or in part in the ADCs or methods described herein are provided below.

[0477] In one implementation, the anti-CD45 antibody is or is derived from clone HI30 (available from...). (Available from San Diego, CA) or its humanized variants. Humanization of the antibody can be performed according to procedures known in the art (such as those described in Example 7 below), by replacing the framework and constant region residues of a non-human antibody with those of a germline human antibody. Other anti-CD45 antibodies that can be used in conjunction with the methods described herein include anti-CD45 antibodies ab10558, EP322Y, MEM-28, ab10559, O.N.125, F10-89-4, HIE-1, 2B11, YTH24.5, PD7 / 26 / 16, F10-89-4, 1B7, ab154885, B-A11, phosphor S1007, ab170444, EP350, Y321, GA90, D3 / 9, X16 / 99, and LT45 (which is available from...). (Acquired from Cambridge, MA) and its humanized variants. Other anti-CD45 antibodies that can be used in conjunction with the patient pretreatment procedures described herein include anti-CD45 antibody HPA000440 (available from SIGMA- (Obtained from St. Louis, MO) and its humanized variants. Other anti-CD45 antibodies that can be used in conjunction with the patient pretreatment methods described herein include the mouse monoclonal antibody BC8, described, for example, in Matthews et al., Blood 78:1864-1874, 1991, the disclosure of which is incorporated herein by reference because it relates to anti-CD45 antibodies and their humanized variants. Other anti-CD45 antibodies that can be used in conjunction with the methods described herein include the monoclonal antibody YAML568, described, for example, in Glatting et al., J. Nucl. Med. 8:1335-1341, 2006, the disclosure of which is incorporated herein by reference because it relates to anti-CD45 antibodies and their humanized variants. Additional anti-CD45 antibodies that can be used in conjunction with the patient pretreatment procedures described herein include the monoclonal antibodies YTH54.12 and YTH25.4, which are described, for example, in Brenner et al., Ann. NY Acad. Sci. 996:80-88, 2003, the disclosure of which is incorporated herein by reference because it relates to anti-CD45 antibodies and their humanized variants. Other anti-CD45 antibodies used in the patient pretreatment methods described herein include UCHL1, 2H4, SN130, MD4.3, MBI, and MT2, which are described, for example, in Brown et al., Immunology 64:331-336, 1998, the disclosure of which is incorporated herein by reference because it relates to anti-CD45 antibodies and their humanized variants. Other anti-CD45 antibodies that can be used in conjunction with the methods described herein include those produced and released from the U.S. Type Culture Collection (ATCC) accessions RA3-6132, RA3-2C2, and TIB122, as well as monoclonal antibodies C363.16A and 13 / 2, which are described, for example, in Johnson et al., J. Exp. Med. 169:1179-1184, 1989, the disclosure of which is incorporated herein by reference as relating to anti-CD45 antibodies and their humanized variants. Other anti-CD45 antibodies that can be used in conjunction with the patient pretreatment methods described herein include monoclonal antibodies AHN-12.1, AHN-12, AHN-12.2, AHN-12.3, AHN-12.4, HLe-1, and KC56(T200), which are described, for example, in Harvath et al., J. Immunol. 146:949-957, 1991, the disclosure of which is incorporated herein by reference because it relates to anti-CD45 antibodies and their humanized variants.

[0478] Other anti-CD45 antibodies that can be used in conjunction with the patient pretreatment methods described herein include, for example, those described in U.S. Patent Nos. 7,265,212 (which describes, for example, anti-CD45 antibodies 39E11, 16C9, and 1G10, together with other clones); 7,160,987 (which describes, for example, anti-CD45 antibodies produced and released by ATCC accession number HB-11873, such as monoclonal antibody 6G3); and 6,099,838 (which describes, for example, anti-CD45 antibody MT3, and antibodies produced and released by ATCC accession numbers HB220 (also designated MB23G2) and HB223), as well as US 2004 / 0096901 and US The publications of those described in 2008 / 0003224 (which describes, for example, anti-CD45 antibodies produced and released by ATCC accession number PTA-7339, such as monoclonal antibody 17.1) are incorporated herein by reference, as they relate to anti-CD45 antibodies.

[0479] Additional anti-CD45 antibodies that can be used in conjunction with the patient pretreatment methods described herein include antibodies produced and released by ATCC accession numbers MB4B4, MB23G2, 14.8, GAP 8.3, 74-9-3, I / 24.D6, 9.4, 4B2, and M1 / 9.3.4.HL.2, as well as their humanized and / or affinity-matured variants. Affinity maturation can be performed, for example, using in vitro display techniques described herein or known in the art, such as phage display, as described in Example 6 below.

[0480] Other anti-CD45 antibodies that can be used in conjunction with the patient pretreatment methods described herein include anti-CD45 antibody T29 / 33, which is described, for example, in Morikawa et al., Int. J. Hematol. 54:495-504, 1991, the disclosure of which is incorporated herein by reference as it relates to anti-CD45 antibodies.

[0481] In some embodiments, the anti-CD45 antibody is selected from entomoclovir (also known as 90Y-BC8, Imoab-B, BC8; as described, for example, in US20170326259, WO2017155937 and Orozco et al. Blood. 127.3 (2016): 352-359) or BC8- (as described, for example, in Li et al. PloS one 13.10 (2018): e0205135), each of which is incorporated herein by reference. Other anti-CD45 antibodies have been described, for example in WO2003 / 048327, WO2016 / 016442, US2017 / 0226209, US2016 / 0152733, US9,701,756; US2011 / 0076270 or US7,825,222, each of which is incorporated herein by reference in its entirety.

[0482] For example, in one embodiment, the anti-CD45 antibody or its antigen-binding fragment includes binding regions, such as CDRs and variable regions, corresponding to those of apamistamab. The amino acid sequence of the heavy chain variable region (VH) of apamistamab is described in SEQ ID NO:337. The amino acid sequence of the light chain variable region (VL) of apamistamab is described in SEQ ID NO:338. In other embodiments, the anti-CD45 antibody or its antigen-binding portion includes a variable heavy chain containing the amino acid residues described in SEQ ID NO:337 and a light chain variable region as described in SEQ ID NO:338. In one embodiment, the anti-CD45 antibody includes a heavy chain containing CDR1, CDR2, and CDR3 of apamistamab and a light chain variable region containing CDR1, CDR2, and CDR3 of apamistamab.

[0483] In one embodiment, the anti-CD45 antibody comprises the heavy chain of the anti-CD45 antibody described herein and the light chain variable region of the anti-CD45 antibody described herein. In one embodiment, the anti-CD45 antibody comprises a heavy chain containing CDR1, CDR2, and CDR3 of the anti-CD45 antibody described herein and a light chain variable region containing CDR1, CDR2, and CDR3 of the anti-CD45 antibody described herein.

[0484] In another embodiment, the antibody or its antigen-binding fragment comprises a heavy chain variable region containing an amino acid sequence having at least 95% identity with the anti-CD45 antibody described herein (e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% identity with the anti-CD45 antibody described herein). In some embodiments, the antibody comprises a modified heavy chain (HC) variable region containing the HC variable region of the anti-CD45 antibody described herein or a variant thereof, which (i) differs from the anti-CD45 antibody in the substitution, addition, or deletion of 1, 2, 3, 4, or 5 amino acids; (ii) differs from the anti-CD45 antibody in the substitution, addition, or deletion of at most 5, 4, 3, 2, or 1 amino acid; or (iii) differs from the anti-CD45 antibody in the substitution of 1-5, 1-3, 1-2, 2-5, or 3-5 amino acids. The modified heavy chain variable region differs from the anti-CD45 antibody in that it is added to or deleted from the antibody; and / or (iv) contains at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the same amino acid sequence as the anti-CD45 antibody, wherein in any of (i)-(iv), the amino acid substitution may be a conserved amino acid substitution or a non-conserved amino acid substitution; and wherein the modified heavy chain variable region has enhanced biological activity relative to the heavy chain variable region of the anti-CD45 antibody while maintaining the CD45 binding specificity of the antibody.

[0485] The entire contents of each of the aforementioned publications are incorporated herein by reference. Antibodies and antigen-binding fragments that may be used in conjunction with the compositions and methods described herein include the antibodies and antigen-binding fragments described above, as well as humanized variants of those non-human antibodies and antigen-binding fragments and antibodies or antigen-binding fragments that bind to the same epitopes described above, as evaluated, for example, by a competitive CD45 binding assay.

[0486] Methods for identifying antibodies

[0487] Methods for high-throughput screening of antibodies or antibody fragment libraries that can bind to antigens expressed by hematopoietic stem cells (e.g., CD117 (e.g., GNNK+CD117) or CD45) or antigens expressed by mature immune cells (e.g., T cells) (e.g., CD2, CD5, CD137, or CD252) can be used to identify and bind mature antibodies for the treatment of cancer, autoimmune diseases, and pretreatment of patients requiring hematopoietic stem cell therapy (e.g., human patients), as described herein. Such methods include in vitro display techniques known in the art, such as phage display, bacterial display, yeast display, mammalian cell display, ribosome display, mRNA display, and cDNA display. The use of phage display to isolate antibodies or antigen-binding fragments that bind to biologically relevant molecules has been outlined in, for example, Felici et al., Biotechnol. Annual Rev. 1:149-183, 1995; Katz, Annual Rev. Biophys. Biomol. Struct. 26:27-45, 1997; and Hoogenboom et al., Immunotechnology 4:1-20, 1998, the contents of which are incorporated herein by reference because they relate to in vitro display techniques. Randomly combinable peptide libraries have been constructed to select peptides that bind to cell surface antigens, as described in, Kay, Perspect. Drug Discovery Des. 2:251-268, 1995 and Kay et al., Mol. Divers. 1:139-140, 1996, the contents of which are incorporated herein by reference because they relate to the discovery of antigen-binding molecules. Proteins, such as multimeric proteins, have been successfully displayed as functional molecules in phages (see, e.g., EP 0349578; EP4527839; and EP 0589877, and Chiswell and McCafferty, Trends Biotechnol. 10:80-84, 1992, the contents of which are incorporated herein by reference because they relate to the use of in vitro display techniques to discover antigen-binding molecules). Additionally, functional antibody fragments, such as Fab and scFv fragments, have been expressed in in vitro display forms (see, e.g., McCafferty et al., Nature 348:552-554, 1990; Barbas et al., Proc. Natl. Acad. Sci. USA 88:7978-7982, 1991; and Clackson et al., Nature). 352:624-628, 1991, the contents of each of which are incorporated herein by reference because they relate to in vitro display platforms for the discovery of antigen-binding molecules.Human anti-HC antibodies (e.g., anti-CD117 antibody, anti-CD45 antibody, anti-CD2 antibody, anti-CD5 antibody, anti-CD137 antibody, or anti-CD252 antibody) may also be used, for example, in HuMAb-. Or XenoMouse TM These technologies can be used to identify and improve the affinity of antibodies, antibody fragments, or fragments that can bind to antigens expressed by hematopoietic stem cells (e.g., CD117 (e.g., GNNK+CD117) or CD45) or antigens expressed by mature immune cells (e.g., T cells) (e.g., CD2, CD5, CD137, or CD252), which can then be used to deplete endogenous hematopoietic stem cells in patients (e.g., human patients) who require hematopoietic stem cells.

[0488] In addition to in vitro display techniques, computational modeling techniques can be used in computers to design and identify antibodies or antibody fragments capable of binding to antigens expressed by hematopoietic stem cells (e.g., CD117 (e.g., GNNK+CD117) or CD45) or antigens expressed by mature immune cells (e.g., T cells) (e.g., CD2, CD5, CD137, or CD252). For example, using computational modeling techniques, those skilled in the art can screen a library of antibodies or antibody fragments in a computer for molecules capable of binding to specific epitopes (e.g., extracellular domains of antigens) on antigens expressed by hematopoietic stem cells (e.g., CD117 (e.g., GNNK+CD117) or CD45) or antigens expressed by mature immune cells (e.g., T cells (e.g., CD2, CD5, CD137, or CD252)). Antibodies or antigen-binding fragments identified by these computational techniques can be used in conjunction with the treatments described herein, such as the cancer and autoimmune disease treatments and patient pretreatment procedures described herein.

[0489] Other techniques can be used to identify antibodies or antibody fragments that can bind to antigens expressed by hematopoietic stem cells (e.g., CD117 (e.g., GNNK+CD117) or CD45) or by mature immune cells (e.g., T cells (e.g., CD2, CD5, CD137, or CD252)) and subsequently be internalized by cells (e.g., via receptor-mediated endocytosis). For example, the in vitro display techniques described above can be adapted to screen for antibodies or antibody fragments that bind to antigens expressed by hematopoietic stem cells (e.g., CD117 (e.g., GNNK+CD117) or CD45) or by mature immune cells (e.g., T cells (e.g., CD2, CD5, CD137, or CD252)) and subsequently be internalized. Phage display represents a technique that can be used in conjunction with this screening modality. To identify anti-HC antibodies (e.g., anti-CD117, anti-CD45, anti-CD2, anti-CD5, anti-CD137, or anti-CD252 antibodies) or antibody fragments, and subsequently internalized by hematopoietic stem cells (or immune cells), those skilled in the art can use the phage display techniques described in Williams et al., Leukemia 19:1432-1438, 2005, the disclosure of which is incorporated herein by reference in its entirety. For example, recombinant phage libraries encoding antibodies, antibody fragments such as scFv fragments, Fab fragments, double-stranded antibodies, triple-stranded antibodies, and... 10 The Fn3 domain, or ligands containing random amino acid boxes (e.g., in one or more or all of the CDRs or their equivalent regions or in antibodies or antibody fragments). The frame regions, hinge regions, Fc regions, and other regions of antibodies or antibody fragments can be engineered to be non-immunogenic in humans, for example, by means of sequences having human lineage antibody sequences or sequences that show only minor variations relative to human lineage antibodies.

[0490] Using the phage display techniques described herein or known in the art, a phage library containing random antibodies or antibody fragments covalently bound to phage particles can be incubated with antigens (e.g., CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, or CD252), for example by first incubating the phage library with a blocking agent (e.g., milk protein, bovine serum albumin, and / or IgG) to remove phages encoding antibodies or antibody fragments that exhibit nonspecific protein binding and phages encoding antibodies or fragments of antibodies that bind to the Fc domain, and then incubating the phage library with a population of hematopoietic stem cells or mature immune cells (e.g., T cells) that express, for example, CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, or CD252). Phage libraries can be incubated with target cells (e.g., cancer cells, immune cells, or hematopoietic stem cells) for a time sufficient to allow anti-HC antibodies (e.g., anti-CD117, anti-CD45, anti-CD2, anti-CD5, anti-CD137, or anti-CD252 antibodies) or antibody fragments thereof to bind to homologous cell surface antigens (e.g., CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, or CD252) and subsequently internalized by hematopoietic stem cells (e.g., 30 minutes to 6 hours at 4°C, or for example, 1 hour at 4°C). Phages containing antibodies or antibody fragments thereof, which do not exhibit sufficient affinity for antigens (CD117 (e.g., GNNK+CD117), CD45, CD2, CD5, CD137, or CD252) to allow binding to and internalization with target cells (e.g., cancer cells, autoimmune cells, or hematopoietic stem cells), can subsequently be removed by washing the cells, for example, with cold (4°C) 0.1M glycine buffer at pH 2.8. Phages that have been internalized with antibodies or antibody fragments thereof and bound to target cells (e.g., cancer cells, autoimmune cells, or hematopoietic stem cells) can be identified, for example, by lysing cells and recovering the internalized phages from the cell culture medium. The phages can then be amplified in bacterial cells, for example, by incubating the bacterial cells with the recovered phages in 2xYT medium using methods known in the art. The phages recovered from this medium can then be characterized, for example, by determining the nucleic acid sequence of the gene encoding the antibody or antibody fragment inserted into the phage genome. The encoded antibody or its antibody fragment can be subsequently prepared by chemical synthesis (e.g., its antibody fragment, such as the scFv fragment) or by recombinant expression (e.g., a full-length antibody).

[0491] The internalization capability of the prepared antibody or its antibody fragment can be assessed, for example, using a radionuclide internalization assay known in the art. For instance, anti-HC antibodies (e.g., anti-CD117, anti-CD45, anti-CD2, anti-CD5, anti-CD137, or anti-CD252 antibodies) or their antibody fragments identified using in vitro display techniques described herein or known in the art can be functionalized by incorporating a radioisotope, for example... 18 F, 75 Br、 77 Br、 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211 At、 67 Ga、 111 In、 99 Tc, 169 Yb、 186 Re、 64 Cu、 67 Cu、 177 Lu、 77 As、 72 As、 86 Y、 90 Y、 89 Zr、 212 Bi、 213 Bior 225 Ac. For example, radioactive halogens, for example 18 F, 75 Br、 77 Br、 122 I, 123 I, 124 I, 125 I, 129 I, 131 I, 211At this stage, beads (e.g., polystyrene beads) containing an electrophilic halogen reagent (e.g., iodide beads, Thermo Fisher Scientific, Inc., Cambridge, MA) can be incorporated into the antibody or fragment. The radiolabeled antibody or fragment thereof, or ADC, can be incubated with target cells (e.g., cancer cells, autoimmune cells, or hematopoietic stem cells) for a time sufficient to allow internalization (e.g., 30 minutes to 6 hours at 4°C, or for example, 1 hour at 4°C). The cells can then be washed to remove uninternalized antibody or fragment thereof (e.g., using cold (4°C) 0.1M glycine buffer at pH 2.8). Internalized antibody or antibody fragment thereof can be identified by comparing the radiation emitted by the resulting target cells (e.g., cancer cells, autoimmune cells, or hematopoietic stem cells) (e.g., gamma radiation) with the radiation emitted by the recovered wash buffer (e.g., gamma radiation). The aforementioned internalization assay can also be used to characterize the ADC.

[0492] Antibodies can be generated using recombinant methods and compositions, for example, as described in U.S. Patent No. 4,816,567. In one embodiment, an isolated nucleic acid encoding an anti-HC antibody (e.g., an anti-CD117 antibody, an anti-CD45 antibody, an anti-CD2 antibody, an anti-CD5 antibody, an anti-CD137 antibody, or an anti-CD252 antibody) as described herein is provided. This nucleic acid may encode an amino acid sequence comprising a VL and / or an amino acid sequence comprising a VH of the antibody (e.g., the light chain and / or heavy chain of the antibody). In another embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In another embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, the host cell comprises (e.g., has been transformed): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VL and an amino acid sequence comprising an antibody VH, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VL, and a second vector comprising a nucleic acid encoding an amino acid sequence comprising an antibody VH. In one embodiment, the host cell is a eukaryotic cell, such as Chinese hamster ovary (CHO) cells or lymphocytes (e.g., Y0, NSO, Sp20 cells). In one embodiment, a method for preparing an anti-CLL-1 antibody is provided, wherein the method includes culturing a host cell containing nucleic acid encoding the antibody under conditions suitable for antibody expression, as provided above, and optionally recovering the antibody from the host cell (or host cell culture medium).

[0493] To recombinantly produce anti-HC antibodies (e.g., anti-CD117, anti-CD45, anti-CD2, anti-CD5, anti-CD137, or anti-CD252 antibodies), the nucleic acid encoding the antibody (e.g., as described above) is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. This nucleic acid can be readily isolated and sequenced using conventional methods (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding the heavy and light chains of the antibody).

[0494] Host cells suitable for cloning or expressing vectors encoding antibodies include prokaryotic or eukaryotic cells as described herein. For example, antibodies can be generated in bacteria, particularly when glycosylation and Fc effector function are not required. For information on the expression of antibody fragments and peptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523 (see also Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo, editor, Humana Press, Totowa, NJ, 2003), pp. 245-254, which describes the expression of antibody fragments in *E. coli*). Following expression, the antibody can be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

[0495] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted for suspension growth can be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 cell lines transformed with SV40 (COS-7); human embryonic kidney lines (293 or 293 cells, as described, for example, in Graham et al., J. Gen Virol. 36:59 (1977)); young hamster kidney cells (BHK); mouse podocytes (TM4 cells, as described, for example, in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK); buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2); mouse mammary tumors (MMT 060562); TRI cells, as described, for example, in Mather et al., Annals As described in NYAcad.Sci.383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NSO, and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, editor, HumanaPress, Totowa, NJ), pp. 255-268 (2003). In one embodiment, the host cell is a eukaryotic cell, such as Chinese hamster ovary (CHO) cells or lymphocytes (e.g., Y0, NSO, Sp20 cells).

[0496] Antibody-drug conjugates (ADCs)

[0497] The antibodies (including anti-CD117 antibodies) and their antigen-binding fragments described herein can be conjugated (linked) to cytotoxic agents via adapters. In some embodiments, the cytotoxic molecule is conjugated to an internalized antibody or its antigen-binding fragment as disclosed herein, such that after cellular uptake of the antibody or fragment, the cytotoxic agent can reach its intracellular target and mediate hematopoietic cell death. Any number of cytotoxic agents can be conjugated to anti-CD117 antibodies (e.g., 1, 2, 3, 4, 5, 6, 7, or 8).

[0498] Cytotoxins suitable for the compositions and methods described herein include DNA intercalators (e.g., anthracyclines), agents capable of disrupting the mitotic spindle (e.g., vinca alkaloids, maytansine, maytansine alkaloids and their derivatives), RNA polymerase inhibitors (e.g., amatoxins, such as α-amatoxins and their derivatives), and agents capable of disrupting protein biosynthesis (e.g., agents exhibiting rrnA N-glycosidase activity, such as saponins and ricin A chains), as well as other substances known in the art.

[0499] Cytotoxins

[0500] Various cytotoxins can be conjugated to anti-HC antibodies (e.g., anti-CD117, anti-CD45, anti-CD2, anti-CD5, anti-CD137, or anti-CD252 antibodies) via a connector used in the therapies described herein. Specifically, anti-HCADCs (e.g., anti-CD117 ADC, anti-CD45 ADC, anti-CD2 ADC, anti-CD5 ADC, anti-CD137 ADC, or anti-CD252 ADC) comprise an antibody (or an antigen-binding fragment thereof) conjugated (i.e., covalently linked via a connector) to a cytotoxic moiety (or cytotoxin). In several embodiments, the cytotoxic moiety exhibits reduced or no cytotoxicity when bound to the conjugate, but recovers cytotoxicity upon cleavage from the connector. In several embodiments, the cytotoxic moiety remains cytotoxic without cleavage from the connector. In some embodiments, the cytotoxic molecule is conjugated to a cell-internalized antibody or an antigen-binding fragment thereof disclosed herein, such that upon cellular uptake of the antibody or fragment thereof, the cytotoxin can reach its intracellular target and, for example, mediate T cell death.

[0501] Therefore, the ADC of this disclosure can have the general formula Ab-(ZLD). n In this embodiment, an antibody or its antigen-binding fragment (Ab) is conjugated (covalently linked) to a cytotoxic moiety (“drug”, D) via a chemical part (Z) and a linker (L), each as disclosed herein.

[0502] Therefore, an antibody or its antigen-binding fragment can be conjugated to multiple drug moieties represented by an integer n, where n represents the average amount of cytotoxicity of each antibody, ranging from, for example, about 1 to about 20. In some embodiments, n is 1 to 4. In some embodiments, n is 1. The average amount of drug moieties of each antibody in an ADC prepared by conjugation reaction can be characterized by conventional means (e.g., mass spectrometry, ELISA assay, and HPLC). The quantitative distribution of the ADC with respect to n can also be determined. In some cases, the separation, purification, and characterization of homogeneous ADCs can be achieved by means such as reversed-phase HPLC or electrophoresis, where n is a value of an ADC derived from other drug-loaded ADCs.

[0503] For some anti-HC ADCs (e.g., anti-CD117 ADC, anti-CD45 ADC, anti-CD2 ADC, anti-CD5 ADC, anti-CD137 ADC, or anti-CD252 ADC), the number of attachment sites on the antibody may be limited. For example, when the attachment is a cysteine ​​thiol, the antibody may have only one or more cysteine ​​thiol groups, or only one or more sufficiently reactive thiol groups through which a linker can be attached. Typically, antibodies do not contain many free and reactive cysteine ​​thiol groups that can be moiequivalent to the drug; primarily, the cysteine ​​thiol residues in the antibody exist as disulfide bonds. In some embodiments, the antibody may be reduced under partial or complete reducing conditions with a reducing agent (e.g., dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP)) to generate reactive cysteine ​​thiol groups. In some embodiments, a high drug loading, such as n>5, may lead to aggregation, insolubility, toxicity, or loss of cellular permeability in some antibody-drug conjugates.

[0504] In some embodiments, less than the theoretically maximum drug moiety binds to the antibody during the conjugation reaction. The antibody may contain lysine residues, for example, that do not react with drug-connector intermediates or connector reagents, as discussed below. Only the most reactive lysine groups may react with amine-reactive connector reagents. In some embodiments, the antibody is subjected to denaturing conditions to reveal reactive nucleophilic groups, such as lysine or cysteine.

[0505] The loading (drug / antibody ratio) of an ADC can be controlled in various ways, such as by: (i) limiting the molar excess of the drug-adaptor intermediate or adaptor reagent relative to the antibody; (ii) limiting the conjugation reaction time or temperature; (iii) partial or limiting reduction conditions of cysteine ​​thiol modification; and (iv) genetically engineering the amino acid sequence of the antibody through recombinant technology so that the number and position of cysteine ​​residues are modified to control the number and / or position of adaptor-drug attachment.

[0506] Cytotoxins suitable for the compositions and methods described herein include DNA intercalators (e.g., anthracyclines), agents capable of disrupting the mitotic spindle (e.g., vinca alkaloids, maytansine, maytansine alkaloids and their derivatives), RNA polymerase inhibitors (e.g., amatoxins, such as α-amatoxins and their derivatives), and agents capable of disrupting protein biosynthesis (e.g., agents exhibiting rrnA N-glycosidase activity, such as saponins and ricin A chains), as well as other substances known in the art.

[0507] In some embodiments, the cytotoxic agent is a microtubule binder (e.g., maytansine or maytanyl alkaloids), amatoxins, Pseudomonas exotoxin A, deBouganin, diphtheria toxin, saponins, maytansine, maytanyl alkaloids, oliguria stomatine, anthracyclines, galizine, irinotecan, SN-38, pyrrolobenzodiazepines, pyrrolobenzodiazepine dimers, indobenzobenzodiazepines, indobenzobenzodiazepine dimers, indobenzobenzodiazepine pseudodimers or variants thereof, or another cytotoxic compound described herein or known in the art.

[0508] In some embodiments, the cytotoxic component of the antibody-drug conjugate is an RNA polymerase inhibitor. In some embodiments, the RNA polymerase inhibitor is amatoxin or a derivative thereof. In some embodiments, the cytotoxic component of the antibody-drug conjugate disclosed herein is amatoxin or a derivative thereof, such as α-amatoxin, β-amatoxin, γ-amatoxin, ε-amatoxin, amatoxin, amatoxin amide, amatoxin non-toxic cyclic peptide, amatoxin non-toxic cyclic peptide acid, pro-amatoxin non-toxic cyclic peptide, or a derivative thereof.

[0509] Further details of the cytotoxins used in the methods of the present invention (e.g., anti-CD117 ADC, anti-CD45 ADC, anti-CD2 ADC, anti-CD5 ADC, anti-CD137 ADC, or anti-CD252 ADC) are described below.

[0510] Amanita mushroom toxin

[0511] The methods and compositions disclosed herein comprise an antibody-drug conjugate (ADC) containing an RNA polymerase inhibitor (e.g., amatoxin) as a cytotoxic agent conjugated to an anti-HC antibody (e.g., an anti-CD117 antibody). In some embodiments, the cytotoxic agent of the antibody-drug conjugate is an RNA polymerase inhibitor. In some embodiments, the RNA polymerase inhibitor is amatoxin or a derivative thereof. In some embodiments, the cytotoxic agent of the antibody-drug conjugate disclosed herein is amatoxin or a derivative thereof. Examples include α-amatoxin, β-amatoxin, γ-amatoxin, ε-amatoxin, amatoxin, amatoxin amide, amatoxin nontoxic cyclic peptide, amatoxin nontoxic cyclic peptide acid, proamatoxin nontoxic cyclic peptide, or a derivative thereof. Suitable amatoxins are disclosed, for example, in Zanotti et al., Int. J. Peptide Protein Res. 30, 1987, 450-459.

[0512] Amanita toxins used in conjunction with the compositions and methods described herein include, but are not limited to, compounds according to formula (III), including α-amaminine, β-amaminine, γ-amaminine, ε-amaminine, amanitin, amanitamide, amanita non-toxic cyclic peptide, amanita non-toxic cyclic peptide acid, or pro-amanita non-toxic cyclic peptide.

[0513] Equation (III) is as follows:

[0514]

[0515] Where R1 is H, OH, or OR A ;

[0516] R2 is H, OH, or OR. B ;

[0517] R A and R B When present, they combine with the oxygen atoms to which they are bonded to form optionally substituted 5-membered heterocyclic alkyl groups;

[0518] R3 is H or R D ;

[0519] R4 represents H, OH, and OR. D Or R D ;

[0520] R5 represents H, OH, and OR. D Or R D ;

[0521] R6 is H, OH, OR D Or R D ;

[0522] R7 represents H, OH, and OR. D Or R D ;

[0523] R8 is OH, NH2, or OR. D ;

[0524] R9 is H, OH, or OR. D ;

[0525] x is -S-, -S(O-) or -SO2-; and

[0526] R DIt is an optionally substituted alkyl group (e.g., C1-C6 alkyl), an optionally substituted heteroalkyl group (e.g., C1-C6 heteroalkyl), an optionally substituted alkenyl group (e.g., C2-C6 alkenyl), an optionally substituted heteroalkenyl group (e.g., C2-C6 heteroalkenyl), an optionally substituted alkynyl group (e.g., C2-C6 alkynyl), an optionally substituted heteroalkynyl group (e.g., C2-C6 heteroalkynyl), an optionally substituted cycloalkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group.

[0527] For example, in one embodiment, the amatoxins used in conjunction with the compositions and methods described herein comprise compounds according to formula (IIIA).

[0528]

[0529] R4, R5, X, and R8 are defined as above.

[0530] For example, in one embodiment, the amanita mushroom toxin used in conjunction with the compositions and methods described herein comprises a compound according to formula (IIIB):

[0531]

[0532] Where R1 is H, OH, or OR A ;

[0533] R2 is H, OH, or OR. B ;

[0534] R A and R B When present, they combine with the oxygen atoms to which they are bonded to form optionally substituted 5-membered heterocyclic alkyl groups;

[0535] R3 is H or R D ;

[0536] R4 represents H, OH, and OR. D Or R D ;

[0537] R5 represents H, OH, and OR. D Or R D ;

[0538] R6 is H, OH, OR D Or R D ;

[0539] R7 represents H, OH, and OR. D Or R D ;

[0540] R8 is OH, NH2, or OR. D ;

[0541] R9 is H, OH, or OR. D ;

[0542] x is -S-, -S(O-) or -SO2-; and

[0543] R D It is an optionally substituted alkyl group (e.g., C1-C6 alkyl), an optionally substituted heteroalkyl group (e.g., C1-C6 heteroalkyl), an optionally substituted alkenyl group (e.g., C2-C6 alkenyl), an optionally substituted heteroalkenyl group (e.g., C2-C6 heteroalkenyl), an optionally substituted alkynyl group (e.g., C2-C6 alkynyl), an optionally substituted heteroalkynyl group (e.g., C2-C6 heteroalkynyl), an optionally substituted cycloalkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group.

[0544] In one embodiment, the amanita mushroom toxin used in conjunction with the compositions and methods described herein further includes a compound according to formula (IIIC):

[0545]

[0546] Where R1 is H, OH, or OR A ;

[0547] R2 is H, OH, or OR. B ;

[0548] R A and R B When present, they combine with the oxygen atoms to which they are bonded to form optionally substituted 5-membered heterocyclic alkyl groups;

[0549] R3 is H or R D ;

[0550] R4 represents H, OH, and OR. D Or R D ;

[0551] R5 represents H, OH, and OR. D Or R D ;

[0552] R6 is H, OH, OR D Or R D ;

[0553] R7 represents H, OH, and OR. D Or R D ;

[0554] R8 is OH, NH2, or OR. D ;

[0555] R9 is H, OH, or OR. D ;

[0556] x is -S-, -S(O-) or -SO2-; and

[0557] R D It is an optionally substituted alkyl group (e.g., C1-C6 alkyl), an optionally substituted heteroalkyl group (e.g., C1-C6 heteroalkyl), an optionally substituted alkenyl group (e.g., C2-C6 alkenyl), an optionally substituted heteroalkenyl group (e.g., C2-C6 heteroalkenyl), an optionally substituted alkynyl group (e.g., C2-C6 alkynyl), an optionally substituted heteroalkynyl group (e.g., C2-C6 heteroalkynyl), an optionally substituted cycloalkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group.

[0558] In one embodiment, the cytotoxin is amanita phalloidin. For example, the antibody and antigen-binding fragments described herein can be conjugated with amanita phalloidin to form a conjugate represented by the formula Ab-ZL-Am, where Ab is an antibody or its antigen-binding fragment, L is a linker, Z is a chemical moiety, and Am is amanita phalloidin. Numerous sites on the amanita phalloidin or its derivatives can be used as sites for covalently binding the linker portion L, and thus as sites for covalently binding the antibody or its antigen-binding fragment. Exemplary methods for amanita phalloidin conjugation and linkerization for such processes are described below. Exemplary linker-containing amanita phalloids that can be conjugated with antibodies or antigen-binding fragments according to the compositions and methods described herein are shown in structural formulas (I), (IA), (IB), (II), (IIA), and (IIB) described herein.

[0559] In some implementations, the amanita-toxin-connector conjugate Am-LZ is represented by formula (I).

[0560]

[0561] Where R1 is H, OH, OR A OR C ;

[0562] R2 represents H, OH, or OR. B OR C ;

[0563] R A and R B When present, they combine with the oxygen atoms to which they are bonded to form optionally substituted 5-membered heterocyclic alkyl groups;

[0564] R3 is H, R C Or R D ;

[0565] R4 represents H, OH, and OR. C OR D R C Or R D ;

[0566] R5 represents H, OH, and OR. C OR D R C Or R D ;

[0567] R6 is H, OH, OR C OR D R C Or R D ;

[0568] R7 represents H, OH, and OR. C OR D R C Or R D ;

[0569] R8 represents OH, NH2, and OR. C OR D NHR C or NR C R D ;

[0570] R9 represents H, OH, and OR. C OR D ;

[0571] x is -S-, -S(O-) or -SO2-;

[0572] R C Yes, it's LZ;

[0573] R D It is optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 heteroalkenyl, optionally substituted C2-C6 ynyl, optionally substituted C2-C6 heteroynyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl;

[0574] L is a connector, such as an optionally substituted alkylene (e.g., C1-C6 alkylene), an optionally substituted heteroalkylene (e.g., C1-C6 heteroalkylene), an optionally substituted alkenyl (e.g., C2-C6 alkenyl), an optionally substituted heteroalkenyl (e.g., C2-C6 heteroalkenyl), an optionally substituted ynylene (e.g., C2-C6 ynylene), an optionally substituted heteroynyl (e.g., C2-C6 heteroynyl), an optionally substituted cycloalkylene, an optionally substituted heterocycloalkylene, an optionally substituted aryl, an optionally substituted heteroaryl, a peptide, a dipeptide, -(C=O)-, a disulfide, a hydrazone, or a combination thereof;

[0575] and

[0576] Z is a chemical moiety formed by the coupling reaction between a reactive substituent present on L and a reactive substituent present in the antibody or its antigen-binding fragment, which binds to the target antigen (e.g., CD117).

[0577] In some implementations, Am specifically includes an R C Substituents.

[0578] In some implementation schemes, LZ is

[0579]

[0580] Where S represents the sulfur atom of a reactive substituent present in the antibody or its antigen-binding fragment, which binds to the target antigen (e.g., the -SH group of a cysteine ​​residue).

[0581] In some implementations, the conjugate Am-LZ-Ab is represented by one of formulas IV, IVA, or IVB:

[0582]

[0583] Where X is S, SO or SO2, and Ab represents Ab attachment point.

[0584] In some implementation...

Claims

1. An antibody or its antigen-binding portion thereof, comprising an Fc region, wherein the Fc region comprises the amino acid sequence of SEQ ID NO: 20, wherein the antibody or its antigen-binding portion thereof is an immunoglobulin G1 (IgG1) isotype, and wherein the antibody is undetectable by biological layer interferometry (BLI) for binding to human FcγR, wherein the human FcγR is human FcγRI, human FcγRIIA 167R, human FcγRIIA 167H, or human FcγRIIIA 176V, and wherein the antibody or its antigen-binding portion thereof specifically binds to CD117 or CD45.

2. The antibody or its antigen-binding portion according to claim 1, wherein the antibody has a reduced half-life relative to the same intact IgG antibody containing an unmodified Fc region.

3. The antibody or its antigen-binding portion according to claim 1, wherein the antibody reduces cytokine release in an in vitro cytokine release assay by at least 50% relative to the cytokine release of the same antibody containing an unmodified Fc region.

4. The antibody or its antigen-binding portion according to claim 3, wherein the reduction in cytokine release is at least 60% relative to cytokine release of the same antibody containing an unmodified Fc region.

5. The antibody or its antigen-binding portion according to claim 3, wherein cytokine release is reduced by at least 70%.

6. The antibody or its antigen-binding portion according to claim 3, wherein cytokine release is reduced by at least 80%.

7. The antibody or its antigen-binding portion according to claim 3, wherein cytokine release is reduced by at least 90%.

8. The antibody or its antigen-binding portion according to claim 3, wherein cytokine release is reduced by at least 95%.

9. The antibody or its antigen-binding portion according to claim 3, wherein cytokine release is reduced by at least 98%.

10. The antibody or its antigen-binding portion according to claim 3, wherein cytokine release is reduced by at least 99%.

11. The antibody or its antigen-binding portion according to claim 3, wherein cytokine release is reduced by at least 100%.

12. The antibody or its antigen-binding portion according to claim 3, wherein the antibody does not exhibit detectable cytokine release.

13. The antibody or its antigen-binding portion according to any one of claims 3 to 12, wherein the in vitro cytokine release assay is a Meso Scale Discovery (MSD) tissue culture (TC) pro-inflammatory assay.

14. The antibody or its antigen-binding portion according to claim 1, wherein the antibody reduces mast cell degranulation in an in vitro mast cell degranulation assay by at least 50% relative to mast cell degranulation of the same antibody containing an unmodified Fc region.

15. The antibody or antigen-binding portion thereof according to claim 14, wherein the reduction in mast cell degranulation is at least 60% relative to mast cell degranulation of the same antibody containing an unmodified Fc region.

16. The antibody or its antigen-binding portion according to claim 14, wherein mast cell degranulation is reduced by at least 70%.

17. The antibody or its antigen-binding portion according to claim 14, wherein mast cell degranulation is reduced by at least 80%.

18. The antibody or its antigen-binding portion according to claim 14, wherein mast cell degranulation is reduced by at least 90%.

19. The antibody or its antigen-binding portion according to claim 14, wherein mast cell degranulation is reduced by at least 95%.

20. The antibody or its antigen-binding portion according to claim 14, wherein mast cell degranulation is reduced by at least 98%.

21. The antibody or its antigen-binding portion according to claim 14, wherein mast cell degranulation is reduced by at least 99%.

22. The antibody or its antigen-binding portion according to claim 14, wherein mast cell degranulation is reduced by at least 100%.

23. The antibody or its antigen-binding portion according to claim 15, wherein the antibody does not show detectable mast cell degranulation.

24. The antibody or its antigen-binding portion according to any one of claims 14 to 23, wherein the in vitro mast cell degranulation assay is based on a β-hexosaminease-based mast cell degranulation assay.

25. The antibody or its antigen-binding portion according to claim 1, wherein the antibody is a human antibody, a chimeric antibody, or a humanized antibody.

26. The antibody or its antigen-binding portion according to claim 1, wherein the antibody is a bispecific antibody.

27. The antibody or its antigen-binding portion according to claim 1, wherein the antibody is a monoclonal antibody.

28. The antibody according to claim 1, wherein the antibody is a complete IgG antibody.

29. An antibody-drug conjugate (ADC) comprising the antibody or its antigen-binding portion according to claim 1, wherein the antibody or its antigen-binding portion is conjugated to a cytotoxin via a linker.

30. The ADC of claim 29, wherein the antibody or its antigen-binding portion is conjugated to a cytotoxin via a cysteine ​​residue in the Fc domain of the antibody.

31. The ADC of claim 30, wherein the cysteine ​​residue is introduced by substitution of an amino acid in the Fc domain of the antibody.

32. A pharmaceutical composition comprising an antibody or antigen-binding portion thereof according to claim 1, and a pharmaceutically acceptable carrier.

33. A composition comprising the antibody or its antigen-binding portion according to claim 1, wherein the composition contains less than 25% hydrophobic degradation products after thermal stress.

34. The composition of claim 33, wherein the composition contains less than 20% hydrophobic degradation products after thermal stress.

35. The composition of claim 33, wherein the composition contains less than 15% hydrophobic degradation products after thermal stress.

36. The composition of claim 33, wherein the composition contains less than 10% hydrophobic degradation products after thermal stress.

37. The composition of claim 33, wherein the composition contains less than 5% hydrophobic degradation products after thermal stress.

Citation Information

Patent Citations

  • Recombinant antibodies and methods for their production

    EP0239400A2

  • Cytotoxic agents comprising maytansinoids and their therapeutic use

    EP0425235B1

  • A method for reducing the immunogenicity of antibody variable domains

    EP0519596A1

  • Methods for producing members of specific binding pairs

    EP0589877A1

  • Resurfacing of rodent antibodies

    EP0592106A1